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Abstract

Transcompartmental Sodium Imaging in Brain Cancer
Muhammad Hammad Khan
2021

According to the World Health Organization (WHO), cancers are the second-leading cause
of death in the United States, next to cardiovascular disease. Although treatments of some
solid tumors with high mortality are showing promise, there is one exception: glioblastoma
multiforme (GBM). Even with advanced therapies, median survival rate for GBM patients
is dismal because most are not diagnosed early enough.
A hallmark of normal physiology is maintenance of large ion gradients across the cell
membrane, mainly for sodium (Na+ ) and potassium (K+ ) ions. Under normal conditions,
+
high and low Na+ in extracellular (Na+
e ) and intracellular (Nai ) milieu, respectively (and
+
the opposite is true for K ), produce strong transmembrane and weak transendothelial Na+
gradients, which contribute to the cell membrane potential (𝑉𝑚 ) and blood-brain-barrier
(BBB) integrity, respectively. The Na+ /K+ -ATPase in the cell membrane plays a crucial
role in transporting Na+ and K+ against their respective electrochemical gradients by
consuming ATP. A universal cancer hallmark is reduced oxidation due to downregulation
of Na+ /K+ -ATPase, a consequence of inefficient metabolism which aids tumor survival.
Electrolyte balance in the body is crucial for proper functioning of processes like action
potential propagation, muscle movement, and maintaining cell volume, but electrolyte
imbalances can lead to pathophysiologies like cancer.
Translational magnetic resonance imaging (MRI) and spectroscopic imaging (MRSI) methods are an integral part of diagnosing and tracking cancer. Clinical MRI is largely based on
detection of the 1 H nuclei in water molecules in soft tissues, where intrinsic 1 H-MRI contrasts provide anatomical separation between healthy tissue and lesion. But paramagnetic
lanthanide(III) ions (Ln3+ ), specifically gadolinium (Gd3+ ), conjugated with a chelating
molecule consisting of electron donors, provide superior 1 H-MRI contrast as the agent (e.g.,
Dotarem) extravasates into the lesion through leaky blood vessels to enhance the lesion’s
appearance. Other nuclei are rarely considered for clinical applications, but these so-called
“X-nuclei” (e.g., 23 Na, 31 P, or 17 O) can offer illuminating insights into the physiological
processes.
23

Na-MRI has the potential to be a helpful screen for early cancer detection. However,
normal 23 Na-MRI cannot separate the overlapping signals between Na+ from different
compartments like the blood vessel (Na+
), extracellular space (Na+
e ), and intracellular space
b
(Na+
).
In
this
thesis,
I
have
developed
a
rigorous
model
which
can be applied in vivo to
i
separate these individual signals by introducing small amounts of a paramagnetic contrast
agent based on Ln3+ metal ions. The model predicts that the induced 23 Na chemical shift and
line broadening are monotonically increasing functions of both the agent’s concentration
and negative charge, which was validated on a set of nine agents. This established model
was then considered for in vivo applications to compartmentalize the 23 Na-MRSI signals

in rat models. Since these agents extravasate from blood vessels, but are too negatively
charged to enter cells, this method is able to separate and readout the 23 Na signals from
+
Na+
, Na+
e , and Nai with high fidelity by inducing chemical shift differences. Examination
b
of several GBM models in rodent brain, shows that tumors redistribute Na+ from the
extracellular milieu to dramatically weaken the transmembrane Na+ gradient (compared
to normal tissue) and concomitantly strengthen the transendothelial Na+ gradient. This is
a significant finding because the lower level of Na+
e imply that the membrane of cancer
cells is depolarized (i.e., and thus are they are non-excitable). Others have shown that
high 𝑉𝑚 is common to cells in a proliferative state. Since even immune cells can sense
+
the level of Na+
e , it is evident the role of compartmental Na in the tumor niche will be
important to study in vivo. I also report novel findings regarding variations in induced
23
Na line broadening and electrical activity between tumors and healthy tissue which have
considerable oncologic significance. Despite the clinical popularity of 1 H-MRI, 1 H-MRSI,
and general imaging-based approaches, this project demonstrates the vast potential of 23 Na
spectroscopic methods to allow novel explorations of the tumor habitat for early diagnosis
and tracking treatments.
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List of Figures
1.1 Mechanisms of electrolyte balance. (a) An electron density map of the
Na+ /K+ -ATPase, with 𝛼 -, 𝛽 -, and 𝛾 -subunits indicated. The actuator (A),
nucleotide-binding (N), and phosphorylation (P) domains of the 𝛼 -subunit
lie on the cytoplasmic end of the plasma membrane. The 𝛽 -subunit touches
the extracellular space. The yellow and red lines indicate the backbones of
the 𝛼 - and 𝛾 -subunits, respectively. Modified from [81]. (b) Sodium proton
exchanger (NHE1) topological structure and binding characteristics. Note its 12
transmembrane segments with a short intracellular N-terminus long intracellular C-terminus, which has binding sites for many regulator molecules which
ultimately sense pHi and affect H+ efflux with simultaneous Na+ influx in a 1:1
stoichiometry. Modified from [90]. (c) A model of sodium calcium exchanger
(NCX1), with 9 transmembrane segments, and a glycosylated extracellular
N-terminus. The Ca2+ binding domain is highlighted on the large intracellular
loop, (not depicted to scale), which spans 550 amino acids which is more than
half the length of NCX1. Modified from [91]. (d) Structure of the sodium channel
(Nav ). Glutamate side chains are shown in purple, and the main pore is shown
in white. The extracellular opening is wide, and narrows immediately at the
Na+ selectivity domain. The remainder of the channel is a water-filled cavity,
lined by S6 segments, through which hydrated Na+ travels until it reaches
the voltage-activated gate at the intracellular end. Modified from [92]. (e) A
cartoon representation of the different Na+ channels mentioned: NHE (green),
Na+ /K+ -ATPase (blue), NCX (teal), and Nav (brown). The voltage-dependence
of Nav is emphasized with a voltage schematic drawn above. Transport is
shown for relevant ions: Na+ (purple), H+ (white), K+ (pink), and Ca2+ (dark
blue). Directionality of transport is indicated by arrows. . . . . . . . . . . . .
1.2 A cartoon of cellular metabolism. Glucose and oxygen uptake are regulated
by blood flow, the former facilitated by glucose transporters (GLUTs) and the
latter happening passively. Under normal conditions, glucose is metabolized at
basal levels (cerebral metabolic rate of glucose, CMRglc ), converted to glucose6-phosphate (G6P) followed by pyruvate, which enters mitochondria alongside
O2 (at the cerebral metabolic rate of oxygen CMRO2 ) to produce adenosine
triphosphate (ATP) 36-fold via oxidative phosphorylation. In tumor cells
(changes indicated with up/down arrows), however, CMRglc is elevated while
CMRO2 decreases, causing pyruvate to be converted to lactate and protons
(H+ ) while ATP production is reduced by a factor of 18. . . . . . . . . . . . . .

18

21

2.1 A schematic representation of the Stern-Gerlach experiment. A beam of
silver atoms was released in a straight line through a magnetic field. Classical
physics would anticipate a uniform distribution of atoms throughout the length
of the plate, but experimental results actually exhibit only two spots in the
plate, one corresponding to spin-up particles, and one to spin-down particles.
This was the first experimental observation that spin angular momentum (and
therefore magnetic moment) is a quantized value. . . . . . . . . . . . . . . . .
2.2 Polarization of spin-1/2 particles. A cartoon depicting the spin angular momenta of a sample of magnetic particles in the (a) absence and (b) presence
®0 . Without the field (a), the spins
of an externally applied magnetic field 𝐵
are randomly oriented and distributed, leading to zero net magnetization on
average. However, when the field is applied (b), the spins orient themselves
with ( 𝛼 ) or against (𝛽 ) the applied field. Note that there is a slight excess of
spins in the 𝛼 state. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3 An illustration of the laboratory and rotating frames. (a) Vector diagram of
® (green) in the laboratory frame. The excitation field 𝐵®1
the magnetization 𝑀
(blue) is applied sinusoidally along the + 𝑥 -axis initially and rotates at angular
® around the + 𝑧 -axis at
frequency 𝜔 , causing simultaneous precession of 𝑀
a frequency 𝜔0 = 𝛾𝐵0 , and nutation about the + 𝑥 -axis onto the + 𝑦 -axis at
a frequency 𝜔1 = 𝛾𝐵1 , resulting in a complex elliptical trajectory. (b) Vector
® (green) in the rotating frame, described by
diagram of the magnetization 𝑀
0
0
0
the primed axes 𝑥 , 𝑦 , and 𝑧 . Both 𝑥 0 and 𝑦 0 are rotating with respect to the
stationary laboratory frame axes at an angular frequency 𝜔𝑅 . The excitation
®1 (blue) is applied stationarily along the + 𝑥 0-axis, which results in a
field 𝐵
simpler trajectory consisting of only nutation about + 𝑥 0-axis onto the + 𝑦 0-axis.
2.4 Electron cloud distribution in methanol. Chemical structure of methanol
(CH3 OH), where the bonds (ellipses) reveal the electron (black dot) cloud
distribution between the two bonded atoms. For the C-O bond (black ellipse),
the comparable electronegativities cause the electrons to be evenly distributed
between them. For C-H bonds (blue ellipse), the electrons are found near the
carbon atom with higher probability. For the O-H bond, are mostly found
near the oxygen atom due to its high electronegativity. Due to these uneven
electron distributions, intermolecular effects will affect the electronic shielding
of different protons and cause chemical shift effects in the 1 H NMR spectrum.

28

30

34

44

2.5 Chemical structures of common chelates used for lanthanide-based NMR
contrast agents.(a) 1,4,7,10-tetraazacyclododecane, also known as cyclen. (b)
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate, also known as DOTA4− .
It is similar to cyclen but has a carboxylate pendant arm attached to each
nitrogen on the cyclododecane ring. (c) 1,4,7,10-tetraazacyclododecane-1,4,7,10tetrakis(methylacetate), also known as DOTMA4− . It is identical to DOTA4− ,
except each carboxylate pendant arm has a methyl group at the H6 proton
position. (d) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylene phosphonate), also known as DOTP8− . It is identical to DOTA4− except each pendant
arm contains a phosphonate group instead of a carboxylate group. This gives
it double the negative charge. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
2.6 In Vivo 23 Na MRS. Sample 23 Na MRS spectra of gerbil leg muscles after infusion
of a contrast agent, and before (top) and after (bottom) introduction of ouabain.
Peak A refers to intracellular sodium, while Peak B refers to extracellular. This
demonstrates the ability of in vivo 23 Na MRS to elucidate physiological changes
with minimal invasion. Modified from[267]. . . . . . . . . . . . . . . . . . . . 69
2.7 Signal-to-noise ratio in different spectra. A demonstration of signal-to-noise
ratio (SNR) where the NMR spectrum on the left has superior SNR due to the
fact that the average noise amplitude at baseline is much smaller compared to
the average noise amplitude at baseline for the spectrum on the right. For this
reason, despite similar peak amplitudes, the spectrum on the right exhibits
poor SNR. Modified from [267]. . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
2.8 In vivo 23 Na MRI. A demonstration of 23 Na MRI used clinically to determine
sodium levels. Images shown are generated by (A) standard pulse-acquire and
(B) inversion recovery sequences based on the 23 Na MRI signal, and (C) a 1 H
MRI of the gray matter. Poor resolution in the 23 Na images compared to the
1
H image is attributed to superior in vivo SNR of the latter nucleus. Modified
from[305]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
2.9 In vivo 23 Na MRSI. An attempt at [Na+ ] quantification using 23 Na MRSI
on the calf muscle (indicated on figure) to produce concentration maps.
Below the depicted slice of the muscle are tubes with standard, known [Na+ ]
concentrations (A is the highest concentration and D is the lowest) and the
[Na+ ] in the muscle was calculated by interpolating the muscular 23 Na MRSI
signal between the 23 Na MRSI signals from the tubes, assuming a one-to-one
correspondence between signal and concentration. Modified from [313]. . . . . 78
2.10 Early NMR chelates. Chemical structures of (a) nitrilotriacetic acid and (b)
triethylenetetraminehexaacetic acid (TTHA), which have been used as early
NMR contrast agents to induce 23 Na chemical shift differences when complexed
with dysprosium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81

3.1 Structures and charges of macrocyclic chelates, with schematic of experimental design. Chemical structures of various chelates (Che): (A) 1,4,7,10tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonate) (DOTP8− ), (B)
1,4,7-triazacyclononane-1,4,7-tris(methylenephosphonate) (NOTP6− ), and (C)
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylacetate) (DOTMA4− ).
Conjugation with different lanthanide (Ln3+ ) metals (Tm3+ , Eu3+ , or Gd3+ )
results in anionic lanthanide-chelate complexes (LnChe𝑛− ) with (A) -5, (B) -3
and (C) -1 charges. Because of the negative charges, they will attract Na+ and
shift the 23 Na-MRSI signal. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
3.2 Mechanism of Na+ exchange for 23 Na peak shiftability and broadening
effects. A shift agent is composed of a paramagnetic lanthanide ion (Ln3+ )
complexed with a negatively charged cyclic chelating agent (Che(𝑛+3)− ) to form a
polyanionic lanthanide complex (LnChe𝑛− ). The Na+ ions (black circles) directly
linked to the Ln3+ ion (white circle) exchange with bulk electrolyte composed of
free Na+ ions, where the exchange rate ( 𝑘 𝑒 𝑥 ) transmits the paramagnetic effect
of the Ln3+ ion to the surrounding milieu. Efficacy of this process depends
on the number of Na+ ions bound to the Ln3+ ion, which in part is dictated
by shape of the cyclic chelating agent (Che(𝑛+3)− , shown in gray) because this
manifests the overall negative charge (𝑛 ) on LnChe𝑛− . The light gray portion of
the chelate represents the region where the anionic charge resides and allows
Na+ coordination. The dark grey portion signifies the closed-off regions where
anionic charge is not concentrated and Na+ would not bind. The scenarios for
𝑛 = 1 , 3 , 5 are shown from left to right. Many factors dictate 𝑘 𝑒 𝑥 , including the
ionic radius, magnetic moment, and electronic configuration of the Ln3+ ion as
well as the rotational correction time (𝜏𝑅 ) of LnChe𝑛− . . . . . . . . . . . . . . 90
3.3 Concentration and charge effects of Tm3+ -based agents on 23 Na chemical
shift. 23 Na spectra are displayed for concentric tubes parallel to magnetic field,
where the LnChe𝑛− added to the outer compartment in the phantom was (A)
TmDOTP5− , (B) TmNOTP3− , or (C) TmDOTMA− . Spectra are shown for 10
(blue), 7.5 (golden), 5 (green), and 3 (red) mM, and 0 ppm corresponds to
the natural, unshifted 23 Na resonance of the inner compartment to which no
LnChe𝑛− was added. The 23 Na chemical shifts clearly display a dependence
on both the concentration and charge of the LnChe𝑛− , with larger shifts
corresponding to both higher concentrations and larger negative charges.
These trends are summarized in (D), where TmDOTP5− displays the highest
shiftability, followed by TmNOTP3− , and then TmDOTMA− . The addition of
LnChe𝑛− also induces line broadening in 23 Na spectra due to 𝑇2 shortening,
which follows similar patterns of dependence on [LnChe𝑛− ] and charge and is
summarized in (E). See Figure 3.4 and Figure 3.5 for similar data from Eu3+ and Gd3+ -based agents, respectively. See Figure 3.6 for pH variations from
these same Tm3+ -based agents. . . . . . . . . . . . . . . . . . . . . . . . . . . . 96

3.4 Concentration and charge effects of Eu3+ -based agents on 23 Na chemical
shift. 23 Na spectra are displayed for concentric tubes parallel to magnetic field,
where the LnChe𝑛− added to the outer compartment in the phantom was
(A) EuDOTP5− , (B) EuNOTP3− , or (C) EuDOTMA− . Spectra are shown for 10
(blue), 7.5 (golden), 5 (green), and 3 (red) mM, and 0 ppm corresponds to
the natural, unshifted 23 Na resonance of the inner compartment to which no
LnChe𝑛− was added. The 23 Na chemical shifts display a dependence on both
the concentration and charge of the LnChe𝑛− much like Tm3+ -based agents,
although to a much lesser extent. These trends are summarized in (D), where
EuDOTP5− displays the highest shiftability, followed by EuNOTP3− , and then
EuDOTMA− . The line broadening trends are summarized in (E), and also
follow these same patterns. See Figure 3.3 and Figure 3.5 for similar data from
Tm3+ - and Gd3+ -based agents, respectively. See Figure 3.7 for pH variations
from these same Eu3+ -based agents. . . . . . . . . . . . . . . . . . . . . . . . . 97
3.5 Concentration and charge effects of Gd3+ -based agents on 23 Na chemical
shift. 23 Na spectra are displayed for concentric tubes parallel to magnetic field,
where the LnChe𝑛− added to the outer compartment in the phantom was (A)
GdDOTP5− , (B) GdNOTP3− , or (C) GdDOTMA− . Spectra are shown for 10
(blue), 7.5 (golden), 5 (green), and 3 (red) mM, and 0 ppm corresponds to
the natural, unshifted 23 Na resonance of the inner compartment to which no
LnChe𝑛− was added. The 23 Na chemical shifts display a dependence on both
the concentration and charge of the LnChe𝑛− much like Tm3+ -based agents,
although to a much lesser extent. These trends are summarized in (D), where
GdDOTP5− displays the highest shiftability, followed by GdNOTP3− , and then
GdDOTMA− . These Gd3+ -based agents produced significant line broadening,
and trends are summarized in (E), also following these same patterns. See
Figure 3.3 and Figure 3.4 for similar data from Tm3+ - and Eu3+ -based agents,
respectively. See Figure 3.8 for pH variations from these same Gd3+ -based agents. 98
3.6 pH effects of Tm3+ -based agents on 23 Na chemical shift. 23 Na spectra are
displayed for concentric tubes parallel to magnetic field, where the LnChe𝑛−
added to the outer compartment in the phantom was (A) TmDOTP5− , (B)
TmNOTP3− , or (C) TmDOTMA− . Spectra are shown for pH 6 (blue), 7(golden),
and 8 (green), and 0 ppm corresponds to the natural, unshifted 23 Na resonance
of the inner compartment to which no LnChe𝑛− was added. The 23 Na chemical
shifts do not display a significant dependence on the pH of the environment.
These trends are summarized in (D). The line broadening also does not exhibit
pH dependence (E). See Figure 3.7 and Figure 3.8 for similar data from Eu3+ and Gd3+ -based agents, respectively. See Figure 3.3 for concentration and
charge effects from these same Tm3+ -based agents. . . . . . . . . . . . . . . . . 99

3.7 pH effects of Eu3+ -based agents on 23 Na chemical shift. 23 Na spectra are
displayed for concentric tubes parallel to magnetic field, where the LnChe𝑛−
added to the outer compartment in the phantom was (A) EuDOTP5− , (B)
EuNOTP3− , or (C) EuDOTMA− . Spectra are shown for pH 6 (blue), 7(golden),
and 8 (green), and 0 ppm corresponds to the natural, unshifted 23 Na resonance
of the inner compartment to which no LnChe𝑛− was added. The 23 Na chemical
shifts do not display a significant dependence on the pH of the environment.
These trends are summarized in (D). The line broadening also does not exhibit
pH dependence (E). See Figure 3.6 and Figure 3.8 for similar data from Tm3+ and Gd3+ -based agents, respectively. See Figure 3.4 for concentration and
charge effects from these same Eu3+ -based agents. . . . . . . . . . . . . . . . . 100
3.8 pH effects of Gd3+ -based agents on 23 Na chemical shift. 23 Na spectra are
displayed for concentric tubes parallel to magnetic field, where the LnChe𝑛−
added to the outer compartment in the phantom was (A) GdDOTP5− , (B)
GdNOTP3− , or (C) GdDOTMA− . Spectra are shown for pH 6 (blue), 7(golden),
and 8 (green), and 0 ppm corresponds to the natural, unshifted 23 Na resonance
of the inner compartment to which no LnChe𝑛− was added. The 23 Na chemical
shifts do not display a significant dependence on the pH of the environment.
These trends are summarized in (D). The line broadening also does not exhibit
pH dependence (E). See Figure 3.6 and Figure 3.7 for similar data from Tm3+ and Eu3+ -based agents, respectively. See Figure 3.5 for concentration and
charge effects from these same Gd3+ -based agents. . . . . . . . . . . . . . . . . 101
3.9 Effect of cation competition on 23 Na chemical shift and line width induced
by 2 mM TmDOTP5− . (A) 23 Na-NMR spectra for 150 mM NaCl solutions
containing 2 mM TmDOTP5− alone (blue), and in the presence of 2 mM Ca2+
(golden), 2 mM Mg2+ (green), 10 mM K+ (red), and all three of these ions (purple). All 23 Na spectra were acquired from concentric tubes parallel to magnetic
field (similar to Figure 3.3-Figure 3.5). Ca2+ , Mg2+ , and K+ were introduced
as the salts CaCl2 , MgCl2 , and KBr, respectively. These concentrations were
all chosen to represent physiological concentrations in the extracellular space.
The changes in 23 Na (B) chemical shift and (C) line width were negligible,
suggesting overall higher affinity for Na+ given the aforementioned amounts.
Chemical shift ranged between 2.433 ppm (B, alone, blue) and 2.352 ppm (B,
all, purple), representing only a 3% change in the presence of all competing
cations. Line width ranged between 0.2433 ppm (C, alone, blue) and 0.2285
ppm (C, all, purple), representing only a 6% change in the presence of all
competing cations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102

4.1 Shifting mechanism of the 23 Na resonance in vitro. (a) Chemical structure of
sodium thulium(III) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonate)
(Na5 TmDOTP). The TmDOTP5 complex consists of the Tm3+ ion chelated
with DOTP8− . Each phosphonate-containing pendant arm on TmDOTP5− has
electron-donating groups on the oxygen atoms (red) to stabilize the Tm3+
conjugation with DOTP8− . The -5 charge simultaneously attracts five Na+
ions(purple), which experience a shift in the observed 23 Na resonance that is
dependent on [TmDOTP5 ]. (b) In vivo, prior to TmDOTP5 administration (left),
the 23 Na spectrum yields only a single peak representing the total sodium
+
+
+
(Na+
T ) comprising blood (Nab ), extracellular (Nae ), and intracellular (Nai )
compartments. Following TmDOTP5 administration (right), the peaks become
spectroscopically separable based on [TmDOTP5 ] in each compartment. Integrals of these peaks will be representative of [Na+ ] in each compartment.
(c) A two-compartment coaxial cylinder tube setup was employed for in vitro
observation of the chemical shift separation scheme (Figure 4.2). The inner tube
(smaller volume) was filled with 150 mM NaCl, while the outer tube (larger
volume) was filled with the same solution in addition to various amounts
of TmDOTP5 , each subject to different pH conditions. Thus, all 23 Na spectra
from this phantom setup displayed a small unshifted peak from the inner
compartment and a larger shifted peak. The outer-to-inner volume ratio was
8.6, explaining the difference in sizes. Exemplary traces of 23 Na spectra show
that the shift is much more sensitive to [TmDOTP5 ] (2.77 ppm/mM) than
to variations in pH (0.25 ppm/pH unit) or temperature (0.03 ppm/◦ C). The
downfield peaks in the red, blue, and/or black spectra are shifted differently
due to varying TmDOTP5 concentrations, and these shifts exceed those caused
by pH, but all of these shifts are detectable independent of broadening caused
by TmDOTP5 (see also Figure 4.2). Plots (d) and (e) show that temperature, pH,
and [TmDOTP5 ] all contribute to variations of the 23 Na chemical shift. However,
these plots depict ranges of pH and temperature that are unlikely for in vivo
settings (i.e., changes over 2 full pH units and temperature changes over 15 ◦ C).
Moreover, [Na+ ] in vivo (150 mM in blood and extracellular space) is extremely
high compared to [TmDOTP5 ]. Therefore, variations in 23 Na chemical shift
are primarily dependent on [TmDOTP5 ]/[Na+ ] thereby rendering (f) pH and
(g) temperature dependencies negligible. Data points were fit to Chebyshev
rational polynomials using TableCurve 3D v4.0.05 (Systat Software, San Jose,
CA, USA; https://systatsoftware.com/products/tablecurve-3d/). . . . . . . . 112

4.2 Depiction of the in vitro experimental setup. A diagram of the two-compartment
coaxial tube setup used for in vitro experiments (left). The overall tube length
was 7 inches, with a 5-mm body in which the second compartment (inner/outer
diameter = 1.258/2.020 mm) was inserted. The length of the tip within the
excitable volume was 50 mm. The outer-to-inner volume ratio was 8.6. A
confirmatory study was conducted in which the inner compartment contained
150 mM NaCl and no TmDOTP5− and the outer contained 150 mM NaCl with
5 mM Na5 TmDOTP (right, red). The pH was set to 7.4, and the temperature
in the spectrometer was 300 K. The outer compartment also contained D2 O
for frequency locking of the spectrometer. The resulting unshifted peak at 0
ppm and shifted peak at 12.5 ppm were consistent with reported apparent
shiftability ( 𝑠 app ) of 2.77 ppm/mM. Integration of the spectra yielded a shiftedto-unshifted integral ratio of 10, which reflects the ratio of moles between
the two compartments (not 8.6 due to the addition of extra Na+ with the
agent). The contents of the compartments were switched (right, blue) and the
resulting spectrum showed the peaks having interchanged positions and an
inverted integral ratio, i.e. 0.1. Both compartments displayed broader peaks
with TmDOTP5− than without. This illustrates that TmDOTP5− caused the
observed shift effects and that only the difference in compartment volume
was responsible for the size of the peak. See Figure 4.1 for more example
of representative data from this phantom setup. Comparison of the Outer
red (+TmDOTP5− ) and Outer blue (no TmDOTP5− ) peaks and/or the Inner
red (+TmDOTP5− ) and Inner blue (no TmDOTP5− ) shows that there is minor
broadening due to TmDOTP5− , but these broadening effects do not confound
the chemical shifts observed. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115

4.3 Demonstration of 23 Na peak separation in vivo following TmDOTP5− administration into a rat brain bearing a U251 tumor. (a) 1 H-MRI of an axial slice
displaying the anatomical tumor boundary (white outline). The 23 Na-MRSI
is overlaid on top of the 1 H-MRI. Candidate voxels (b) inside and (c) outside
the tumor are indicated (yellow boxes). Before TmDOTP5− delivery, a single
23
Na peak was observed at 0 ppm, corresponding to total sodium (Na+
T ), both
5−
inside and outside the tumor (black spectra). Following TmDOTP delivery,
compartmental peak separation was achieved to varying extents throughout
the brain (blue spectra). Within the tumor (top spectra), this separation was
most pronounced due to a compromised blood-brain barrier (BBB), which
permits substantial accumulation of TmDOTP5− in the extracellular space.
Outside of the tumor (bottom spectra), such a high degree of extravasation
would not be possible, but some shifting is still observed. The TmDOTP5−
distribution in the brain warrants labeling the most shifted peak as blood
sodium (Na+
), which occurred consistently around 2 ppm. The unshifted
b
peak, which has no access to TmDOTP5− , is intracellular sodium (Na+
i ). The
+
intermediate peak, therefore, is extracellular sodium (Nae ), which is shifted
more inside the tumor than outside in healthy tissue. Similar spectroscopic
patterns are observed throughout all voxels in vivo. See Figure 4.4 for a slice
below the present. (d) in vitro analysis of blood samples from the tumor-bearing
rat show that the 23 Na blood peak occurred around 2 ppm, which coincided
with the most-shifted peak we observed in tumor voxels. This confirmed that
the most-shifted peak in the observed 23 Na spectra after TmDOTP5− infusion
comes from blood. All spectra were magnitude-corrected and line-broadened
by 10 Hz. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
4.4 Multi-voxel demonstration of 23 Na peak separation in vivo following TmDOTP5−
administration into a rat brain bearing a U251 tumor. 1 H MRI of an axial slice
displaying the anatomical tumor boundary (white outline). The 23 Na-MRSI is
overlaid on top of the MRI. Candidate voxels inside and outside the tumor are
indicated (yellow boxes with numbers). Before delivery of the agent, a single
23
Na peak was observed at 0 ppm in all voxels (black spectra), corresponding
5−
to total sodium (Na+
delivery, compartmental peak
T ). Following TmDOTP
separation was achieved to varying extents throughout the brain (green spectra). Tumor voxels (1-3) exhibited a fair amount of peak separation due to the
leaky blood-brain barrier (BBB), with blood sodium (Na+
) consistently around
b
+
2 ppm, extracellular sodium (Nae ) in the range 0.5-1 ppm, and the unshifted
intracellular sodium (Na+
i ) at 0 ppm. Voxels outside the tumor (4-6) were
slightly shifted in the positive direction, suggesting the paramagnetic effects
of TmDOTP5− reach the extracellular space even with limited extravasation.
Similar spectroscopic patterns are observed throughout all voxels in vivo. See
Figure 4.3 for a slice above the present. All spectra were magnitude-corrected
and line-broadened by 10 Hz. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129

4.5 Comparison of 23 Na peak separation in rats bearing RG2 and U87 tumors.
For rats bearing an (a) RG2 and (b) U87 tumor, the tumor boundary is outlined
in white, with voxels of interest indicated in yellow squares (with numbers),
and spectra acquired before and after TmDOTP5− delivery shown in black and
green, respectively. Tumor voxels 3 and 4 in (a) RG2 and (b) U87 tumor rats
exhibited a fair amount of peak separation due to the leaky BBB. Na+
shift
b
+
was consistently around 2 ppm, and Nai shift was at 0 ppm, whereas Na+
e
shift in the tumor was in the range 0.5-1 ppm. Healthy tissue voxels 5 and 6 in
(a) RG2 and (b) U87 tumor rats were slightly shifted in the positive direction,
suggesting the paramagnetic effects of TmDOTP5− reach the extracellular space
even with limited extravasation. Ventricular voxels 1 and 2 in (a) RG2 and (b)
U87 tumor rats displayed a single unshifted Lorentzian peak before and a
shifted Lorentzian peak after TmDOTP5− injection. This is attributed to the
dominant 23 Na signal contribution in the ventricles coming from cerebrospinal
fluid (CSF), which contains free (i.e., unbound) aqueous Na+ . The position of
the shifted ventricle peak coincided with the Na+
e peak position in other regions
of the brain. This agrees with expectation because CSF is in physical contact
with the extracellular space with free exchange of aqueous Na+ between the
two compartments. Similar spectroscopic patterns are observed throughout
all voxels in vivo. See Figure 4.6 for several slices for each rat shown here. All
spectra were magnitude-corrected and line-broadened by 10 Hz. . . . . . . . . 130
4.6 Multi-slice comparison of RG2 and U87 tumors. Comparison of 23 Na peak
separation in rats bearing an (a) RG2 and (b) U87 tumor. The tumor boundary
is outlined in white, spectra acquired before and after TmDOTP5− delivery
are shown in black and green, respectively, and the yellow dots represent the
same transverse coordinates across multiple slices. In both cases, “slice 1” is
the most superficial axial slice with a visible tumor and slice thickness is 1
mm with no gap. The Na+
peak was present at 2 ppm throughout the entire
b
depth of the brain in both tumors, and was more shifted than Na+
e , which
+
was encountered around 0.5-1 ppm. The Nai peak was observable at 0 ppm.
Similar spectroscopic patterns are observed throughout all voxels in vivo. See
Figure 4.5 for detailed comparison of voxels inside and outside these tumors.
All spectra were magnitude-corrected and line-broadened by 10 Hz. . . . . . . 131

+
4.7 Spatial distributions of compartmentalized 23 Na signals (Na+
, Na+
e , Nai ) as
b
well as transendothelial (ΔNa+
) and transmembrane (ΔNa+
mem ) gradients
end
1
in an RG2 tumor. The high-resolution H-MRI data are shown in the left four
columns, whereas the lower resolution 23 Na-MRSI data are shown in the next
five columns on the right. The left column shows the tumor location (white
outline) on the anatomical 1 H-MRI (left), whereas the next two columns show
the 𝑇2 maps (range shown: 0-100 ms) before and after TmDOTP5− injection,
and the subsequent column depicts the Δ𝑅 2 map (i.e., difference between
1/𝑇2 maps before and after, range shown: 0 – 30 s−1 ), which is proportional
to [TmDOTP5− ] in healthy and tumor tissues. Since Δ𝑅 2 values are more
heterogeneous within the tumor, the 23 Na-MRSI data are needed to separate
the blood and extracellular compartment signals for the tumor. Since the
integral of each 23 Na peak represents the [Na+ ], the respective three columns
∫
+
+
+
+
show
the
integral
maps
of
Na
,
Na
,
and
Na
from
left
to
right
(i.e.,
e
i
b
∫
∫
∫
∫ Nab ,
+
+
Na+
Na+
The last two
e,
i ). ∫
∫ columns
∫ on the right show 𝑑 = Nab − Nae
and ΔNa+
Na+
Na+
map reveals low values in healthy
Na+
mem =
e −
i . The
b
tissue compared to tumor tissue,
and within the tumor boundary a high
∫
degree of heterogeneity. The Na+
e map reveals low values in tumor and
normal tissues, but within the tumor boundary a small degree of heterogeneity
∫
is visible while ventricular voxels show very high values. The Na+
i map
reveals low values ubiquitously except some ventricular voxels. The ΔNa+
end
+
map reveals dramatically high values
within
the
tumor
only.
The
Δ
Na
was
end
∫
driven primarily by an increase of Na+
inside
the
tumor
and
which
was
more
b
pronounced in superficial regions of the brain compared to deeper slices. The
ΔNa+mem map shows low values in tumor tissue compared to normal tissue,
although ventricular voxels
show very high values. The ΔNa+
mem is driven
∫
+
primarily
∫ by decreased Nae and thus shows similar level of heterogeneity
as the Na+
e map. All maps use the same color scale and are relative. See
Figure 4.8 for an example for a U87 tumor. . . . . . . . . . . . . . . . . . . . . 132

+
4.8 Spatial distributions of compartmentalized 23 Na signals (Na+
, Na+
e , Nai ) as
b
well as transendothelial (ΔNa+
) and transmembrane (ΔNa+
mem ) gradients
end
1
in a U87 tumor. The high-resolution H-MRI data are shown in the left four
columns, whereas the lower resolution 23 Na-MRSI data are shown in the next
five columns on the right. The left column shows the tumor location (white
outline) on the anatomical MRI (left), whereas the next two columns show
the 𝑇2 maps (range shown: 0-100 ms) before and after TmDOTP5− injection,
and the subsequent column depicts the Δ𝑅 2 map (i.e., difference between
1/𝑇2 maps before and after, range shown: 0-30 s−1 ), which is proportional
to [TmDOTP5− ] in healthy and tumor tissues. Since Δ𝑅 2 values are more
heterogeneous within the tumor, the 23 Na-MRSI data are needed to separate
the blood and extracellular compartment signals for the tumor. Since integral
of 23 Na peak in each compartment represents the [Na+ ], the respective three
+
+
+
columns
∫
∫ show the
∫ integral maps of Nab , Nae , and Nai from left to right (i.e.,
+
+
+
on the ∫right show the ΔNa+
end
∫Nab , Na
∫ e , Nai ). The last two
∫ columns
∫
+
+
+
+
+
Na
Na
Na
Na
= Na+
and
Δ
Na
=
.
The
map
reveals
low
e
e
mem
i
b
b
values in healthy tissue compared to tumor tissue, ∫and within the tumor
boundary high degree of heterogeneity is visible. The Na+
e map reveals low
values in tumor and normal tissues, but within the tumor boundary small
degree of heterogeneity
is visible while ventricular voxels show very high
∫
+
values. The Nai map reveals low values ubiquitously except some ventricular
voxels. The ΔNa+
map reveals dramatically high values within
the tumor
end
∫
+
+
only. The ΔNaend was driven primarily by an increase of Nab inside the
tumor and which was more pronounced in superficial regions of the brain
compared to deeper slices. The ΔNa+
mem map shows low values in tumor tissue
compared to normal tissue, although ventricular∫ voxels show very high values.
The ΔNa+
by decreased Na+
mem is driven primarily
e and thus shows similar
∫
+
level of heterogeneity as the Nae map. All maps use the same color scale and
are relative. See Figure 4.7 for an example for a RG2 tumor. . . . . . . . . . . . 133

+
4.9 Coronal projections of compartmentalized 23 Na signals (Na+
, Na+
e , Nai ) as
b
well as transendothelial (ΔNa+
) and transmembrane (ΔNa+
mem ) gradients
end
1
in an RG2 tumor. (a) Axial H-MRI indicating the tumor (white outline) across
slices (same as Figure 4.7), where the yellow line indicates the position for a
+
coronal projection. (b) Spatially varying 23 Na signals for Na+
, Na+
e , and Nai are
b
shown with blue, orange, and yellow lines, respectively, where the vertical black
lines indicate the tumor boundary. The Na+
signal (blue) is clearly elevated
b
in the tumor, and most elevated in slices 1-4 (or superficially). Behavior of
Na+
signal (blue) is inversely related to Na+
e signal (orange), which is high
b
outside the tumor and weaker inside the tumor. While intratumoral Na+
signal
b
+
(blue) is high in slices 1-4, the peritumoral Nae signal (orange) is highest in
slices 3-4. Comparatively, the Na+
i signal (yellow) does not vary significantly
across slices, but slightly lower inside the tumor than outside the tumor. (c)
+
Behaviors of ΔNa+
mem (green) and ΔNaend (magenta) signals closely mimic
+
patterns of Na+
e and Nab signals, respectively, indicating that each of those
Na+ compartments is the primary driver of the respective Na+ gradient. See
Figure 4.10 for a similar example for a U87 tumor. . . . . . . . . . . . . . . . . 134
+
4.10 Coronal projections of compartmentalized 23 Na signals (Na+
, Na+
e , Nai ) as
b
+
+
well as transendothelial (ΔNaend ) and transmembrane (ΔNamem ) gradients in
an U87 tumor. (a) Axial MRI indicating the tumor (white outline) across slices
(same as Figure 4.8), where the yellow line indicates the position for a coronal
+
projection. (b) Spatially varying 23 Na signals for Na+
, Na+
e , and Nai are shown
b
with blue, orange, and yellow lines, respectively, where the vertical black lines
indicate the tumor boundary. The Na+
signal (blue) is clearly elevated in the
b
tumor, and most elevated in slice 3 (or medially). This pattern is similar for
Na+
e signal (orange) but the elevation is outside the tumor. Thus behavior of
Na+
signal (blue) is inversely related to Na+
e signal (orange). Both intratumoral
b
+
+
Nab signal (blue) and peritumoral Nae signal (orange) are highest in slices 3.
The Na+
i signal (yellow) varies slightly across slices. It is highest in slices 1-2,
+
and negligible in slice 3-5. (c) Behaviors of ΔNa+
mem signal (green) and ΔNaend
+
signal (magenta) closely mimic patterns of Na+
e and Nab signals, respectively,
indicating that each of those Na+ compartments is the primary driver of the
respective Na+ gradient. See Figure 4.9 for a similar example for a RG2 tumor. 135

4.11 Statistical comparisons between intracellular, extracellular, and vascular
23
compartments across RG2, U87, and
Na-MRSI and 1 H∫ U251
∫ tumors with
∫
+
DCE-MRI. (a) Relation between Na+
, Na+
e and ∫ Nai across tumor and
b
healthy tissues. For the RG2 and U87 tumors, the Na+
values were sigb
nificantly
higher than normal tissue ( 𝑝 < 0.005, #). Also for these tumors,
∫
+
the Nae values were significantly lower than normal tissue ( 𝑝 < 0.05, *).
The mean values for the U251 tumor roughly followed the same trend but
were
not significant. Furthermore, there was no significant difference between
∫
+
Nai values in tumor and normal tissues for any of the three tumor types. (b)
Relations between tumor and normal tissues for ΔNa+
and ΔNa+
mem for the
end
+
three tumor types. Tumor ΔNaend values were significantly larger than normal
values ( 𝑝 < 0.005, #), which were non-positive (data not shown). Moreover,
ΔNa+end in RG2 and U87 tumors was significantly greater than in the U251
tumor ( 𝑝 < 0.05, *), indicative of vascular differences between the tumor types.
ΔNa+mem values were, on average, weaker in tumor compared to normal tissue,
but significant only in RG2 and U87 tumors ( 𝑝 < 0.05, *). Based on Figure 4.9
and Figure 4.10, it is clear that the relation between ΔNa+
and ΔNa+
mem is
end
1
trans
negative. (c) H-DCE-MRI data for 𝐾
and 𝑣 𝑝 values, which are known to
reveal information regarding
vascular structure and function. 𝐾 trans follows
∫
the same patterns as Na+
and ΔNa+
across tumor types. 𝐾 trans ( 𝑝 < 0.005,
b
end
#) and 𝑣 𝑝 ( 𝑝 < 0.05, *) were both significantly larger in RG2 and U87 tumors,
compared to U251. See Figure 4.12 for the 𝐹𝑝 and 𝑣 𝑒 1 H-DCE-MRI parameters
for each tumor type. See Figure 4.13 for exemplary maps of 1 H-DCE-MRI
parameters for individual animals from each tumor type. . . . . . . . . . . . . 136
4.12 Comparisons of 𝐹𝑝 and 𝑣 𝑒 1 H-DCE-MRI parameters between RG2, U87 and
U251 tumors. For all tumor types, mean 𝐹𝑝 values (left) closely followed
patterns for 𝐾 trans (see Figure 4.11c), but there was only a marginally significant
difference between tumor types. There was also no significant difference
between 𝑣 𝑒 values (right) for the different tumor types. These values, however,
are smaller than the observed 𝑣 𝑝 values (see Figure 4.11c), which suggests that
the vascular portion of all tumor types studied dominates over the interstitial
space. See Figure 4.13 for exemplary maps of 1 H-DCE-MRI parameters for
animals from each tumor type. . . . . . . . . . . . . . . . . . . . . . . . . . . . 137

4.13 Exemplary maps of 1 H-DCE-MRI parameters from representative animals
from each tumor type. 1 H-DCE-MRI parameters were calculated only for the
tumor, and overlaid on 𝑇1 -weighted anatomical images. Values for 𝐾 trans and
𝐹𝑝 are reported in 10−3 min−1 . As measures of vascularity, these values reveal
heterogeneity throughout all three tumor types, but overall significantly larger
values are present for RG2 and U87 relative to U251 (see Figure 4.11c). Small
regions with low 𝐾 trans and 𝐹𝑝 near the center of the U251 tumor suggest areas
of low perfusion and are indicative of a necrotic core, which U251 tumors have
been shown to have. Furthermore, 𝑣 𝑝 values tend to be larger throughout the
tumor compared to 𝑣 𝑒 which suggests the large presence of vasculature within
tumor tissue. The necrotic core in U251, defined by the low-𝐹𝑝 region within
the tumor, shows a corresponding region of elevated 𝑣 𝑒 suggesting the lack of
vasculature in areas with low perfusion. These findings help to confirm the
elevated Na+
signals observed in 23 Na-MRSI are consequences of enhanced
b
vascularity. See Figure 4.11c for the distribution of 𝐾 trans and 𝑣 𝑝 values, and
Figure 4.12 for the distribution of 𝐹𝑝 and 𝑣 𝑒 values. . . . . . . . . . . . . . . . . 138
+
4.14 Representative maps of compartmentalized 23 Na signals (Na+
, Na+
e , Nai ) as
b
well as transendothelial (ΔNa+
) and transmembrane (ΔNa+
mem ) gradients
end
in U251, U87, and RG2 tumors. The left column shows the tumor location
(white outline) on the anatomical 1 H-MRI for animals bearing
∫ (a) U251,
∫ (b) U87
+
+
and
∫ (c) RG2 tumors. The respective three columns show Nab , Nae , and
+
+
Na+
i maps. The last two
∫ columns on
∫ the right show the ΔNaend and ΔNamem
maps. In all tumors the Na+
and Na+
e are high and low, respectively, and
b
thus are the main drivers for a high ΔNa+
and a low ΔNa+
mem . . . . . . . . . 139
end
5.1 Demonstration of 23 Na line broadening with TmDOTP5− . (a) 1 H MRI of
an exemplary brain slice from a U87-bearing rat overlaid with 23 Na-MRSI
(red), with (b) spectra before (black) and after (green) TmDOTP5− infusion
from a tumor voxel (brown square in (a)). The black and green spectra are
before (Γ0 ) and after (ΓTm ) TmDOTP5− infusion. Γ0 and ΓTm maps for the
slice are displayed in (c) and (d) where the colors represent different extent
of line broadening in ppm units, while the difference of these (ΔΓTm ) are
shown in (e). The transendothelial (ΔNa+
) and transmembrane (ΔNa+
mem )
end
+
Na gradients are displayed in (f) and (g). Finally the inverse transmembrane
Na+ gradient map (1/ΔNa+
mem ) is shown in (h). In all images, the tumor
boundary is outlined in white and the brown square indicates the voxel shown
in (b). Broadening was observed more strongly in the tumor than outside,
although broadening was observed peritumorally as well. TmDOTP5− -based
broadening was confounded by the fact that separation into three peaks resulted
in abnormally large linewidths, in part due to significant shifting as well. All
data are from the same rat. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150

5.2 Demonstration of 23 Na line broadening with GdDOTP5− . (a) 1 H MRI of brain
slices from a U87-bearing rat overlaid with 23 Na-MRSI (red), with linewidth
maps (b) before (Γ0 ) and (c) after (ΓGd ) GdDOTP5− infusion. The change in
linewidth (ΔΓ = ΓGd − Γ0 ) is shown in (d). In all columns, the tumor boundary
is outlined in white. Slice 1 is the most superficial slice, while slice 3 is the
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Notation
The next list describes several symbols that will be later used within the body of the
document.
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ΔNa+end Transendothelial sodium gradient
ΔNa+mem Transmembrane sodium gradient
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Introductory Information

Introduction to Cancer
Physiology

Cancer is a disease typified by aberrant proliferation of cells,
which can have far-reaching consequences for a patient’s life.
Over the years, cancer has risen to become the second-leading
cause of death in the world – next, only, to cardiovascular
disease[1]. Every sixth death in the world is due to some
kind of cancer, and 2017 witnessed almost 250,000 deaths
due to brain and nervous system cancers alone. While global
incidence of malignant brain tumors is on the rise, standard
therapies like surgical resection, chemotherapy and radiation
have not improved for several decades[2]. Glioblastoma multiforme (GBM) in particular, comprising 57% of all gliomas,
exhibits an incidence of 9.23 per 100,000 in the United States,
with a 1-year average survival rate of only 41.4% and median
survival rate of only 15 months in patients who receive treatment[3]. Long-term prognosis is poor, and despite advances
in diagnostics and therapy, GBM has undoubtedly devastating impacts on patients, physicians, and their families.
While there is no definite association for GBM onset with
any particular risk factors, the patient population generally
skews towards older individuals, with a higher incidence in
men[4].

1.1 Clinical Markers of Brain Tumors
and Therapies
Gliomas are solid tumors of the brain primarily comprising
glial cells and astrocytes. The World Health Organization
(WHO) has developed tumor classification schemes based
mainly on histology, which divides general gliomas into four
grades. In general, patient prognosis and survival shorten
with increasing tumor grade, where GBM belongs to grade
IV, and lower-grade gliomas have the potential to become
malignant GBMs. Gliomas also tend to resurge even after
treatment, and almost nearly at the initial location of tumor
onset. Certain GBM biomarkers have been identified which
can enhance patient prognosis, such as genetic mutations in
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isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2), or methylation of the deoxyribonucleic acid (DNA) repair enzyme
O6-methylguanine-DNA-methyltransferase (MGMT)[5, 6].
IDH1 and IDH2 are responsible for converting isocitrate
to alpha-ketoglutarate ( 𝛼 KG) through oxidative decarboxylation in the Krebs cycle during energy metabolism, and
various mutations of either enzyme can result in atypical
phenotypes which set the stage for tumorigenesis[7]. These
enzymes also participate in glutamine metabolism, lipogenesis, and oxidation-reduction regulation. IDH1 is generally
located in the cytoplasm and peroxisomes, whereas IDH2 is
located in the mitochondria[8]. The active sites on these two
isoforms display an affinity for isocitrate (the main substrate)
in addition to nicotinamide adenine dinucleotide phosphate
(NADP+ ) and a divalent metal ion, usually Mg2+ or Mn2+ .
Altogether, these result in the conversion of isocitrate to 𝛼 KG.
There is a third IDH isoform (IDH3) which also resides in the
mitochondria and catalyzes the formation of 𝛼 KG but instead
employing nicotinamide adenine dinucleotide (NAD+ ). IDH
mutations are prevalent in GBM, albeit more so in secondary
GBM (comprising 73% of clinical cases) than in primary
(comprising 3.7%)[9]. Cancer-associated IDH mutations are
found on an arginine (R) residue in the binding domain
that is crucial for isocitrate recognition (R132 for IDH1, and
R140/R172 for IDH2)[10]. Usually, this arginine is replaced by
a lower-polarity amino acid such as cysteine, histidine, or lysine, inhibiting the ability to hydrogen bond with isocitrate’s
𝛼 - and 𝛽-carboxyl groups and overall lowering isocitrate
affinity[11, 12].
These IDH mutations in tumors, however, tend to confer
favorable disease outcomes compared to wild-type. IDH
enzymes require homodimerization to enable catalysis[13],
but tumor cells usually only contain one mutant copy of the
IDH gene. This is because IDH homodimers in homozygousmutant tumors are completely inactive. Therefore, tumors
with heterozygous IDH mutations usually exhibit IDH heterodimers where one is wild-type and the other mutated.
This results in the wild-type IDH correctly converting isocitrate to 𝛼 KG, but the mutant IDH erroneously converts
𝛼 KG to D-2-hydroxyglutarate (D-2-HG)[14], which disrupts
the Krebs cycle and the oxidative phosphorylation pathway. Compensatory pathways, however, are known to take
effect. Glutamate dehydrogenase 2 (GDH2) is an enzyme
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which converts glutamate directly to 𝛼 KG, and is present
in high concentrations in the brain[15]. The fact that GDH2
helps to counteract 𝛼 KG depletion in IDH-mutant tumor
cells is corroborated in studies which show these cells to
be more sensitive to glutaminase inhibition (i.e., glutamate
synthesis from glutamine is downregulated)[16]. Moreover,
IDH-mutant gliomas do not express lactate dehydrogenase
A (LDHA)[17, 18], which converts glycolytic pyruvate to
L-lactate and suppresses glycolysis in addition to the alreadysuppressed oxidative phosphorylation pathway[19]. D-2-HG
is also known to suppress DNA repair pathways[20–22].
Current standards for D-2-HG measurement involve in vitro
staining and chromatographic assays[23–25]. However, in
vivo proton (1 H) magnetic resonance spectroscopy (MRS),
which will be explained in Chapter 2, is widely used to noninvasively measure regional D-2-HG levels[26, 27]. Overall,
these metabolic hindrances caused by IDH mutations explain why IDH-mutant gliomas grow more slowly compared
to IDH wild-type gliomas[17, 28], and why they are more
sensitive to radiation and chemotherapies[29–31].
There have been a great number of therapeutic approaches
used to alleviate the biochemical complications of IDHmutant gliomas. Several drugs directly target the mutant
enzyme, such as AGI-5198[32] (impairs D-2-HG production),
ivosidenib, and vorasidenib (FDA-approved for IDH-mutant
acute myeloid leukemia)[33], which are also under consideration for GBM treatment[34]. However, other studies have
shown that these direct therapies have limitations, such as the
possibility of repairing DNA damage to the tumor cells[21,
35]. Thus, other therapies targeting different aspects of IDHmutant gliomas have been sought, such as surviving DNA
repair mechanisms that are not been inactivated by D-2-HG.
An example of this includes inhibition of the poly-ADP ribose
polymerase (PARP), a common chemotherapy target[21, 36,
37].
Furthermore, MGMT, a DNA repair enzyme, reverses the
naturally occurring methylation of guanine residues at the O6
position to prevent errors during DNA replication and transcription, but also protects cancer cells by the same measure.
MGMT is encoded by the MGMT gene, a 30-kbp sequence
located on chromosome 10q26.3[38, 39], whose expression
is generally determined by epigenetic factors[40]. For example, the main reason for MGMT downregulation has been
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hypermethylation of the 762-bp CpG island on the MGMT
promoter region[41–45]. Under normal (i.e., unmethylated)
conditions, initiation of MGMT transcription occurs at four
precise locations, each with a particular nucleosome-like
structure. CpG island methylation yields rearrangement
and randomization of nucleosomes which upsets gene transcription[46, 47] and inhibits promoter access of transcription factors like Sp1[48]. Regardless of tumor heterogeneity,
MGMT expression can be detected using immunohistochemistry[40]. To date, there are still no suitable non-invasive
in vivo methods to measure MGMT. Clinically, however,
methylation-specific polymerized chain reaction is used to
assess MGMT promoter methylation[49–51].
MGMT methylation specifically in tumor cells can inhibit
MGMT activity and confer a favorable prognosis to patient
outcomes. Temozolomide (TMZ) is a well-known alkylating agent which is part of regular chemotherapy regimens
and targets several DNA moieties[52], the most prevalent
being the O6 position on guanine residues. MGMT will reverse DNA lesions of this kind as part of the natural repair
mechanism, but in tumor cells can counteract TMZ activity.
Therefore, MGMT promoter methylation in tumors will stifle MGMT expression and increase sensitivity to TMZ[53].
Clinically, MGMT profiling (i.e., determining whether the
cancer is MGMT-positive or MGMT-negative) provides a
good assessment of aggressiveness, survival and sensitivity to alkylating chemotherapies. Clinical trials have also
confirmed that MGMT promoter methylation can predict
GBM patient prognosis well in groups that receive both
TMZ and radiotherapy as opposed to the latter alone[54,
55]. Therefore, therapies that inhibit the MGMT protein itself are also of interest. O6 -benzylguanine, for example, is a
low-molecular-weight analog of O6-methylguanine which
can pass the blood-brain barrier (BBB), a strong network
of tight junctions which prevents the extravasation of most
substances circulating in the blood into the brain tissue except water and certain gases (like O2 )[56]. O6 -benzylguanine
still has affinity for MGMT due to similar structure to O6methylguanine, but can inactivate MGMT through transfer
of an alkyl group and ultimately make the tumor cell more
vulnerable to TMZ[57, 58]. Also, it was shown that TMZ in
the presence of O6 -benzylguanine has resulted in delayed tumor recurrence[59], and a combination therapy of TMZ and
O6 -benzylguanine has shown promising effects for a variety
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of cancers in clinical trials[60–63]. MGMT and methylation
of its promoter region play inextricable roles in GBM and
our understanding of clinical prognoses have been improved
due to the large number of studies done on this system.
There are other anomalous molecular pathways as well during GBM progression, such as changes in receptor tyrosine
kinase signaling and p53 pathways[64]. Furthermore, there
are developmental biomarkers which can suggest the onset of GBM from so-called “cancer stem cells” (CSCs) that
exhibit putative biomarkers like expressions of CD133 and
CD44 (among others), though these have found more applications in preclinical research than in the clinic[65]. Even a
small amount of residual CSCs following efficacious tumor
treatment can still be activated to initiate a new cycle of
differentiation and GBM progression[40]. Thus, CSCs are
often implicated in the recurrence of cancers. CD133+ cells
actually have demonstrated high MGMT expression and
TMZ resistance[66, 67], but there is still compelling evidence
that not all CSC lines express MGMT[68]. There are also
studies that demonstrate gradual loss of MGMT expression
and concomitant TMZ sensitivity for more differentiated
glioma stem cells[69, 70]. There is still more to be discovered regarding CSCs especially in the context of gliomas to
provide more conclusive results.
GBM generally is initially diagnosed with imaging, often
using computed tomography (CT) or magnetic resonance
imaging (MRI)[71]. However, it is usually detected unintentionally during scans commissioned for other reasons, or
screened for after serious symptoms have started occurring.
For example, tumor growth and progression cause compression of surrounding brain tissue, which in turn can produce
neurological issues. Therefore, the lack of early detection
means that tumors will most likely be large (greater than 1
cm in diameter) upon diagnosis. While imaging can certainly
alert the patient and the physician of the possibility of cancer,
only a true validation can confirm an official diagnosis. Usually, this validation comes in the form of biopsy or surgical
resection of the problematic region[72].
As mentioned previously, standard treatment regimens for
GBM include surgical resection, chemotherapy and radiation therapy. Notwithstanding these treatments, GBM still
presents poor prognosis. This can be attributed to a variety of
reasons, such as the strong invasiveness, which has become
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a GBM hallmark, and thus complete surgical resection is
near impossible. The goal of resection is to remove as much
of the compromised tissue as possible without disrupting
neurological function[73]. This method is palliative at best,
since the infiltrating tumor cells at the periphery of the tumor region are hard to identify and remove. The existence of
these limitations speaks to the need for superior techniques
of delineating tumor margins, or at least regions of infiltrating tumor cells, which at present is quite challenging[74].
The BBB provides a major barrier for chemotherapy. Thus,
chemotherapeutic agents are not readily delivered to these
regions of invading tumor cells, although the BBB in the solid,
mature tumor is leaky and can be targeted more readily. As
was discussed, TMZ is the most common chemotherapy,
but can be rendered less effective in MGMT-positive presentations of GBM. Following these avenues of treatment,
radiation therapy can be administered, usually focused to a
particular region[75].

1.2 Overview of Electrolyte Balance
One of the hallmarks of a normal, healthy cell is the ability to maintain large differences in ionic concentrations
across the plasma membrane – namely, those of sodium
(Na+ ), potassium (K+ ), and chloride (Cl− ). The extracellular
−
space is abundant with Na+ and Cl− (Na+
e , Cle ≈ 150 mM
each) but low in K+ (K+
e ≈ 15 mM), while the intracellular
−
space exhibits reversed conditions (Na+
i , Cli ≈ 15 mM each,
K+
e ≈ 150 mM). These strong transmembrane gradients
−
+
(ΔNa+
mem , ΔKmem , ΔClmem ) between the extracellular and intracellular spaces are responsible for many processes such as
action potentials (APs), muscle contractions, and osmoregulation. Furthermore, the ionic composition of the blood
compartment closely mimics that of the extracellular space
(Na+
, Cl−b ≈ 150 mM each, K+b ≈ 15 mM), resulting in norb
mally weak transendothelial gradients (ΔNa+
, ΔK+end , ΔCl−end )
end
across the blood vessel wall. In the context of brain tissue,
these transendothelial gradients support the integrity of the
BBB.
The strengths of these naturally occurring transmembrane
and transendothelial gradients arise due to the equilibrium
between many charged species in vivo. As a result, these
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gradients are responsible for the ultimate electric potential
differences across the cell membrane. The membrane potential (𝑉𝑚 ) is determined by a logarithmic dependence on ion
concentrations:

𝑃𝑁 𝑎 [Na+ ]e + 𝑃𝐾 [K+ ]e + 𝑃𝐶𝑙 [Cl− ]i
𝑅𝑇
𝑉𝑚 =
ln
𝐹
𝑃𝑁 𝑎 [Na+ ]i + 𝑃𝐾 [K+ ]i + 𝑃𝐶𝑙 [Cl− ]e




(1.1)

where 𝑅 is the ideal gas constant (8.314 J/mol·K), 𝑇 is the
absolute temperature (K), 𝐹 is the Faraday constant (96.49
kC/mol), 𝑃𝑋 refers to the permeability of ion X, and [𝑋]𝑒/𝑖
refers to the extracellular/intracellular concentration of ion
X. Under normal conditions 𝑉𝑚 = −70 mV. Often, excitable
cells were the only context in which 𝑉𝑚 was studied, since
APs serve as the mechanism by which signals are passed by
neurons in the brain. However, 𝑉𝑚 also plays a role in the
function of non-excitable cells such as regulation of circadian
rhythm[76, 77], hearing[78], and cellular volume control[79,
80].
Integral membrane proteins provide channels for ion fluxes,
which can perturb these gradients but restorative mechanisms exist such that deviations from these electrochemical equilibria are only transient. For example, APs require
rapid depolarization through stimulus-driven Na+ influx
upon opening of voltage-gated sodium channels, and concomitant K+ efflux. However, the concentrations are restored through the adenosine triphosphate (ATP)-dependent
sodium-potassium pump (or Na+ /K+ -ATPase), which simultaneously transports three Na+ and two K+ against their
electrochemical gradients (i.e., Na+ efflux and K+ influx)
through the consumption of ATP. This is achieved by enzymatic conformational changes in the structure of the pump
(between two states: 𝐸1 and 𝐸2 )[81]. The majority of this
ATP is supplied by the Krebs cycle, the favorable oxidative
pathway for healthy cellular metabolism, in which 36 units of
ATP are generated by the oxidation of one unit of glucose.
The Na+ /K+ -ATPase is a very important for energetics. In
gray matter alone, Na+ /K+ -ATPases are involved with ∼ 75%
of the energy supply, while the remainder is sufficient
for all other housekeeping processes such as biosynthesis[82]. The Na+ /K+ -ATPase is a heterotrimeric P-type ATPase, consisting of 𝛼 -, 𝛽 -, and 𝛾 -subunits, with actuator (A),
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nucleotide-binding (N), and phosphorylation (P) domains
(Figure 1.1a), which respectively operate as the phosphatase,
kinase, and the substrate[82]. The 𝛼 -subunit, homologous to
other monomeric P-type ATPases like the sarcoendoplasmic
reticulum Ca2+ -ATPase (SERCA), is primary responsible for
Na+ , K+ , and ATP binding, and spans the plasma membrane.
There are presently four known isoforms of the 𝛼 -subunit,
labeled 𝛼 1 , 𝛼 2 , 𝛼 3 , and 𝛼 4 [83]. The 𝛽 -subunit, located on
the extracellular end of the membrane, is unique to K+ countertransporting P-type ATPases, and helps to route the
𝛼 -subunit to the plasma membrane and to occlude bound
K+ ions[81]. There are also three isoforms of the 𝛽 -subunit,
labeled 𝛽 1 , 𝛽 2 , and 𝛽 3 . Different combinations of the 𝛼 - and
𝛽-subunit isoforms give rise to different Na+ /K+ -ATPase subtypes, which are distributed differently in various tissues[84].
In the brain, the most common combinations are 𝛼 2 𝛽 2 (glia
and astrocytes) and 𝛼 3 with any 𝛽 isoform (neurons)[82]. This
astrocytic and glial 𝛼 2 𝛽 2 combination is one with high voltage
sensitivity and enhanced K+ clearance ability[85, 86], which
confers the efficiency necessary for crucial brain functions
like action potential propagation. In the Na+ /K+ -ATPase,
the only intramolecular interaction is a salt bridge between a
glutamate residue on the A domain and an arginine residue
on the N domain – unlike the SERCA, in which the A and
N domains strongly interact via hydrogen bonds[87]. Because of this difference, the SERCA is more compact near the
cytoplasmic end compared to the Na+ /K+ -ATPase. Moreover, these different geometries affect ATP binding; the ATP
turnover rate for the Na+ /K+ -ATPase is 200 s−1 compared
to 30 s−1 for the SERCA[87, 88], highlighting how efficiently
the Na+ /K+ -ATPase performs its function.
The Na+ /K+ -ATPase is ubiquitously expressed throughout
the body, with most of the previous discussion pertaining to brain-specific isoforms. Outside of the brain, the
Na+ /K+ -ATPase also serves as a receptor for cardiotonic
steroid signaling in addition to its pumping activity[89].
The Na+ /K+ -ATPase is also the target of the toxin ouabain,
which can bind readily to the pump and prevent the 𝐸1 /𝐸2
conformational change necessary for Na+ and K+ transport.
Therefore, the Na+ /K+ -ATPase is fundamental to healthy
cellular electrophysiology, and hĳack of this mechanism can
have devastating consequences in terms of energy failure.
Other Na+ channels exist as well, such as the sodium-proton
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exchanger (NHE) and sodium-calcium exchanger (NCX),
which do not require phosphorylation to function. NHE activity couples Na+ and H+ transport, thereby having effects
on both extracellular and intracellular pH (pHe and pHi ,
respectively)[93–95]. One isoform of this exchanger, NHE1,
has been implicated in tumor acidification and neoplastic
induction[96]. There are 8 other isoforms of NHE, but NHE1
has been studied the most. NHE1 is an integral membrane
protein which extrudes intracellular H+ while importing
extracellular Na+ in a 1:1 fashion, with a Michaelis constant
𝐾 𝑀 of 10 − −50 mM[97]. Therefore, NHE1 will usually be
saturated on the extracellular side regarding Na+ levels. Encoded by the SLC9A gene family, the NHEs are members
of the superfamily of monovalent cation-proton antiporters
(CPA). The 60-kbp SLC9A1 gene which encodes NHE1 is
located on the short arm of chromosome 1 (i.e., 1p36.11)[90].
Human NHE1 weighs approximately 91 kDa, though gel
electrophoresis has shown a range between 90 (for immature,
unmodified proteins) and 110 (for mature and glycosylated
proteins) kDa[98, 99]. It consists of 12 transmembrane segments, with intracellular N- and C-termini. This C-terminal
tail is sensitive to pHi due to an internal H+ binding site, such
that NHE1 is activated when pHi drops below a particular
threshold[97] (Figure 1.1b). In other words, NHE1 naturally
responds by counteracting large intracellular H+ concentrations. The distal part of this tail was shown to be intrinsically
disordered across a variety of vertebrate NHE1, indicative of
the functional role it plays[100, 101].
Conclusive evidence regarding the mechanism of transport
and sensitivity to pHi has not yet been reached. For a while,
an allosteric binding domain for H+ was proposed on a
supposed monomeric NHE1 functional unit[102, 103]. The
binding kinetics favorably aligned with the observed sigmoidal dependence on intracellular H+ concentration and
activation dynamics. However, other mathematical models
indicate that this functional unit may be dimeric, with the
sigmoidal relationship stemming from two binding domains
on this dimer rather than an allosteric monomeric site[104,
105]. The dimer theory was also supported by electron microscopy studies of human NHE1 expressed in Brewer’s yeast
(Saccharomyces cerevisiae)[106].
NHE1 activity can be regulated by various extracellular
stimuli common to both normal and tumor cells, including
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activation of receptors by soluble growth factors and hormones, extracellular ligand receptors like integrins and CD44,
and morphological pressures like cell shrinkage or applied
shear stresses[107–111]. However, certain additional stimuli
are unique for tumoral NHE1[112–118] which constitute a
positive-feedback loop that further produces more extracellular acidification and paves the way for tumor progression.
In breast cancer, for example, tumor cells are activated by
extracellular CD44 which results in extracellular acidification,
which in turn activates NHE1[107]. This self-driving NHE1
activity for interstitial acidification also implies a significant
Na+ influx, which has electrophysiological consequences.
An osmotic effect also results from this, since the net Na+
influx, with negligible change in pHi , yields a higher overall
intracellular osmolarity which requires water influx through
aquaporin channels[119]. When cells were exposed to hyperosmotic solutions, NHE1 activity was quickly upregulated
which resulted in intracellular alkalinization[120].
This cytoplasmic alkalosis is one of the first biomarkers of tumorigenesis, suggesting an inextricable role played by NHEs
in driving neoplastic transformation. Oncogenes exploit the
elevated pHi caused by NHE1 to produce a variety of cancer hallmarks such as elevated growth rates independent
of substrates, aerobic glycolysis (described in more detail
below), and others[93, 121]. Cancer development and invasion necessitate a combination of increased cellular motility
and extracellular remodeling. As a result, tumor cells have
adopted altered membrane characteristics at the migratory
edge[122] to actualize these needs. The main mechanism
by which these needs are met involves the development of
proteolytic invadopodia, which are membrane structures
rich in protease, actin, and 𝛽 1 -integrin to help degrade the
extracellular space[123, 124]. NHE1 has been shown to be
localized to the invadopodia in tumor cells, with its Na+ /H+
operation serving a dual purpose. In addition to its role in
overall cytoplasmic alkalinization, NHE1 also propagates
invadopodia function and formation by respectively acidifying the extracellular end of the invadopodia, which is
crucial to proteolysis of the extracellular space[125], and
alkalinizing the intracellular end of the invadopodia, which
stimulates release of cofilin from cortactin to upregulate
protrusion of invadopodia[116]. This involvement of NHE1
in invadopodia maintenance and function is also facilitated
by cancer-associated hypoxia which promotes invadopodia
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by upregulating serine 703 phosphorylation on NHE1 via
p90RSK[126]. Cellular localization of NHE1 to the invadopodia was confirmed in vivo in a C6-glioma-bearing rat brain
where NHE1 expression was found concentrated at the tumor’s invasive edge whereas other pH-related proteins like
carbonic anhydrase IX and monocarboxylate transporters 1
and 4 were localized in its interior[127].
Inhibition of NHE1 has been a desirable target for cancer therapies. One of the most studied NHE1 inhibitors has been the diuretic drug 3,5-diamino-6-chloro-N-(diaminoethylene)pyrazinecarboxamide,
otherwise known as amiloride, and its structural derivatives.
Although amiloride inhibits NHE1 most strongly, NHE2
and NHE5 also have displayed sensitivity[128]. Furthermore,
while amiloride is effective for NHE1, it is relatively nonspecific and also affects other non-NHE Na+ transport channels. However, other amiloride-based drugs have shown
both higher efficacy for NHE1 inhibition and improved specificity for NHE1, such as dimethylamiloride (DMA) and Nethylisopropylamiloride (EIPA)[129]. These were achieved by
double substitutions of R5 and R’5 nitrogens on the 5-amino
pyrazine of amiloride. More drastic alterations, such as the replacement of the entire pyrazine by pyridine or phenyl rings,
resulted in 36- and 54-fold higher NHE1 inhibition while also
improving NHE1 specificity[130]. Simultaneous replacement
of the 6-chloro group by a sulfomethyl and the removal of
the 2-amino (or replacement by a methyl) group resulted
in a class of inhibitors with the benzoylguanidine group
such as cariporide[131], eniporide[132], and BIIB-513[133]. At
present, only amiloride, cariporide, and eniporide have gone
through clinical trials, and the latter two were for ischemicreperfusion injury rather than cancer. However, cariporide
shows promise for cancer therapy as its activity is enhanced
by the low extracellular pH that is common to tumors[97].
Cariporide’s efficacy is related to the charge on the guanidine
group (p𝐾 𝑎 = 6.28), so tumor acidity will actually increase
its potency to inhibit NHE1[129, 134–136]. In fact, its median
inhibitory concentration (IC50 ) for NHE1 is 22 nM at a pHe
of 6.2, versus 120 nM at pHe 6.7[137]. In these ways, the NHE
family (and especially NHE1) plays a very important role in
tumorigenesis and is responsible for altered Na+ levels in
tumors.
NCX is also a sodium channel whose role in cancer is recently
being discovered. It is found in the most cells, and counter-
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transports Na+ and Ca2+ in a 3:1 ratio[92] in either direction.
It is primarily part of the Ca2+ transport system and serves
to export intracellular Ca2+ (the so-called “forward-mode”)
utilizing the energy of the Na+ influx brought about by the
Na+ /K+ -ATPase. The first isoform, NCX1, was isolated and
cloned from cardiac sarcolemma[138, 139]. It was initially observed to have 12 transmembrane segments, similar to NHE1.
However, later studies showed that an initial hydrophobic
segment was cleaved during processing in the endoplasmic
reticulum, leaving only 9 transmembrane segments spanning
a total of 938 amino acids in length[140]. The N-terminal
hydrophobic region contains 5 of these segments, and the
remaining 4 belong to the C-terminal hydrophobic region
(Figure 1.1c). These transmembrane segments are primarily
involved in facilitating the Na+ -Ca2+ exchange, but other
domains in the structure like a large intracellular loop exhibit regulatory function of NCX1. NCX1 expression has
been found ubiquitous across mammalian cells[141, 142],
but isoforms NCX2 and NCX3 are expressed predominantly
in the brain, particularly in the cerebellum and the hippocampus[143–145], and also have interesting connections to
gliomas.
The importance of NCX1 in tumor development has started to
become more evident. NCX1 expression is regulated by transcription factors like zinc finger transcription factor (Zn3-Sp1),
nuclear factor 𝜅 B (NF-𝜅 B), hypoxia-inducible factor 1 alpha
(HIF1 𝛼 ) and cyclic adenosine monophosphate (cAMP) response element binding protein (CREB), which are activated
in tumor cells[146]. Since GBM initially becomes hypoxic,
HIF1 𝛼 involvement in NCX1 gene transcription is not unusual.
Hypoxia-stimulated NCX1 expression is well documented
in tumors[147, 148]. Recent evidence also demonstrates that
in solid tumors, NCX1 acts in “reverse-mode,” meaning it
exports Na+ and imports Ca2+ as opposed to extruding the
latter in forward-mode. The high metabolic activity of solid
tumors results in the rapid development of hypoxic domains,
which produce large amounts of acid and lactate, causing
pHi and pHe changes via NHE1 as discussed earlier. The
large Na+ influx resulting from the upregulated NHE1 activity requires additional machinery to renormalize Na+ levels.
In addition to the aforementioned water transport through
aquaporins, reverse-mode NCX1 activity also contributes to
this. Reverse-mode NCX1 activity can also be a consequence
of altered Na+ /K+ -ATPase behavior in tumors, resulting
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from upregulated activity of extracellular signal-regulated
kinase 1 and 2 (ERK1 and ERK2), although conclusive evidence of interactions between the two is yet to be found[146].
Furthermore, reverse-mode NCX1 operation has been stimulated by the drug 1-[-[3-(4-methoxyphenyl)propoxyl]-4methoxyphenethyl]-1H-imidazole hydrochloride, or SKF96365,
which suppresses GBM growth by blocking transient receptor potential canonical (TRPC) channels, thereby inhibiting
Ca2+ entry[149, 150]. The compensatory NCX1 response is
therefore to operate in reverse-mode to increase intracellular
Ca2+ concentration.
Although NCX1 has been much more extensively studied,
the NCX2 and NCX3 isoforms also show involvement in
tumorigenesis. For example, baby hamster kidney cells transfected with NCX3 exhibited superior resistance to hypoxia
compared to those transfected with NCX1 or NCX2, suggesting a protective role played by NCX3 during tumor-induced
hypoxia[151]. Moreover, dynamic sub-cellular localization
of NCX3 was observed during the cell cycle. During interphase, NCX3 is found in the endoplasmic reticulum and
nuclear membrane, whereas during less quiescent phases
(S-phase, mitosis, and cell division), NCX3 is found in the
plasma membrane. A possible mechanism for this intracellular translocation is by N-linked glycosylation at asparagine
(N) residue N45[152]. NCX3 activity is further regulated by
protein kinase A (PKA, dependent on cAMP), and protein
kinase C (PKC, dependent on Ca2+ and/or diacylglycerol).
PKA and PKC both downregulate reverse-mode NCX3 operation, although PKC does not affect forward-mode. PKA, on
the other hand, can affect forward-mode activity that results
from elevated intracellular Ca2+ levels in two NCX3 variants
(NCX3-AC and NCX-B) which are products of alternative
splicing of the relevant gene. This phenomenon is relevant
for long-term potentiation in the hippocampus[153]. NCX3,
therefore, plays an interesting role in tumors. NCX3 expression and activity were shown to be higher in human ovarian
cancers and medulloblastomas, and linked to chemotherapeutic resistance. Additionally, apoptosis was enhanced
when NCX3 was inhibited[154]. These observations illustrate the relationship between NCX3 and cell survival, an
imperative feature for tumor cells. For gliomas in particular, suppression of the solute carrier family 8, member 2
(SLC8A2) gene, which encodes NCX2, may be involved in
cancer progression. Genetic anomalies are typical for gliomas,
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which most frequently manifest as deletions on the long arm
of chromosome 19, which is where SLC8A2 is located[155].
Therefore, SLC8A2 may be a tumor suppressor gene whose
downregulated transcription confers survival to GBM. Overall, understanding of NCX activity in tumor physiology and
metabolism is nascent relative to NHE which was discovered
earlier and has been much more extensively studied. However, based on current knowledge, NCX has the potential to
provide a possible route of cancer therapy.
In addition to these channels described, there are other
voltage-gated sodium channels (Nav s) which selectively
transport Na+ only and whose opening/closing is mediated by Vm. They are also transmembrane proteins like the
aforementioned transporters, composed of a large subunit
(Nav 𝛼 ) which makes up the channel pore, and one or two
smaller 𝛽 subunits (Nav 𝛽 ), which may be either the same or
different[156]. In humans, there are nine Nav 𝛼 isoforms, labeled Nav 1.1 to Nav 1.9, respectively encoded by the following
nine genes: SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A,
SCN9A, SCN10A, and SCN11A[157]. Nav 1.1-Nav 1.3 and Nav 1.6
are primarily expressed in the central nervous system, while
Nav 1.7-Nav 1.9 are in the peripheral nervous system. Nav 1.4
is the primary channel of skeletal muscle, and Nav 1.5 is of
the heart[92]. It is also possible to find these channels outside
of their primary tissues. There is a tenth structurally similar
protein involved in salt sensing but is not voltage-gated[158].
Each Nav 𝛼 consists of four mutually homologous domains,
labeled I-IV, each of which possesses six transmembrane
𝛼 -helices, labeled S1-S6[159]. The S1-S4 helices on each domain make up the voltage-sensitive region, while S5 and S6
(connected by an extracellular P loop) constitute the main
pore[160]. Likewise, there are five Nav 𝛽 isoforms, labeled
𝛽1 , 𝛽 1B , 𝛽 2 , 𝛽 3 , and 𝛽 4 and encoded by SCN1B (for 𝛽 1 and
𝛽1B )[161–163], SCN2B (for 𝛽 2 )[164], SCN3B (for 𝛽 3 )[165], and
SCN4B (for 𝛽 4 )[166]. All Nav 𝛽 except 𝛽 1B consist of one transmembrane 𝛼 -helix and a short intracellular region. All five
isoforms facilitate Nav 𝛼 localization in the plasma membrane
and also regulate the activation/inactivation 𝑉𝑚 thresholds
along with the inactivation kinetics[167]. They also influence
the pharmacological sensitivity of Nav 𝛼 subunits, such as the
efficacy of lidocaine[168] and conotoxins[169, 170] on Nav 𝛼
functionality.
Moreover, just as ouabain is toxic to the Na+ /K+ -ATPase,
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tetrodotoxin (TTX) is toxic to Nav s. Specifically, TTX binds to
amino acids on the P loop between S5 and S6 and reduces
Na+ permeability through the pore[171–173]. Nav 1.1-Nav 1.7
(excluding Nav 1.5) are called “TTX-sensitive” since they can
be blocked even by low concentrations (i.e., nM range) of TTX.
Conversely, Nav 1.5, Nav 1.8, and Nav 1.9 are the “TTX-resistant”
sodium channels since they are inhibited by 1000-fold larger
TTX concentrations (i.e., 𝜇M range)[174].
The main Nav 𝛼 pore consists of a general hollow cylinder
shape with a relatively large extracellular funnel opening
followed by a narrow selectivity domain which is responsible
for the channel’s exclusive Na+ conductance (Figure 1.1d).
After this filter is a large cavity filled with water and lined
by the S6 segments, and a voltage-activated gate at the
intracellular end of the S6 segments which toggles Na+
influx[92]. The selectivity domain in particular has a strong
local electric field on the extracellular end produced by
four glutamate residue side chains[171]. This strong field
site resembles a 4.6 × 4.6 Å2 square, which is large enough
to permit Na+ coupled with two planar water molecules
of hydration. Hydrated Na+ is then conducted through the
remainder of the channel by interacting with the pore through
bound water in its sphere of hydration[160].
Mutations or other epigenetic anomalies in the Nav 𝛼 -encoding
genes mentioned give rise to “sodium channelopathies,”
which can lead to a variety of muscular and neurological disorders especially in the brain. For example, Nav 1.4 mutations
can prevent Nav inactivation resulting in downregulated
excitability and subsequent muscular pathologies[175]. Nav 𝛽
mutations are equally pathological due to Nav 𝛽 regulation
of Nav 𝛼 function and stability. In particular, oncogenic mutations have resulted in Nav overexpression in various cancer
cells and biopsies when compared to their respective normal
tissues[176]. In the late 1980s, it was shown, for instance,
that in both the drug-sensitive leukemia cell line CCRF-CEM
and its drug-resistant variant CEM/VLB100, 1 𝜇M TTX fully
erased the inward Na+ current but had no effect on proliferation, suggesting other mechanisms of depolarization like
overexpression of TTX-resistant Nav 𝛼 isoforms[177]. In the
following decades, there were many studies which showed
abnormal Nav 𝛼 overexpression in a variety of cancers, including human[178] and rat[179, 180] prostate cancer lines,
T-cell leukemias[181], and human small-cell lung cancers[182].
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Nav 𝛼 was also demonstrated as an effective target for ovarian
cancer therapy[183]. There was also a proposed “excitability
hypothesis” that secondary tumors formed from metastatic
non-excitable cells gained Nav expression and adopted an
excitable phenotype, but studies were inconclusive about the
validity of the proposal. The involvement of Nav 𝛽 aberrations
in oncogenesis has not been studied to the same extent as
Nav 𝛼 , but anomalous expression of certain Nav 𝛽 isoforms
have been reported in breast and prostate cancers[156].
These various Na+ transport mechanisms all work in concert
to maintain ionic homeostasis (Figure 1.1e), and cancer cells
decouple them advantageously to allow for tumor development by causing electrolyte imbalances. In particular, NHE
activity is upregulated and Na+ /K+ -ATPase activity is downregulated, while NCX and Nav channels exhibit aberrant
activity. This is mainly achieved through metabolic compromise by expressing certain factors, which make inefficient
processes more favorable, as will be discussed in the next
section.
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Figure 1.1: Mechanisms of electrolyte balance. (a) An electron density map of the Na+ /K+ -ATPase, with 𝛼 -,
𝛽 -, and 𝛾 -subunits indicated. The actuator (A), nucleotide-binding (N), and phosphorylation (P) domains of the
𝛼 -subunit lie on the cytoplasmic end of the plasma membrane. The 𝛽 -subunit touches the extracellular space.
The yellow and red lines indicate the backbones of the 𝛼 - and 𝛾 -subunits, respectively. Modified from [81]. (b)
Sodium proton exchanger (NHE1) topological structure and binding characteristics. Note its 12 transmembrane
segments with a short intracellular N-terminus long intracellular C-terminus, which has binding sites for many
regulator molecules which ultimately sense pHi and affect H+ efflux with simultaneous Na+ influx in a 1:1
stoichiometry. Modified from [90]. (c) A model of sodium calcium exchanger (NCX1), with 9 transmembrane
segments, and a glycosylated extracellular N-terminus. The Ca2+ binding domain is highlighted on the large
intracellular loop, (not depicted to scale), which spans 550 amino acids which is more than half the length
of NCX1. Modified from [91]. (d) Structure of the sodium channel (Nav ). Glutamate side chains are shown in
purple, and the main pore is shown in white. The extracellular opening is wide, and narrows immediately at the
Na+ selectivity domain. The remainder of the channel is a water-filled cavity, lined by S6 segments, through
which hydrated Na+ travels until it reaches the voltage-activated gate at the intracellular end. Modified from
[92]. (e) A cartoon representation of the different Na+ channels mentioned: NHE (green), Na+ /K+ -ATPase
(blue), NCX (teal), and Nav (brown). The voltage-dependence of Nav is emphasized with a voltage schematic
drawn above. Transport is shown for relevant ions: Na+ (purple), H+ (white), K+ (pink), and Ca2+ (dark blue).
Directionality of transport is indicated by arrows.
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1.3 Cancer Metabolism and Electrolyte
Imbalance
Metabolism in tumors is dramatically altered compared to
healthy tissue. Normal cells usually undergo oxidative phosphorylation for generation of ATP, relying on glycolysis solely
during anaerobic conditions. Cancer cells, however, show
preference for glycolysis even in the presence of sufficient
oxygen. This phenomenon of aerobic glycolysis in tumor cells
is known as the Warburg effect, named after Otto Warburg
who made this discovery in the 1920s when his colleagues
and he observed exorbitant glucose uptake in tumors relative
to normal tissue. Moreover, even without glucose, respiration
(i.e., O2 consumption) could also maintain tumor viability.
Thus, both pathways of breaking down of glucose needed
to be cut off for the tumor to be deprived of energy[184].
Further studies corroborated Warburg’s findings and also
revealed heterogeneity in tumoral respiration, suggesting
variability in glycolytic fermentation due to environmental/genetic influences[185]. However, a few decades later,
Warburg spoke contrary to his earlier findings and instead
proposed that mitochondrial dysregulation was at the root of
aerobic glycolysis, and that this was the main cause of cancer
altogether[186]. Efraim Racker then in the 1970s interrogated
this phenomenon, which he coined the “Warburg effect,”
discovered connections between aerobic glycolysis and pHi
imbalances[187]. Racker and his contemporaries throughout the 1980s realized that aerobic glycolysis actually was
controlled by growth factor signaling[188–191]. These findings were only possible with the development of oncogenic
theories which eluded them a decade prior.
There are several molecular markers which typify this effect.
Lactate dehydrogenase A (LDHA), which is upregulated
in IDH wild-type gliomas as mentioned previously, is one
of most common biomarkers of a Warburg phenotype[17,
18]. Elevated glucose consumption, especially in the brain,
quantified by the cerebral metabolic rate of glucose (CMRglc ),
is also an interesting metabolic feature of tumors. It has been
posited as an advantageous carbon source to feed anabolic
processes required for cellular proliferation[184], such as
de novo formation of nucleotides, proteins and lipids. For
instance, phosphoglycerate dehydrogenase (PHGDH) facilitates de novo serine synthesis in tumors using the enhanced
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glycolytic flux[192]. It is also proposed that the Warburg effect
is required for the reformation of NAD+ from its reduced
form (NADH) during the conversion of glycolytic pyruvate to
lactate. NADH generated by glyceraldehyde phosphate dehydrogenase (GAPDH) must be oxidized at a relatively fast rate
to NAD+ to maintain glycolysis and its associated processes
like regenerating NADPH and nucleotides by consuming
biosynthetic serine[192] with 3-phosphoglycerate[193, 194].
The Warburg effect also exhibits advantages for a proliferating
cellular environment. High rates of glycolysis indicate that the
majority of the glucose supply is being taken up by tumor cells
at the expense of host cells, some of which might be trying to
fight the cancer such as tumor-infiltrating lymphocytes (TILs)
and other immune cells[195]. Support for this idea has been
shown experimentally, where inhibiting aerobic glycolysis
in the tumor also stimulated TIL activity. This demonstrates
how tumor cells and immune cells compete for the former to
develop by suppressing local immunity[196]. The Warburg
effect also has been shown to enable signaling between tumor
cells through generation of reactive oxygen species (ROS)
and alteration of chromatin. Elevated ROS levels damage the
plasma membrane and free nucleic acids, while insufficient
levels do not favor signaling between proliferating cells,
through the inactivation of phosphatase and tensin homolog
(PTEN) and tyrosine phosphatases[197]. The Warburg effect
changes the redox potential in mitochondria, affecting ROS
generation. Mitochondrial NADH is an important factor for
the redox potential, and certain endogenous mechanisms
exist to regulate redox potential and NADH when glycolysis
rates are high, such as the malate-aspartate shuttle[192].
When rates are too high, NAD+ generation through LDHA
requires more of the reducing agents, leaving less available
for the mitochondria.
While much research has elucidated the mechanisms and survival advantages conferred by the Warburg effect[192, 198],
its ontology is less clear[184]. Regardless, it cannot be argued
that the Warburg effect upregulates an energy-inefficient
pathway. The consequential ATP production is therefore
subpar (Figure 1.2), and detrimental to the proper function of
the Na+ /K+ -ATPase. Consequentially, the body’s restorative
mechanisms are significantly impaired, and maintenance of
strong transmembrane and weak transendothelial gradients
of Na+ becomes untenable. Thus, these altered transmem-
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brane and weak transendothelial concentrations of Na+ are a
strong biomarker of tumors.

Figure 1.2: A cartoon of cellular metabolism. Glucose and oxygen uptake are regulated by blood flow, the
former facilitated by glucose transporters (GLUTs) and the latter happening passively. Under normal conditions,
glucose is metabolized at basal levels (cerebral metabolic rate of glucose, CMRglc ), converted to glucose-6phosphate (G6P) followed by pyruvate, which enters mitochondria alongside O2 (at the cerebral metabolic rate
of oxygen CMRO2 ) to produce adenosine triphosphate (ATP) 36-fold via oxidative phosphorylation. In tumor
cells (changes indicated with up/down arrows), however, CMRglc is elevated while CMRO2 decreases, causing
pyruvate to be converted to lactate and protons (H+ ) while ATP production is reduced by a factor of 18.

The altered transmembrane concentrations of Na+ change
the membrane potential ((Equation (1.1))) from its resting
-70 mV value. It has been shown that membrane potential
changes are associated with a cell’s stage in the cell cycle,
with a depolarized 𝑉𝑚 (i.e., a voltage difference less negative
than -70 mV) corresponding to more proliferative phenotypes (like in the 𝑀 phase) and a hyperpolarized 𝑉𝑚 (i.e., a
voltage difference more negative than -70 mV) corresponding
to more quiescent phenotypes (like in the 𝐺0 phase)[199]. Fittingly, tumors display sustained depolarized 𝑉𝑚 due to their
constant proliferation, while normal (non-proliferating) cells
in healthy tissue exhibit 𝑉𝑚 closer to resting and hyperpolarized values[200]. This has been demonstrated, for example,
in Chinese hamster ovary cells when forcing 𝑉𝑚 = −70 mV
led to mitotic arrest reversibly, because proliferation was
restored when 𝑉𝑚 was set to -10 mV again[201]. In fact, nonproliferating cells, like many in the central nervous system,
could be forced back into proliferation by sustained depolarization. Astrocytes depolarized with ouabain exhibited
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upregulated proliferation and DNA synthesis[202]. A vast
number of studies relating 𝑉𝑚 to proliferation were conducted on K+ channels, as opposed to Na+ . It was shown
that inhibiting K+ currents in many different cell types (lymphocytes, Schwann cells, astrocytes, oligodendrocytes, and
various tumor cells) also inhibited proliferation[202, 203].
Several studies have analyzed the mechanism behind this association between 𝑉𝑚 and proliferation. The general hypothesis is that voltage-gated Na+ channels open to depolarize cells
and initiate the change from 𝐺0 /𝐺1 -phase (quiescence) to
𝑆 -phase (DNA synthesis), and opening of voltage-gated K+
channels with closing of said Na+ channels during S-phase
repolarize the cell to quiescence[204]. It has been shown that
arresting astrocytes in the 𝐺0 /𝐺1 -phase yields premature
expression of an inward rectifying K+ channel that facilitates
hyperpolarization, while arresting them in 𝑆 -phase downregulates expression of an outward rectifying K+ channel
which facilitates depolarization[202]. Moreover, inhibiting
K+ channels in non-𝛽 lymphocytes and cytolytic T-cells precludes progression through 𝐺1 -phase and their subsequent
activation[205]. Findings like these confirm the degree to
which 𝑉𝑚 participates in cancer onset and progression. This
involvement can be attributed to the fact that cancer ultimately is a disease of perturbed cell regulation, comprising
the decoupling of cells from their surroundings and modifying the extracellular space. The cell membrane is the junction
where the cell meets its extracellular environment, and 𝑉𝑚 is
a critical property of this meeting point.

1.4 Angiogenesis and the Tumor
Microenvironment
The combination of tumor cells (in our case, GBM), the
extracellular space and many other types of host cells, intratumoral blood vessels, and all constituents therein, is called
the tumor microenvironment (TME)[206]. Often, the TME
is also said to include immune/inflammatory cells when it
is described as a consequence of sustained tissue inflammation[207]. Tumor metabolism and the TME are also highly
intertwined, because the tumor exhibits metabolically distinct features such as angiogenesis, hypoxia, and in some
cases, edema[208]. These are facilitated by certain aspects of
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the TME, such as the presence of glycoproteins and proteoglycans in the extracellular space of gliomas[209]. In particular,
collagen, laminin, fibronectin and tenascin-C have proven
to enhance invasiveness of tumor cells into the surrounding
parenchyma[210], and provide a favorable environment for
CSC development[211].
Neovascularization, and specifically angiogenesis, is a striking phenotype of the TME. The vascular system is responsible
for nutrient and oxygen delivery to cells and tissues, especially within the brain. Gas exchange, for example, occurs
exclusively in capillaries. Furthermore, the vasculature provides avenues for clearance of waste products. Initially in
tumors, the rate of cell proliferation and division far outweighs the rate of change of vascularization. This leads to a
transient intermediate state where tumor cells are cut off from
blood supply, and leads to initial hypoxia. However, they
adapt by upregulating certain factors which promote neovascularization. One such molecule is vascular endothelial
growth factor (VEGF), which promotes both angiogenesis
and vascular permeability. The resulting new vessels are
immature, characterized by leakiness and tortuosity which
have become key biomarkers of tumor vasculature[212]. Were
it not for angiogenesis, tumor cells would remain hypoxic,
which would lead to necrosis and prevent tumor growth[213].
For this reason, angiogenesis is critical for tumor survival,
and anti-VEGF therapies have shown efficacy in disrupting
tumor development[214].
The leaky vasculature also permits delivery of therapeutic
agents to tumors, a phenomenon known as the enhanced
permeation and retention (EPR) effect[215]. This is particularly useful in the context of GBM where the intact BBB
would ordinarily prevent drug delivery to the brain. The
EPR effect is a consequence of in tumor vascular structure,
in terms of varying sizes and leakiness. The abnormality in
the vasculature leads to high cerebral blood volume (CBV),
but the tortuosity can impair cerebral blood blow (CBF); perfusion can be low even in tumoral regions of high vascular
density. However, the concomitant increase in permeability
allows for greater retention of delivered therapeutic agents.
Furthermore, retention is also increased by the inability of
tumors to easily clear unwanted foreign agents due to an
immature lymphatic system[216].
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1.5 Preclinical Glioblastoma Models
The experiments carried out in this project were performed
on preclinical (i.e., animal) GBM models due to their invasive
nature. Manipulation of the TME, administration of exogenous agents, and probing vascular patterns could not be
performed on human GBM subjects. Although patient samples have provided invaluable information regarding tumor
growth, development, morphology and metabolism, testing
biomarkers rigorously and allowing testing of therapeutic
drugs cannot be done in humans. To this end, preclinical
models which mimic human models must be used. A number
of rat glioma models were employed, both syngeneic and
patient-derived xenograft models.
The syngeneic GBM model employed in this project was the
rat-glioma-2 (RG2) line. The advantage to using such a model
is the ability to grow the tumor in an immunocompetent
animal. The RG2 tumor cell line was first developed by giving
ethylnitrosurea to pregnant Fisher 344 rats, resulting in tumor development in the children which could be harvested
and maintained in vitro[217]. The tumor is characterized
by invasive growth patterns, and does not elicit immune
responses in Fisher 344 rats due to its syngeneic origins. Genetically, RG2 tumors exhibit wild-type p53 and upregulated
expression of Ras, cyclin D2, platelet-derived growth factor
𝛽 (PDGF𝛽 ), insulin-like growth factor 1 (IGF-1), and human
epidermal growth factor receptor 3 (HER3)[218]. They reliably develop solid tumors when injected intracranially in vivo
and develop only minor necrotic regions regardless of tumor
size, with only minimal signs of complications like gliosis
or inflammation occurring at the periphery. RG2 tumors
are also known to disrupt the BBB and produce edematous
regions around the tumor[217]. Angiogenesis and vascular
permeability in RG2 tumors, which have been discussed earlier, are supported by pericytes. While these properties make
RG2 tumors a favorable GBM model for in vivo preclinical
studies, the fact they are nonimmunogenic makes them less
representative of human GBM models which are considered
at least slightly immunogenic. To attain this level of similarity,
we must turn to patient-derived xenograft models.
The xenograft models employed in this project include the Uppsala 87 Malignant Glioma (U87-MG, or U87) and U251 cell
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lines, which were both derived from patients with pleomorphic gliomas[219] at Uppsala University (Uppsala, Sweden).
Due to their xenogeneic origins, cells from these tumor lines
must be injected into immunosuppressed animal models,
such as athymic/nude rats. As a result, these tumor lines cannot be used to study immune responses or immunotherapy.
However, they are sufficient for studying the TME and other
characteristics like invasiveness, aggressiveness, angiogenesis and non-immune therapeutic agents. Both lines induce
inflammation, but U251 is known to be more invasive than
U87, with the former’s cells infiltrating to a farther distance
from the primary tumor site compared to the latter. U251
tumors also are more necrotic, and express HIF1 𝛼 and Ki67
to a greater extent, suggesting hypoxia and higher rates of
cellular proliferation, respectively. U251 tumors exhibit expression of glial fibrillary acidic protein (GFAP) and vimentin,
a type-III intermediate filament protein often expressed in
mesenchymal cells in animals and bacteria[220]. U87 cells
also express vimentin and display a fair amount of angiogenesis, but are not as necrotic as U251 tumors. However, neither
U87 nor U251 cells exhibit endothelial proliferation, in line
with human GBMs[221].
These preclinical GBM models, particularly the U87 and
U251 xenograft models, have provided a great foundation
for studying the TME. Because these two in particular elicit
immune responses, their study has been crucial for studying
immune responses and cancer immunotherapies. However,
imaging methods conducted presently on these xenograft
models still are too invasive for translation into the clinic.
This has motivated the development of translational imaging
sequences which can provide relevant physiological information non-invasively.

1.6 The Need to Measure
Compartmental Sodium
Concentrations in Cancer
The previous discussions highlight the roles played by the
sensitive ion balances in vivo for healthy function, and the
manner by which the TME hĳacks the normal machinery to
alter metabolism and perturb the ionic balance across cellular
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compartments. Changes in vascular dynamics allow for unrestricted transport of many species between the vascular and
extracellular spaces, which includes Na+ . The presence of
many Na+ channel families, each with several isoforms and
variants thereafter, and their roles in cancer, highlight the
complex network of Na+ transport occurring in both normal
and healthy tissues. While Na+ influxes might be implicated
in cancer progression for some studies, compensatory Na+
effluxes might restore or possibly even alter in vivo Na+
levels across different physiological compartments. The need
to be able to non-destructively measure ion concentrations is
therefore imperative. Traditional methods for determining
concentrations have been highly invasive, such as inserting
voltammetric microelectrodes into tissues of interest and
reading the voltage difference as a surrogate for concentrations. This is a technique which dates back to the 1930s, when
tumors were identified based on voltmeter readings[222,
223]. Practical issues like accurate microelectrode positioning and possible cell rupture prevent human translation
of these methods, necessitating non- or minimally-invasive
techniques. Nuclear magnetic resonance (NMR) is a method,
which detects nuclei with non-zero spin angular momentum
(𝐼 > 0). The most abundant ion in vivo is the proton (H+ ),
and therefore the 1 H nucleus (𝐼 = 1/2) provides the strongest
signal. Most medical applications of NMR, including MRI
and magnetic resonance spectroscopy (MRS), rely on the 1 H
signal. However, NMR can be used to detect any nucleus
with 𝐼 > 0 – the so-called “X-nuclei.” Among X-nuclei in vivo,
the 100% abundant sodium-23 isotope (23 Na) provides the
strongest signal. For this project, the 23 Na NMR signal was
measured in vivo in a novel way to characterize Na+ distribution changes in the TME. The following chapter explores
the theoretical basis behind NMR.
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Nuclear magnetic resonance (NMR) is a quantum mechanical phenomenon, which has been studied for decades, and
powerful applications of NMR have been developed in the
fields of physics, chemistry, biology, and medicine. Atomic
nuclei with non-zero spin angular momentum exhibit a
magnetic dipole moment which can be manipulated by
applying external magnetic fields in order to measure macroscopic properties like metabolite concentrations, produce
high-resolution images very efficiently, and even measure
physiological parameters like temperature, pH, and other
ionic distributions. The majority of NMR applications are
based on the proton (1 H) signal due to its high abundance,
but sodium (23 Na) provides a strong signal which can be
used to determine electrophysiological information which
1
H NMR cannot divulge. The following chapter presents the
NMR foundations for real-world applications.

2.1 Historical Development
NMR has a rich history from its discovery decades ago to
its ubiquity in healthcare and medical imaging today. The
1920s saw the development of concepts like the quantization
of spin angular momentum and magnetic moment for the
electron by many experiments, particularly the Stern-Gerlach
experiment (SGE, Figure 2.1) which separated atoms in an
external heterogeneous magnetic field by direction of magnetic moment. Further refinements elucidated incongruities
in atomic spectra data and which pointed to the existence of
spin and magnetic moments for nuclei.
In 1939, Isidor Isaac Rabi sent a hydrogen beam through
both the external heterogeneous field from the SGE as well
as through a homogenous radiofrequency (RF) magnetic
field. The subsequent absorption of RF energy (at a particular
frequency) caused a slight deflection of the beam, which
illustrated NMR for the first time. For this discovery, Rabi
received the Nobel Prize in 1944.
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However, these NMR studies were limited to measuring deflection of at most a beam of small molecules in near-vacuum
conditions. Attempts by Cornelius Gorter unsuccessfully
tried to measure NMR by production of heat produced and
dispersion of the RF field following RF absorption in LiF.
Felix Bloch, however, along with Hansen and Packard, placed
a copper coil near a sample of water and detected electrical
signal in the coil, confirming a precessing magnetic field
resulting from application of RF energy. Around the same
time, Edward Purcell, along with Torrey and Pound, measured 1 H NMR signals from a block of paraffin. Following
these seminal findings, important strides were made both
theoretically, like Bloembergen’s explanations on nuclear relaxation and differences between solid- and liquid-state NMR
on the basis of Brownian motion, and practically, in terms of
designing electronic circuits better tailored to detecting NMR
signals. To this latter point, Russell Varian was instrumental
by commercializing a homogeneous electromagnetic system
which provided an out-of-box solution for researchers and
laboratories to conduct NMR experiments.
On the whole, NMR has fundamentally revolutionized the
fields of physics, chemistry, and medicine by providing a
non-invasive tool to detect molecular structures, crystal structures, protein conformations and even diseases altogether.
Magnetic resonance imaging (MRI) and spectroscopy (MRS)
have paved the way for clinicians and researchers alike to
interrogate and probe the human body without ionizing
radiation or injectable tracers, as are required for other clini-

Figure 2.1: A schematic representation of the Stern-Gerlach experiment. A beam of silver atoms
was released in a straight line
through a magnetic field. Classical physics would anticipate
a uniform distribution of atoms
throughout the length of the plate,
but experimental results actually
exhibit only two spots in the plate,
one corresponding to spin-up particles, and one to spin-down particles. This was the first experimental observation that spin angular momentum (and therefore
magnetic moment) is a quantized
value.
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cal imaging modalities like computed tomography (CT) or
positron emission tomography (PET). The remainder of this
chapter will be dedicated to a deep and theoretical basis
of the NMR phenomenon, and with a mindset to grasp
the foundation for the method and findings of my thesis
project.

2.2 Classical Treatment of NMR
Spins, Magnetization, and Polarization
A classical formalism of NMR physics provides an intuitive
basis by which the reader may better understand both the
fundamental experiments conducted by Bloch, Purcell, etc.,
as well as modern medical applications, and ultimately the
project set forth in this thesis. All nuclei contain protons
(positively charged) and neutrons (no charge), where an
NMR-visible nucleus possesses an odd number of these
constituents. Given a sample, each NMR-visible nucleus
within the sample possesses a spin angular momentum
𝑆® = ~®𝐼 , where ~ = 1.05457 × 10−23 J·s/rad is the reduced
Planck’s constant and ®𝐼 is the dimensionless spin vector
whose direction lies along the nucleus’s axis of rotation and
whose magnitude (𝐼 ≡ | ®𝐼 | ) is called the spin number of the
nucleus, where nuclei with 𝐼 = 0 possess no spin. Associated
® given by
with every spin is also the magnetic moment 𝜇

® = 𝛾 𝑆® = 𝛾~®𝐼
𝜇

(2.1)

where the proportionality constant 𝛾 is called the gyromagnetic ratio (units of rad/s/T or MHz/T, where T is the Tesla,
the SI unit of magnetic field strength; Table 2.1), and is an
intrinsic property of each nucleus (with a charge 𝑞 and mass
𝑚 ) given by
𝑞
𝛾=
(2.2)
2𝑚

® is defined macroscopically as the
A magnetic moment 𝜇
product of the electric current in a loop of wire and the
area enclosed by the wire. Since spin angular momentum
𝑆® corresponds to rotational motion, the magnetic moment
® is related to the orbital angular momentum of the charge
𝜇
carriers (see (Equation (2.1)) and (Equation (2.2))). Thus, as
observed in Table 2.1, some nuclei have positive 𝛾 values,
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Nucleus
1

H
H
7
Li
13
C
15
N
19
F
23
Na
31
P
39
K
2

Nuclear Spin Number (𝐼 )
1/2
1
3/2
1/2
1
1/2
3/2
1/2
3/2

Gyromagnetic Ratio ( 𝛾 )
[MHz/T]
42.58
6.536
16.55
10.71
-4.316
40.05
11.26
17.24
2.0

Table 2.1: Spin numbers and gyromagnetic ratios of nuclei commonly studied with NMR

but a few nuclei have negative 𝛾 values. For 𝛾 > 0, the spin
® point in
the angular momentum 𝑆® and magnetic moment 𝜇
the same direction, whereas for 𝛾 < 0 they are in opposite
directions. Thus, the precession directions of nuclei with
positive and negative 𝛾 are in opposite directions.

® belongs to individual nuclei,
Because the magnetic moment 𝜇
summing these vectorially over the set 𝐴 of all nuclei within
®:
the sample gives the sample’s bulk magnetization 𝑀

X
1 X
® = 𝑑
®𝑖 ≈
®𝑖
𝜇
𝜇
𝑀
𝑑𝑉 𝑖∈𝐴
𝑉 𝑖∈𝐴

(2.3)

where 𝑉 is the volume of the sample. Since this is a vector
sum, it is natural to ask about the magnitude and direction
® . What direction will it face? How many
of the resultant 𝑀
directions are allowed?

(a)

(b)
α

B0 = 0

B0

α
α

β
β

β

α α

Consider a system of a large number 𝑁 of a spin-1/2 nucleus
𝑋 with volume 𝑉 . In the absence of any external fields,
these nuclei and their individual magnetic moments are

Figure 2.2: Polarization of spin1/2 particles. A cartoon depicting
the spin angular momenta of a
sample of magnetic particles in
the (a) absence and (b) presence
of an externally applied magnetic
®0 . Without the field (a), the
field 𝐵
spins are randomly oriented and
distributed, leading to zero net
magnetization on average. However, when the field is applied (b),
the spins orient themselves with
( 𝛼 ) or against (𝛽 ) the applied field.
Note that there is a slight excess
of spins in the 𝛼 state.
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free to translate and rotate isotropically. In other words, all
directions are equiprobable. Therefore, the vector sum of
these different moments, identical in magnitude but varying
in direction is 0 (Figure 2.2a). However, if this sample were
®0 , then only two directions are
placed in a magnetic field 𝐵
possible for the magnetic moments: parallel (referred to as the
𝛼 or “spin-up” state) and antiparallel (referred to as the 𝛽 or
®0 (Figure 2.2b). This is a consequence
“spin-down” state) to 𝐵
of 𝑋 being spin-1/2, meaning 𝐼 = 21 . In general, a nucleus
with spin number 𝐼 will exhibit 2𝐼 + 1 possible orientations.
These orientations exhibit different energies ( 𝛼 and 𝛽 states
are low and high, respectively, for 𝐼 = 12 ). The energy 𝐸 of a
® in a magnetic field 𝐵®0 is
magnetic dipole moment 𝜇

® · 𝐵®0
𝐸 = −𝜇

(2.4)

Therefore, for a spin-1/2 nucleus, the energy 𝐸 𝛼 of the 𝛼
® is
state will be lower than the energy 𝐸𝛽 of the 𝛽 state, since 𝜇
®0 in the 𝛼 state. Employing Equation (2.1) shows
parallel to 𝐵

𝐸 𝛼 = −𝛾~𝐼𝐵0 and 𝐸𝛽 = 𝛾~𝐼𝐵0 . Because the nuclei in this
®0 follow Maxwell-Boltzmann statistics, the
external field 𝐵
fractions of nuclei 𝑝 𝛼 and 𝑝 𝛽 in the 𝛼 and 𝛽 states, respectively,
are given by

𝑝𝛼 =
𝑝𝛽 =

𝑒

− 𝑘𝐸 𝛼𝑇
𝐵

𝑄
𝑒

=

𝐸𝛽

−𝑘

𝐵𝑇

𝑄

=

𝑒

𝛾~𝐼𝐵0
𝑘𝐵 𝑇

𝑄
𝑒

−

(2.5a)

𝛾~𝐼𝐵0
𝑘𝐵 𝑇

𝑄

(2.5b)

where 𝑘 𝐵 = 1.38 × 10−23 J/K is the Boltzmann constant, 𝑇
is the absolute temperature of the sample and 𝑄 = 𝑒
−

𝛾~𝐼𝐵0
𝑘𝐵 𝑇

𝛾~𝐼𝐵0
𝑘𝐵 𝑇

+

𝛾~𝐼𝐵0
𝑘𝐵𝑇

𝑒
= 2 cosh
is the canonical partition function for
the sample. Note that 𝑝 𝛼 + 𝑝 𝛽 = 1. Because 𝐸 𝛼 < 𝐸𝛽 , we
likewise have that 𝑝 𝛼 > 𝑝 𝛽 , meaning there are slightly more
®0 than against it. Vectorially, this means
spins aligned with 𝐵
® points in the same direction as 𝐵®0 . It has a magnitude
𝑀
𝑀0 = (𝑝 𝛼 − 𝑝 𝛽 )𝑁 , where 𝑁 is the total number of spins in
the sample. By substituting in the expressions for 𝑝 𝛼 and 𝑝 𝛽
(Equation (2.5)) and using Taylor approximations, we have
𝑁 𝛾2 ~2 𝐵0
𝑀0 =
4 𝑘 𝐵 𝑇𝑉

(2.6)
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The Taylor expansion is warranted since the exponent in Equation (2.5) is very small. For a field strength of 11.7 T and
𝛾~𝐼𝐵
assuming room temperature (298 K), 𝑘 𝐵 𝑇 0 ≈ 6.39 × 10−6 ,
which indicates how small 𝑝 𝛼 − 𝑝 𝛽 will be. This illustrates
how the strength of the initial magnetization (i.e., degree
of polarization) is dependent on the external field applied.
® is a property of an
It is important to reiterate that while 𝜇
® is a property of the entire sample, or
individual nucleus, 𝑀
the system. For the remainder of the classical discussion, we
®.
will explore NMR from the evolution of 𝑀
Magnetic dipoles in a magnetic field also experience a torque
® in our
𝜏® about the direction of the field. A dipole moment 𝜇
® experiences a torque given
scenario, with a magnetic field 𝐵
by
® × 𝐵®
𝜏® = 𝜇
(2.7)
This can be rewritten when considering the fact that dipole
moment is directly related to the spin angular momentum 𝑆®
®

(Equation (2.1)). Because 𝜏® = 𝑑𝑑𝑡𝑆 by Newton’s Second Law of
Motion (for rotating bodies), Equation (2.7) can be combined
with Equation (2.1) and rewritten as

®
𝑑𝜇
® × 𝐵®
= 𝛾𝜇
𝑑𝑡

(2.8)

Summing over all dipoles in the sample (Equation (2.3)), this
becomes
®
𝑑𝑀
® × 𝐵®
= 𝛾𝑀
(2.9)
𝑑𝑡
which when expanded for evolution of the transverse and
® are known as the Bloch
longitudinal components of 𝑀
equations, named after Felix Bloch. These equations are
a set of vector differential equations, and at this point it
behooves us to define a coordinate system which facilitates
our understanding of them.

®0 is traditionally
The direction of the external magnetic field 𝐵
taken to be the + 𝑧 -direction. If 𝑥ˆ , 𝑦ˆ , and 𝑧ˆ are the unit vectors
pointing in these orthogonal directions of the + 𝑥 -, + 𝑦 -, and
+ 𝑧 -directions, then the general magnetization is given by
® = 𝑀 𝑥 𝑥ˆ + 𝑀 𝑦 𝑦ˆ + 𝑀 𝑧 𝑧ˆ and the applied field is 𝐵®0 = 𝐵0 𝑧ˆ .
𝑀
However, as we have shown in the previous discussion,
® 0 = 𝑀0 𝑧ˆ is parallel to 𝐵®0 , such that 𝑑 𝑀® = 0 and 𝑀
® is
𝑀
𝑑𝑡

®0 is externally applied.
stationary when only 𝐵
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Excitation and Relaxation
®0 ,
When another orthogonal field is applied in addition to 𝐵
® , yielding a non-zero
the net field is no longer parallel to 𝑀
® to change as described by
torque which in turn causes 𝑀
the Bloch equations. Usually, for NMR, the additional field
®1 and circularly polarized, rotating in the plane
is termed 𝐵
®0 is normal. In the coordinate system defined
for which 𝐵
above, this refers to the 𝑥𝑦 -plane (Figure 2.3a). Without loss
®1 to be rotating clockwise in the 𝑥𝑦 of generality, consider 𝐵
plane with magnitude 𝐵1 and angular frequency 𝜔 , meaning
®1 = 𝐵1 cos(𝜔𝑡)𝑥ˆ − 𝐵1 sin(𝜔𝑡) 𝑦ˆ . The net
it takes the form 𝐵
® = 𝐵®0 + 𝐵®1 = 𝐵1 cos(𝜔𝑡) 𝑥ˆ − 𝐵1 sin(𝜔𝑡) 𝑦ˆ +
magnetic field is 𝐵
𝐵0 𝑧ˆ . Expanding Equation (2.9) in this field yields a system
of differential equations:
𝑑𝑀 𝑥
= 𝛾[𝐵0 𝑀 𝑦 (𝑡) + 𝐵1 𝑀 𝑧 (𝑡) sin(𝜔𝑡)]
𝑑𝑡
𝑑𝑀 𝑦
= 𝛾[−𝐵0 𝑀 𝑥 (𝑡) + 𝐵1 𝑀 𝑧 (𝑡) cos(𝜔𝑡)]
𝑑𝑡
𝑑𝑀 𝑧
= −𝛾𝐵1 [𝑀 𝑥 (𝑡) sin(𝜔𝑡) + 𝑀 𝑦 (𝑡) cos(𝜔𝑡)]
𝑑𝑡

(2.10a)
(2.10b)
(2.10c)

® changes with
which illustrates how each component of 𝑀
time. This entire phenomenon is known as excitation of the
magnetization vector.
Meanwhile, there are processes also experienced by the magnetization while it is not parallel to the net magnetic field
which serve to counteract the excitation torque brought about
®1 . After allowing the torque to act for a certain amount of
by 𝐵
®1 is immediately turned off. The perturbation
time, assume 𝐵
® results in energy absorption by the system from the
of 𝑀
applied field, and most relaxation processes dissipate energy
from the system. Relaxation in NMR consists of two simultaneous facets. Relaxation of the first kind, or longitudinal
®
relaxation, refers to the restoration of the component of 𝑀
®0 - which is 𝑀 𝑧 in our coordinate systhat is parallel to 𝐵
tem. Longitudinal relaxation occurs due to energy transfer
between the perturbed magnetization and the surroundings,
termed “spin-lattice” relaxation. This happens exponentially
with a rate 𝑅 1 known as the longitudinal relaxation rate (or
1
𝑇1 , where 𝑇1 is the longitudinal relaxation time constant).
At the same time, relaxation of the second kind - or trans-
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verse relaxation - refers to the loss of phase coherence, or
“dephasing”, of the components of the spins in the plane of
𝐵®1 , which is called the transverse plane. This occurs due to
small fluctuations in the local magnetic field experienced
by each precessing spin due to its proximity to neighboring
spins, which causes each spin to gain different amounts of
transverse phase. Ultimately, the net transverse magnetization loses magnitude. This relaxation process also happens
exponentially, with a decay rate 𝑅 2 known as the transverse
relaxation rate (or 𝑇12 , where 𝑇2 is the transverse relaxation
time constant). We can incorporate these relaxation terms
into Equation (2.10) to get a complete picture of the evolution
® under the field 𝐵® :
of 𝑀

𝑑𝑀 𝑥
= 𝛾[𝐵0 𝑀 𝑦 (𝑡) + 𝐵1 𝑀 𝑧 (𝑡) sin(𝜔𝑡)] − 𝑅 2 𝑀 𝑥 (𝑡) (2.11a)
𝑑𝑡
𝑑𝑀 𝑦
= 𝛾[−𝐵0 𝑀 𝑥 (𝑡) + 𝐵1 𝑀 𝑧 (𝑡) cos(𝜔𝑡)] − 𝑅2 𝑀 𝑦 (𝑡)
𝑑𝑡
(2.11b)
𝑑𝑀 𝑧
= −𝛾𝐵1 [𝑀 𝑥 (𝑡) sin(𝜔𝑡) + 𝑀 𝑦 (𝑡) cos(𝜔𝑡)]
𝑑𝑡
− 𝑅 1 [𝑀 𝑧 (𝑡) − 𝑀0 ]
(2.11c)

(a)
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x

B1

ω
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y
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z = z’

x

ωR

M
B1

x’

y

Rotating Frame

®
Figure 2.3: An illustration of the laboratory and rotating frames. (a) Vector diagram of the magnetization 𝑀
®
(green) in the laboratory frame. The excitation field 𝐵1 (blue) is applied sinusoidally along the + 𝑥 -axis initially
® around the + 𝑧 -axis at a frequency
and rotates at angular frequency 𝜔 , causing simultaneous precession of 𝑀
𝜔0 = 𝛾𝐵0 , and nutation about the + 𝑥 -axis onto the + 𝑦 -axis at a frequency 𝜔1 = 𝛾𝐵1 , resulting in a complex
® (green) in the rotating frame, described by the
elliptical trajectory. (b) Vector diagram of the magnetization 𝑀
0
0
0
0
0
primed axes 𝑥 , 𝑦 , and 𝑧 . Both 𝑥 and 𝑦 are rotating with respect to the stationary laboratory frame axes at an
®1 (blue) is applied stationarily along the +𝑥 0-axis, which results in a
angular frequency 𝜔𝑅 . The excitation field 𝐵
simpler trajectory consisting of only nutation about + 𝑥 0-axis onto the + 𝑦 0-axis.
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The Rotating Frame
The expressions in Equation (2.11) can be simplified with a
dynamic coordinate system. Consider a frame of reference
typified by a coordinate system rotating about the 𝑧 -axis with
angular frequency 𝜔𝑅 ; call this the “rotating frame.” The
unit vector that corresponds to this rotating frame is 𝜔
ˆ 𝑅.
Similarly, the original stationary frame of reference is the
® in the
“laboratory frame” (Figure 2.3a). The magnetization 𝑀
rotating frame can be derived from its general expression in
the laboratory frame, treating the Cartesian unit vectors 𝑥ˆ , 𝑦ˆ ,
and 𝑧ˆ as functions of time as well:

® = 𝑀 𝑥 𝑥ˆ + 𝑀 𝑦 𝑦ˆ + 𝑀 𝑧 𝑧ˆ
𝑀
®
X
𝜕𝑀𝜈
𝑑𝑀
𝜕 𝜈ˆ
=
=⇒
𝜈ˆ + 𝑀𝜈
𝑑𝑡
𝜕𝑡
𝜕𝑡
𝜈∈{𝑥,𝑦,𝑧}





Because the unit vectors are only rotating, without any change
in magnitude, their time-derivatives are given simply by
𝜕 𝜈ˆ
= 𝜔ˆ 𝑅 × 𝜈ˆ . Rewriting the above expression, and simplifying,
𝜕𝑡
we get

®
X
𝑑𝑀
𝜕
ˆ + 𝜔ˆ 𝑅 × (𝑀𝜈 𝜈)
ˆ
=
(𝑀𝜈 𝜈)
𝑑𝑡
𝜕𝑡
𝜈∈{𝑥,𝑦,𝑧}





Or, in other words,

®
𝑑𝑀
𝑑𝑡

!
lab

®
𝜕𝑀
=
𝜕𝑡

!
®
+ 𝜔ˆ 𝑅 × 𝑀

(2.12)

rot

® in the rotating
Equation (2.12) relates the time-evolution of 𝑀
frame in relation to the laboratory frame. The total derivative
®
on the left-hand side represents the overall motion of 𝑀
in the laboratory frame, while the partial derivative on the
right-hand side represents only the explicit dependence of
® on time without rotation effects being relevant.
𝑀


Ignoring relaxation for the time being, we know

®
𝑑𝑀
𝑑𝑡



=
lab

® × 𝐵® ( Equation (2.9)). Therefore, Equation (2.12) can be
𝛾𝑀
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rewritten as

®
𝜕𝑀
𝜕𝑡
=⇒

®
𝜕𝑀
𝜕𝑡

®
𝜕𝑀
=⇒
𝜕𝑡

!
® × 𝐵® − 𝜔ˆ 𝑅 × 𝑀
®
= 𝛾𝑀

(2.13)

! rot
® × 𝐵® + 𝑀
® × 𝜔ˆ 𝑅
= 𝛾𝑀

! rot
rot

® × 𝐵® + 𝜔ˆ 𝑅 ≡ 𝛾 𝑀
® × 𝐵®eff
= 𝛾𝑀
𝛾





®eff ≡ 𝐵+
® 𝜔ˆ 𝑅 is the effective magnetic field experienced
where 𝐵
𝛾
®
by 𝑀 in the rotating frame. The 𝜔ˆ 𝑅 term represents a fictitious
𝛾

magnetic field brought about by the rotation. In other words,
® rotates about 𝐵®eff in the rotating frame, whereas 𝑀
® rotates
𝑀
® in the laboratory frame.
about 𝐵
As a quick example, consider the case where the only applied
®0 , meaning 𝐵® = 𝐵®0 = 𝐵0 𝑧ˆ . We can choose 𝜔ˆ 𝑅 = −𝛾 𝐵®0
field is 𝐵
®eff = 0, meaning 𝑀
® does not change with time. As a
and get 𝐵
more interesting example, consider the case where there are
®0 and sinusoidal field 𝐵®1 oscillating
both the external field 𝐵
®eff = 𝐵®0 + 𝜔ˆ 𝑅 + 𝐵®1 . We can
at a frequency 𝜔 . In this case, 𝐵
𝛾
choose 𝜔
ˆ 𝑅 = −𝛾 𝐵®0 again and get 𝐵®eff = 𝐵®1 . This means that
® only interacts with 𝐵®1 .
at this rotating frame frequency, 𝑀
®1 be applied along the rotating
Without loss of generality, let 𝐵
®1 , 𝑀
® will precess only
+ 𝑥 -axis, called the + 𝑥 0-axis. Under 𝐵
about the + 𝑥 0-axis in the rotating frame. In the laboratory
® consists of simultaneous precession
frame, the motion of 𝑀
about the + 𝑧 - and + 𝑥 -axes.
If we set 𝜔
ˆ 𝑅 = −𝛾 𝐵®0 , this is called the Larmor frequency
𝜔0 ≡ 𝛾𝐵0 with corresponding vector 𝜔ˆ 0 = −𝛾 𝐵®0 . It is the
® around the direction of 𝐵®0 and
frequency of precession of 𝑀
is the observed frequency when no other fields are present.
® being stationary
For this reason, setting 𝜔𝑅 = 𝜔0 results in 𝑀
in the rotating frame. This is known as being on-resonance.
®eff = 𝜔ˆ 𝑅 −𝜔ˆ 0 + 𝐵®1 .
When 𝜔𝑅 ≠ 𝜔0 (off-resonance), then 𝐵
𝛾

Solutions to the Bloch Equations
The following analysis is adapted from recent work by
Johnston[224]. The rotating frame allows us to recast Equa-
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tion (2.11) into Equation (2.12), which can further be expanded
as

 𝑅2 Δ
0 
®

𝑑𝑀
® + 𝑅1 𝑀0 𝑧ˆ
= −  −Δ 𝑅2 𝜔1  𝑀
𝑑𝑡
 0 −𝜔1 𝑅1 



(2.14)

where Δ ≡ |𝜔0 −𝜔𝑅 | and 𝜔1 ≡ 𝛾𝐵1 . Without loss of generality,
®1 is applied along the + 𝑥 0-axis
Equation (2.14) assume 𝐵
(rotating frame). Let 𝐴 be the matrix in Equation (2.14). Then
solutions of Equation (2.14) take the form

h

®
® SS + 𝑒 −𝐴𝑡 𝑀(
® 0) − 𝑀
® SS
𝑀(𝑡)
=𝑀

i
(2.15)

® SS is the steady-state magnetization. The solution
where 𝑀
in this form is best expressed in the eigenbasis of 𝐴. The
eigenvalues 𝜆 of 𝐴 are calculated based on its characteristic
equation det(𝐴 − 𝜆𝐼) = 0 (where 𝐼 is the identity matrix),
or
𝜆3 − (𝑅 1 + 2𝑅 2 )𝜆2 + (𝑅 22 + 2𝑅 1 𝑅 2 + Δ2 + 𝜔12 )𝜆
− (𝑅 1 𝑅 2 + 𝑅 1 Δ2 + 𝑅 2 𝜔12 ) = 0

(2.16)

where the solutions to Equation (2.16) are

𝜆1 = 𝑅 1 cos2 𝜙 + 𝑅2 sin2 𝜙 ≡ 𝑅 𝜙



𝜆2 , 3 = 𝑅 2 −
and Ω ≡

q

sin2 𝜙
(𝑅 2 − 𝑅 1 ) ± 𝑖Ω ≡ 𝑏 ± 𝑖Ω
2

(2.17a)



Δ2 + 𝜔12 and 𝜙 ≡ arctan

(2.17b)

𝜔1 
Δ .

The corresponding eigenvector associated with each eigenvalue 𝜆 is found by computing the null space of 𝐴 − 𝜆𝐼 . The
eigenvectors of 𝐴 are given by the columns of a matrix 𝑋
(where the 𝑖 th column of 𝑋 is the eigenvector corresponding
to 𝜆 𝑖 ):
 cos 𝜙 cos 𝜙
cos 𝜙 

𝑖
−𝑖 
𝑋 =  0
(2.18)
 csc 𝜙 − sin 𝜙 − sin 𝜙 



With the eigenvalues and eigenvectors, 𝐴 can be diagonalized
 𝜆1 0 0 


−
1
as 𝐴 = 𝑋𝐷𝑋 , where 𝐷 =  0 𝜆2 0  . Likewise, this
 0 0 𝜆3 


means the corresponding exponential matrix 𝑊 is given
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by 𝑊 = 𝑒 −𝐴𝑡 = 𝑋 𝑒 −𝐷𝑡 𝑋 −1 . 𝑋 −1 can be computed rather
straightforwardly:

𝑋

−1

1
=
2

 2 sin 𝜙 tan 𝜙 0 2 sin 𝜙


cos 𝜙
−𝑖 − sin 𝜙


cos
𝜙
𝑖 − sin 𝜙









(2.19)

Plugging in 𝑋 (Equation (2.18)), 𝑋 −1 (Equation (2.19)), and
𝐷 (Equation (2.17)), we find

 𝑒 −𝑅 𝜙 𝑡 sin2 𝜙 + 𝑒 −𝑏𝑡 cos2 𝜙 cos(Ω𝑡) −𝑒 −𝑏𝑡 cos 𝜙 sin(Ω𝑡) 


 [𝑒 −𝑅 𝜙 𝑡 − 𝑒 −𝑏𝑡 cos(Ω𝑡) sin 𝜙 cos 𝜙]



−𝑏𝑡
−𝑏𝑡


𝑒 cos 𝜙 sin(Ω𝑡)
𝑒 cos(Ω𝑡)


W= 




𝑒 −𝑏𝑡 sin 𝜙 sin(Ω𝑡) 

 𝑒 −𝑅 𝜙 𝑡 cos2 𝜙 + 𝑒 −𝑏𝑡 sin2 𝜙 cos(Ω𝑡)



(2.20)
The steady-state solutions are simply found by equating Equa® − 𝑅 1 𝑀0 𝑧ˆ ) = 0. Using Cramer’s rule to
tion (2.14) to 0: 𝐴( 𝑀
solve this matrix equation, we find

® SS
𝑀

𝑅2 sin 𝜙
𝑅 1 𝑀0
=
𝑦ˆ + cos2 𝜙 𝑧ˆ
sin 𝜙 cos 𝜙 𝑥ˆ −
𝑅𝜙
Ω




(2.21)

which is analogous to Equation (2.15).

The Bloch Equation Solutions Following
Excitation and Relaxation
Consider the case of on-resonance excitation, i.e. 𝜔𝑅 = 𝜔0 .
In this case, Δ = 0 (Equation (2.14)) and 𝜙 = 𝜋/2 (Equation (2.17)). As a result, 𝑅 𝜙 = 𝑅 2 (Equation (2.17a)) and
2
𝑏 = 𝑅1 +𝑅
(Equation (2.17b)). Also, because this is excitation,
2
®
initially 𝑀0 = 𝑀0 𝑧ˆ . In this case, 𝑊 simplifies to

𝑊exc

 𝑒 −𝑅2 𝑡
0
0

−𝑏𝑡
−𝑏𝑡

𝑒 cos 𝜔1 𝑡 −𝑒 sin 𝜔1 𝑡
= 0
 0
𝑒 −𝑏𝑡 sin 𝜔1 𝑡 𝑒 −𝑏𝑡 cos 𝜔1 𝑡
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which results in

𝑀 𝑥 (𝑡) = 0
𝑅 1 𝑀0
𝑀 𝑦 (𝑡) = −𝑀0 𝑒 −𝑏𝑡 sin 𝜔1 𝑡 −
(1 − 𝑒 −𝑏𝑡 cos 𝜔1 𝑡)
𝜔1
𝑅 1 𝑅 2 𝑀0 −𝑏𝑡
+
𝑒 sin 𝜔1 𝑡
𝜔12
𝑅 1 𝑅 2 𝑀0
(1 − 𝑒 −𝑏𝑡 cos 𝜔1 𝑡)
𝑀 𝑧 (𝑡) = 𝑀0 𝑒 −𝑏𝑡 cos 𝜔1 𝑡 −
2
𝜔1
𝑅 1 𝑀0 −𝑏𝑡
+
𝑒 sin 𝜔1 𝑡
𝜔1
®1 applied along the + 𝑥 0-axis causes nutation
indicating that 𝐵
from the 𝑧 0-axis to the 𝑦 0-axis.
® has been tipped onto the
Now consider the case where 𝑀
𝑦 -axis, and 𝐵®1 is turned off. Relaxation will occur to restore
the magnetization to its original orientation. In this situation,
𝜔1 = 0 and therefore 𝜙 = 0 (Equation (2.17)). As a result, 𝑏 =
® = 𝑀0 𝑦ˆ and ultimately 𝑀
® SS = 𝑀0 𝑧ˆ .
𝑅 2 . Moreover, initially 𝑀
Relaxation is also best studied in the laboratory frame, i.e.
𝜔𝑅 = 0, since there is no applied field anymore other than
𝐵®0 . Now in this scenario, 𝑊 becomes
𝑊rlx

 𝑒 −𝑅2 𝑡 sin Δ𝑡 −𝑒 −𝑅2 𝑡 cos Δ𝑡
0

−𝑅
𝑡
−𝑅
𝑡

2
2
cos Δ𝑡 𝑒
sin Δ𝑡
0
=  −𝑒
−𝑅

0
0
𝑒 1𝑡









and therefore

𝑀 𝑥 (𝑡) = 𝑀0 𝑒 −𝑅2 𝑡 sin Δ𝑡
𝑀 𝑦 (𝑡) = 𝑀0 𝑒 −𝑅2 𝑡 cos Δ𝑡
𝑀 𝑧 (𝑡) = 𝑀0 (1 − 𝑒 −𝑅1 𝑡 )
In other words, 𝑀 𝑥 and 𝑀 𝑦 interconvert with transverse
oscillations at an angular frequency Δ, while decaying to 0
with a rate 𝑅 2 , whereas 𝑀 𝑧 returns to equilibrium with a
rate 𝑅 1 , and is the solution to Equation (2.14).

Fourier Transforms and NMR Spectroscopy
In NMR, the signal measured by a receiver is the decaying
transverse magnetization during the relaxation phase (see
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Equations 2.22). Because there are two components to transverse magnetization, modern hardware has developed to
detect both components simultaneously using different channels with quadrature detection. A plot of either component
shows a damped sinusoid, whose amplitude exponentially
decays to 0 and known as the free induction decay (FID),
also referred to as the time-domain signal. When a single
frequency ( 𝜔0 ) is present, the FID provides enough information to measure the frequency from the plot, since it is easy to
measure the distance in time between consecutive sinusoid
peaks. However, when multiple frequencies are present with
different relative contributions to the time-domain signal, it
becomes impossible to ascertain every frequency from this
time-domain signal alone. A decomposition of the frequencies can be attained through use of the Fourier Transform on
the time-domain signal. The Fourier Transform of a function
of time 𝑓 (𝑡) is a different function of angular frequency 𝐹(𝜔)
related by
∫
∞

𝑓 (𝑡)𝑒 −𝑖𝜔𝑡 𝑑𝑡

𝐹(𝜔) = −

−∞

There are other definitions of the Fourier Transform which
differ by various proportionality constants, but this one
is valid for the subsequent discussion. It is supposed to
encompass the entire domain of the input function. While
the domain of a function can range between ±∞, for NMR
we are transforming a function of time, the lower bound on
the integral is 0. The Fourier Transform of the FID provides
insight into the frequencies present in the time-domain signal
when the transform is plotted against the angular frequency.
For this reason, the Fourier Transform of the FID is called
the frequency-domain signal.
Mathematically, the quadrature signal is treated as a complex number where the real part carries the magnetization
magnitude of one component and the imaginary part carries
the other. Without loss of generality, let the real part carry
the 𝑦 -component. Then the complex time-domain signal is
given by

e 𝑥 𝑦 (𝑡) = 𝑀 𝑦 (𝑡) + 𝑖𝑀 𝑥 (𝑡) = 𝑀0 𝑒 −𝑅2 𝑡 (cos Δ𝑡 + 𝑖 sin Δ𝑡)
𝑀
= 𝑀0 𝑒 (𝑖Δ−𝑅2 )𝑡

(2.22)

Equation (2.22) describes the complex FID, whose Fourier
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Transform is given by

𝐹(𝜔) =

∫

∞

e 𝑥 𝑦 (𝑡)𝑒
𝑀

−𝑖𝜔𝑡

0

𝑑𝑡 = 𝑀0

∫

𝑀0
𝑒 [𝑖(Δ−𝜔)−𝑅2 ]
𝑖(Δ − 𝜔) − 𝑅 2
𝑀0
=
𝑅 2 − 𝑖(Δ − 𝜔)
𝑀0 [𝑅 2 + 𝑖(Δ − 𝜔)]
=
𝑅 22 + (Δ − 𝜔)2

∞

𝑒 [𝑖(Δ−𝜔)−𝑅2 ] 𝑑𝑡

 0∞

=

0

or, written explicitly as the sum of real and imaginary components,

𝐹(𝜔) =

𝑅 22

𝑀0 (Δ − 𝜔)
𝑀0 𝑅 2
+𝑖 2
+ (Δ − 𝜔)2
𝑅 2 + (Δ − 𝜔)2

(2.23)

where the real and imaginary parts of Equation (2.23) are
called the absorption spectrum and the dispersion spectrum, respectively, and these spectra carry information about
magnitude and phase. Equation (2.23) also describes a
Lorentzian peak for both absorption and dispersion spectra.
If we examine the absorption spectrum as a function of 𝜔 ,
we see that it is symmetric about 𝜔 = Δ, where it is also maximum value. According to Equation (2.23), this maximum
value is 𝑀0 /𝑅 2 , but the amplitudes are not often as important as the peak position on the 𝜔 -axis. This peak position is
termed the chemical shift. When multiple peaks are present,
each peak can be identified by its distinct chemical shift.
The term refers to the peak’s displacement - or “shift” - in
frequency space from some reference frequency, usually 𝜔0 .
Numerically, these shifts are rather small in frequency units,
and are dependent on the external magnetic field strength.
Therefore, the shift is usually expressed in parts per million
(ppm) by normalizing to the reference frequency (or Larmor
frequency). If 𝜔0 is the reference frequency and 𝜔 is the
frequency (i.e., peak position) of any other peak, then its
chemical shift is given by

𝛿=

𝜔 − 𝜔0
× 106
𝜔0

(2.24)

Thus, the reference frequency is assigned a chemical shift of
0 ppm by definition of Equation (2.24).
Also of interest is the width of the peak, or linewidth (Γ). The
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standard metric used for linewidth is the full width at half
maximum (FWHM) of the peak. In other words, if 𝜔1 and
𝜔2 are the two values of 𝜔 such that 𝐹(𝜔1 ) = 𝐹(𝜔2 ) = 21 𝐹(Δ),
|𝜔 −𝜔 |

then Γ = 12𝜋 2 , where the 2𝜋 factor comes from the fact that
Γ is measured in units of s−1 while 𝜔 is measured in units
of rad/s. Measuring FWHM for the absorption spectrum in
Equation (2.23), we find

𝑀0 𝑅 2
𝑀0
= 2
2𝑅 2
𝑅 2 + (Δ − 𝜔)2
𝑅 22
1
=⇒ = 2
2 𝑅 2 + (Δ − 𝜔)2
Δ−𝜔
=⇒ 1 =
𝑅2
Δ − 𝜔1 , 2
=⇒ ±1 =
𝑅2
=⇒ 𝜔1,2 = Δ ± 𝑅 2
|𝜔1 − 𝜔2 | 𝑅 2
=⇒ Γ =
=
2𝜋
𝜋



2

(2.25)

Equation (2.25) is a crucial observation, indicating that transverse relaxation affects the linewidth of the observed NMR
spectrum, with faster relaxation producing broader peaks.

Summary of Analysis and Discussion of
Multiple Frequencies
The prior derivations describe the evolution of a single bulk
magnetization inclusive of a large number of nuclei all experiencing the same Larmor frequency 𝜔0 . This is an idealization
that is not representative of real-world samples, which are
heterogenous and in which nuclei are interacting with each
other depending on their immediate surroundings (both
inter- and intramolecular interaction). These complications
are also useful for spectroscopic studies.
Firstly, when nuclei of different atoms are present in one
sample, they all follow the same principles of NMR physics
outlined above. However, if their gyromagnetic ratios 𝛾 are
®1
different enough (see Table 2.1), then the application of 𝐵
on-resonance for nuclei X will not affect the spins and overall magnetization for nuclei Y or others. More interestingly,
nuclei X can still experience different overall magnetic fields
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®0 . This is
despite being subject to the same external field 𝐵
due to electronic shielding which can occur because of variations in bond characteristics, like length, angles, and electron
densities around the bonded atoms. Electrons orbiting the
nucleus are also magnetic particles, and their motion gener®0 and lowers the
ates a small magnetic field which opposes 𝐵
effective magnetic field experienced by the nucleus. Therefore, depending on the exposure a nucleus has to electrons,
there will be a small deviation from the regular Larmor
frequency. Electronic shielding is the principal cause for
chemical shift. For a nucleus experiencing a chemical shift 𝛿
® = 𝐵®0 (1 + 𝛿).
(Equation (2.24)), the field it senses is given by 𝐵
Plugging this expression into Equation (2.24) results in 𝛿 .
®0 .
Consider methanol, CH3 OH, in an external magnetic field 𝐵
The molecule contains four hydrogens, and it would seem
that each has the same Larmor frequency since each has the
same gyromagnetic ratio and is in the same field. However,
since C is less electronegative than O, the electron cloud
surrounding the C-H bond is more evenly split between
C and H than it is in the O-H bond, where the electron
cloud skews more toward the O (Figure 2.4). Therefore, the
resonance frequency of the exchangeable hydroxyl proton
is larger than the other protons coming off the C because
the electron cloud is smaller around the former, resulting
in less electronic shielding. These two classes of protons
are called magnetically distinguishable, because they are
inequivalent protons in terms of the chemical shift in the
1
H NMR spectrum. The three methyl protons, however, are
magnetically indistinguishable because there are no primary chemical effects which would alter the magnetic field
felt by any nucleus, and thus no change in the resonance
frequency. Therefore, they are considered spectroscopically
equivalent.
®1 will account for
A broad enough frequency profile for 𝐵
slight variations in the Larmor frequencies in a sample that
can arise from electronic shielding factors, both inter- and
intramolecular.
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Figure 2.4: Electron cloud distribution in methanol. Chemical
structure of methanol (CH3 OH),
where the bonds (ellipses) reveal
the electron (black dot) cloud distribution between the two bonded
atoms. For the C-O bond (black ellipse), the comparable electronegativities cause the electrons to be
evenly distributed between them.
For C-H bonds (blue ellipse), the
electrons are found near the carbon atom with higher probability. For the O-H bond, are mostly
found near the oxygen atom due
to its high electronegativity. Due
to these uneven electron distributions, intermolecular effects will
affect the electronic shielding of
different protons and cause chemical shift effects in the 1 H NMR
spectrum.

2.3 Quantum Mechanical Treatment of
NMR
While the classical treatment of NMR provides a good and
intuitive framework for understanding the principles behind
spectroscopy, magnetic resonance is fundamentally a quantum phenomenon and it is worth exploring NMR physics
through this lens. The following discussion attempts to characterize the quantum framework, and assumes the reader’s
familiarity with basic quantum mechanics concepts like the
wavefunction, operators and their algebra, and the overall
Hilbert space in which wavefunctions reside. The discussion also uses concepts introduced earlier in the classical
treatment.
Regardless of the scenario, the goal of the analysis will be to
determine the wavefunction 𝜓(𝑡) which describes nuclei in
the magnetic field, and its evolution under the Hamiltonian
ˆ , which in the most general case is also time-dependent.
𝐻(𝑡)
They are related by the Schrödinger equation

ˆ
𝐻(𝑡)
𝜓(𝑡) = 𝑖~

𝜕 𝜓(𝑡)
𝜕𝑡

(2.26)

and determination of this wavefunction will enable calculation of the expectation value of other operators.
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Spin Operators
As a first example, consider a single spin in a uniform mag®0 . Analogous to Equation (2.1), the magnetic
netic field 𝐵
moment and spin angular momentum operators are linearly
related via the gyromagnetic ratio:

𝜇ˆ 𝜈 = 𝛾 𝑆ˆ 𝜈 = 𝛾~𝐼ˆ𝜈

(2.27)

where 𝜈 ∈ {𝑥, 𝑦, 𝑧} is any of the Cartesian directions. Under
𝐵®0 , polarization will occur as discussed in Section 2.2. For
spin-1/2 nuclei, there are two possible energy states: the
spin-up 𝛼 state and spin-down 𝛽 state. Let |𝛼i and 𝛽 be
the corresponding wavefunctions for spins in these states,
respectively. For the 𝛼 state, the associated spin number (for
𝐼ˆ𝑧 ) is + 12 , and for the 𝛽 state is − 12 . Therefore, |𝛼i and 𝛽
must be eigenkets of 𝐼ˆ𝑧 , with respective eigenvalues of + 12
and − 12 : 𝐼ˆ𝑧 |𝛼i = 12 |𝛼i and 𝐼ˆ𝑧 𝛽 = − 12 𝛽 . In this {|𝛼i , 𝛽 }
eigenbasis of 𝐼ˆ𝑧 , the spin operators 𝐼ˆ𝑥 , 𝐼ˆ𝑦 , and 𝐼ˆ𝑧 take the form
of the Pauli matrices 𝜎𝑥 , 𝜎 𝑦 , and 𝜎𝑧 :
1
𝐼ˆ𝑥 =
2
1
𝐼ˆ𝑦 =
2



1
𝐼ˆ𝑧 =
2





0 1
1 0



0 −𝑖
𝑖 0



1 0
0 −1



(2.28a)

(2.28b)

(2.28c)

As can be seen from these matrix representations, the spin
operators follow the same commutator relations as angular
momentum: [𝐼ˆ𝑎 , 𝐼ˆ𝑏 ] = 𝑖𝜖 𝑎𝑏𝑐 𝐼ˆ𝑐 , where 𝜖 𝑎𝑏𝑐 is the Levi-Civita
tensor. Note that the three spin operators cyclically commute.
It is also worthwhile to define the operator 𝐼ˆ2 which corresponds to the square of the total spin angular momentum:

𝐼ˆ2 ≡ 𝐼ˆ𝑥 𝐼ˆ𝑥 + 𝐼ˆ𝑦 𝐼ˆ𝑦 + 𝐼ˆ𝑧 𝐼ˆ𝑧

(2.29)

𝐼ˆ2 commutes with each of the component spin operators
𝐼ˆ𝜈 by inspection. Specifically, this means that |𝛼i and 𝛽
are also eigenkets of 𝐼ˆ2 since [𝐼ˆ2 , 𝐼ˆ𝑧 ] = 0. To determine the
eigenvalues for these operators in a general sense, define the
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“ladder operators”:

𝐼ˆ+ ≡ 𝐼ˆ𝑥 + 𝑖 𝐼ˆ𝑦
𝐼ˆ− ≡ 𝐼ˆ𝑥 − 𝑖 𝐼ˆ𝑦

(2.30a)
(2.30b)

These operators don’t represent anything physically because
they are non-Hermitian but are useful mathematically. Note
that

[𝐼ˆ𝑧 , 𝐼ˆ+ ] = 𝐼ˆ𝑧 (𝐼ˆ𝑥 + 𝑖 𝐼ˆ𝑦 ) − (𝐼ˆ𝑥 + 𝑖 𝐼ˆ𝑦 )𝐼ˆ𝑧
= 𝐼ˆ𝑧 𝐼ˆ𝑥 + 𝑖 𝐼ˆ𝑧 𝐼ˆ𝑦 − 𝐼ˆ𝑥 𝐼ˆ𝑧 − 𝑖 𝐼ˆ𝑦 𝐼ˆ𝑧
= [𝐼ˆ𝑧 , 𝐼ˆ𝑥 ] + 𝑖[𝐼ˆ𝑧 , 𝐼ˆ𝑦 ]
= 𝑖 𝐼ˆ𝑦 + 𝑖(−𝑖 𝐼ˆ𝑥 )
= 𝐼ˆ+
By similar reasoning but sparing the algebra, [𝐼ˆ𝑧 , 𝐼ˆ− ] = 𝐼ˆ− .
To determine the eigenvalues, let 𝜓 be an eigenket of 𝐼ˆ𝑧
with eigenvalue 𝑚 ,i.e., 𝐼ˆ𝑧 𝜓 = 𝑚 𝜓 . What would happen
if 𝐼ˆ+ were applied before 𝐼ˆ𝑧 ? We observe that

𝐼ˆ𝑧 𝐼ˆ+ 𝜓 = (𝐼ˆ+ 𝐼ˆ𝑧 + [𝐼ˆ𝑧 , 𝐼ˆ+ ]) 𝜓
= (𝐼ˆ+ 𝐼ˆ𝑧 + 𝐼ˆ+ ) 𝜓
= 𝐼ˆ+ 𝐼ˆ𝑧 𝜓 + 𝐼ˆ+ 𝜓
= 𝑚 𝐼ˆ+ 𝜓 + 𝐼ˆ+ 𝜓
= (𝑚 + 1)𝐼ˆ+ 𝜓
The important finding here is that when 𝜓 is an eigenket
of 𝐼ˆ𝑧 with eigenvalue , then 𝐼ˆ+ 𝜓 is also an eigenket with
eigenvalue 𝑚 + 1. This is why 𝐼ˆ+ is a “ladder operator” because successive applications of it would increase the
eigenvalue by 1. But this cannot go on forever, because the
total spin angular momentum 𝐼 2 = 𝐼 𝑥2 + 𝐼 𝑦2 + 𝐼 𝑧2 is finite, and
𝐼 𝑧 = 𝑚 , so there exists some eigenvalue 𝑚max associated with
an eigenket 𝜓max such that if 𝐼ˆ𝑧 𝜓max = 𝑚max 𝜓max , then
𝐼ˆ+ 𝜓max = 0. By similar reasoning, 𝐼ˆ𝑧 𝐼ˆ− 𝜓 = (𝑚 − 1)𝐼ˆ− 𝜓
and there exists some eigenvalue 𝑚min associated with an
eigenket 𝜓min such that if 𝐼ˆ𝑧 𝜓min = 𝑚min 𝜓min , then
𝐼ˆ− 𝜓min = 0.
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Now, we also note that

𝐼ˆ− 𝐼ˆ+ = (𝐼ˆ𝑥 − 𝑖 𝐼ˆ𝑦 )(𝐼ˆ𝑥 + 𝑖 𝐼ˆ𝑦 ) = 𝐼ˆ𝑥2 + 𝐼ˆ𝑦2 + 𝑖[𝐼ˆ𝑥 , 𝐼ˆ𝑦 ] = 𝐼ˆ𝑥2 + 𝐼ˆ𝑦2 − 𝐼ˆ𝑧
which means that 𝐼ˆ2 = 𝐼ˆ𝑥2 + 𝐼ˆ𝑦2 + 𝐼ˆ𝑧2 = 𝐼ˆ− 𝐼ˆ+ + 𝐼ˆ𝑧 + 𝐼ˆ𝑧2 . With 𝐼ˆ2
written this way, applying it to 𝜓max results in

𝐼ˆ2 𝜓max = 𝐼ˆ− 𝐼ˆ+ 𝜓max + 𝐼ˆ𝑧 𝜓max + 𝐼ˆ𝑧2 𝜓max
2
= 0 + 𝑚max 𝜓max + 𝑚max
𝜓max

= 𝑚max (𝑚max + 1) 𝜓max
Similarly, observe that

𝐼ˆ+ 𝐼ˆ− = (𝐼ˆ𝑥 + 𝑖 𝐼ˆ𝑦 )(𝐼ˆ𝑥 − 𝑖 𝐼ˆ𝑦 ) = 𝐼ˆ𝑥2 + 𝐼ˆ𝑦2 + 𝑖[𝐼ˆ𝑦 , 𝐼ˆ𝑥 ] = 𝐼ˆ𝑥2 + 𝐼ˆ𝑦2 + 𝐼ˆ𝑧
so 𝐼ˆ2 can also be written as 𝐼ˆ2 = 𝐼ˆ𝑥2 + 𝐼ˆ𝑦2 + 𝐼ˆ𝑧2 = 𝐼ˆ+ 𝐼ˆ− − 𝐼ˆ𝑧 + 𝐼ˆ𝑧2 .
Now, with 𝐼ˆ2 written this way and applied to 𝜓min , we
find

𝐼ˆ2 𝜓min = 𝐼ˆ+ 𝐼ˆ− 𝜓min − 𝐼ˆ𝑧 𝜓min + 𝐼ˆ𝑧2 𝜓min
2
= 0 − 𝑚min 𝜓min + 𝑚min
𝜓min

= 𝑚min (𝑚min − 1) 𝜓min
Without loss of generality, due to the nature of the ladder
operators, we assume 𝑚max > 𝑚min . Because 𝐼ˆ2 and 𝐼ˆ𝑧 commute, let 𝜓 be a common eigenket to both, and let 𝑚 be its
eigenvalue for 𝐼ˆ𝑧 . The eigenvalue for 𝐼ˆ2 has to be independent
of 𝑚 since 𝐼 2 = 𝐼 𝑥2 + 𝐼 𝑦2 + 𝑚 2 is finite. Specifically, the 𝐼ˆ2
eigenvalues for 𝜓max and 𝜓min must also be independent
of 𝑚 . Therefore, 𝑚max (𝑚max + 1) = 𝑚min (𝑚min − 1), which
has only one feasible solution: 𝑚min = −𝑚max . The other
solution 𝑚min = 𝑚max + 1 is not possible because we assume
𝑚max > 𝑚min . For ease of notation, define 𝑙 ≡ 𝑚max . Then we
have found that

𝐼ˆ2 𝜓 = 𝑙(𝑙 + 1) 𝜓
𝐼ˆ𝑧 𝜓 = 𝑚 𝜓

(2.31a)
(2.31b)

where −𝑙 ≤ 𝑚 ≤ 𝑙 . Note that 𝑚 has to be either an integer or
half-integer otherwise 𝑚min = −𝑚max is not possible when
𝑚 increments or decrements by 1 via the ladder operators.
Thus, there are 2 𝑙 + 1 possible values of 𝑚 .
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The Hamiltonian and Polarization
®0 (including
For a spin system subject to an external field 𝐵
polarization) characterized by a wavefunction 𝜓 , the total
energy 𝐸 of the system is given by the expectation value of
ˆ , defined as
the Hamiltonian operator 𝐻(𝑡)
ˆ 𝜓 = h𝜓| 𝐻𝜓i
ˆ
𝐸 = h𝐻i
=

∫

∞

𝜓 ∗ (𝑡)𝐻(𝑡)𝜓(𝑡) 𝑑𝑡

(2.32)

0

Analogous to the classical description of energy (Equation (2.1)), substituting the operator 𝜇ˆ 𝑧 = 𝛾~𝐼ˆ𝑧 (Equation (2.27))
gives the Hamiltonian operator

𝐻ˆ = −~𝛾𝐵0 𝐼ˆ𝑧 = −~𝜔0 𝐼ˆ𝑧

(2.33)

Based on this definition, it is clear to see that the energy
eigenvalues for the eigenkets of 𝐼ˆ𝑧 are 𝐻ˆ |𝛼i = − 12 ~𝜔0 |𝛼i
and 𝐻ˆ 𝛽 = 12 ~𝜔0 𝛽 . The difference between these energy
eigenvalues is Δ𝐸 = 𝐸𝛽 − 𝐸 𝛼 = ~𝜔0 .
Given Equation (2.33), 𝐻ˆ is time-independent. Thus, the
Schrödinger equation (Equation (2.26)) is easily solved as
2
ˆ
(−𝑖𝑡 𝐻/~)
ˆ
ˆ
𝜓(0) = 1 + (−𝑖𝑡 𝐻/~) +
𝜓(𝑡) = 𝑒
+ · · · 𝜓(0)
2!
(2.34)
ˆ
where 1 is the identity operator. Given the form of Equation (2.34), it would be helpful to expand 𝜓(𝑡) in the eigenbasis of 𝐻ˆ . Therefore, the most general solution with this
Hamiltonian is



ˆ

− 𝑖𝑡~𝐻

𝜓(𝑡) = 𝑐 𝛼 𝑒

𝑖



𝜔0 𝑡
2 +𝜙 𝛼







|𝛼i + 𝑐 𝛽 𝑒

𝑖 −

𝜔0 𝑡
2 +𝜙 𝛽



𝛽

(2.35)

where 𝑐 𝛼 , 𝑐 𝛽 , 𝜙 𝛼 , and 𝜙𝛽 are real constants such that 𝑐 2𝛼 + 𝑐 𝛽2 =

1. The latter condition is to ensure that 𝜓(𝑡) is normalized
properly and can be used as an accurate probability distribution function to calculate expectation values over any
operator. 𝜙 𝛼 and 𝜙𝛽 are included to account for any phase
the solutions may have.
With this wavefunction now solved, we can use it to calculate
quantities relevant to NMR. The longitudinal magnetization
of the system is given by the expectation value of the 𝜇ˆ 𝑧
operator (Equation (2.27)) with respect to the wavefunction
𝜓(𝑡) calculated in Equation (2.35). Writing everything out,
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this becomes

h𝜇ˆ 𝑧 i𝜓 = ~𝛾h𝐼ˆ𝑧 i𝜓



= ~𝛾 𝑐 𝛼 𝑒



𝑐𝛼 𝑒

=

𝑖



−𝑖

𝜔0 𝑡
2 +𝜙 𝛼



𝜔0 𝑡
2 +𝜙 𝛼





h𝛼| + 𝑐 𝛽 𝑒





|𝛼i + 𝑐 𝛽 𝑒

𝑖 −

−𝑖 −

𝜔0 𝑡
2 +𝜙 𝛽

𝜔0 𝑡
2 +𝜙 𝛽



𝛽





𝛽 ·



~𝛾 2
(𝑐 𝛼 − 𝑐 𝛽2 )
2

(2.36)

Because 𝑐 2𝛼 + 𝑐 𝛽2 = 1, 𝑐 2𝛼 and 𝑐 𝛽2 represent the probabilities

of finding the system in the |𝛼i and 𝛽 states, respectively.
Following Maxwell-Boltzmann statistics as was done in Section 2.2, and using the energy eigenvalues for the |𝛼i and
𝛽 states (Equation (2.35)), we find that
0
1 2~𝜔
𝑒 𝑘𝐵 𝑇
𝑄
1 − ~𝜔0
𝑐 𝛽2 = 𝑒 2𝑘𝐵 𝑇
𝑄

𝑐 2𝛼 =

~𝜔0

−

~𝜔0

where 𝑄 = 𝑒 2𝑘𝐵 𝑇 + 𝑒 2𝑘𝐵 𝑇 is again the canonical partition function. Since NMR energy (~𝜔0 /2) is much less than thermal
energy ( 𝑘 𝐵 𝑇 ), the Taylor approximations for these exponentials can be made, and we find

~2 𝛾 2 𝐵 0
~𝛾 ~𝜔0
=
h𝜇ˆ 𝑧 i =
2 2 𝑘𝐵𝑇
4 𝑘𝐵𝑇





(2.37)

This is the value for one spin. Since all spins undergo this
same polarization, when we consider the ensemble average of
~2 𝛾2 𝐵

all spins ( 𝑁 ), we find it to be identical, i.e. that h𝜇ˆ 𝑧 i = 4 𝑘 𝐵 𝑇 0 ,
where the bar indicates ensemble average. Normalizing by
® =
the volume (Equation (2.3)) yields the magnetization 𝑀
𝑁 h𝜇ˆ 𝑧 i
𝑉

=

𝑁~2 𝛾2 𝐵0
4 𝑘 𝐵 𝑇𝑉

which is in agreement with Equation (2.6).

We can also look at the transverse magnetization by considering the expectation values h𝜇ˆ 𝑥 i𝜓 and h𝜇ˆ 𝑦 i𝜓 . Employing
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Equation (2.28), it is easy to see that
1
𝐼ˆ𝑥 |𝛼i = 𝛽
2
1
𝐼ˆ𝑥 𝛽 = |𝛼i
2
𝑖
𝐼ˆ𝑦 |𝛼i = 𝛽
2
𝑖
𝐼ˆ𝑦 𝛽 = − |𝛼i
2
Calculating h𝜇ˆ 𝑥 i𝜓 is done similarly as for h𝜇ˆ 𝑧 i𝜓 earlier. Therefore,

h𝜇ˆ 𝑥 i𝜓 = ~𝛾h𝐼ˆ𝑥 i𝜓



= ~𝛾 𝑐 𝛼 𝑒

−𝑖



𝜔0 𝑡
2 +𝜙 𝛼





h𝛼| + 𝑐 𝛽 𝑒

−𝑖 −

𝜔0 𝑡
2 +𝜙 𝛽



𝛽 ·

𝜔 𝑡
𝜔 𝑡
1
1
𝑖 20 +𝜙 𝛼
𝑖 − 20 +𝜙𝛽
𝑐𝛼 𝑒
𝛽 + 𝑐𝛽 𝑒
|𝛼i
2
2
~𝛾
=
[𝑐 𝛼 𝑐 𝛽 𝑒 −𝑖(𝜔0 𝑡+Δ𝜙) + 𝑐 𝛽 𝑐 𝛼 𝑒 𝑖(𝜔0 𝑡+Δ𝜙) ]
2
= ~𝛾𝑐 𝛼 𝑐 𝛽 cos(𝜔0 𝑡 + Δ𝜙)















(2.38a)

With the same math, we also find that

h𝜇ˆ 𝑦 i𝜓 = −~𝛾𝑐 𝛼 𝑐 𝛽 sin(𝜔0 𝑡 + Δ𝜙)

(2.38b)

As we can see from Equation (2.38), the expectation values
for the transverse components of a single magnetic moment
undergo Larmor precession. However, due to the arbitrary
nature of the phase, the ensemble averages h𝜇ˆ 𝑥 i = h𝜇ˆ 𝑦 i = 0,
which is why macroscopically no transverse magnetization
is observed.

The Hamiltonian Under Excitation
Again, we consider the scenario where now an excitation
®1 is applied at an angular frequency 𝜔𝑅 , giving rise to a
field 𝐵

nutation frequency 𝜔1 = 𝛾𝐵1 . Without loss of generality, we
®1 is applied along the +𝑥 -direction. The Hamiltonian
will say 𝐵
from Equation (2.33) is appended to now include effects from
®0 and 𝐵®1 :
both 𝐵

ˆ
𝐻(𝑡)
= −~𝜔0 𝐼ˆ𝑧 − ~𝜔1 (𝐼ˆ𝑥 cos 𝜔𝑅 𝑡 − 𝐼ˆ𝑦 sin 𝜔𝑅 𝑡)

(2.39)
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Due to the periodic nature of this Hamiltonian, we again
ˆ
switch to a rotating frame also rotating at 𝜔𝑅 . Recall that if 𝑈
ˆ
is a unitary operator which transforms another operator 𝑂
ˆ 𝑓 ) to another basis 𝑔 𝑗
from one basis 𝑓𝑖 (represented as 𝑂
ˆ 𝑔 ), then 𝑂ˆ 𝑓 = 𝑈
ˆ 𝑂ˆ 𝑔 𝑈
ˆ † where the dagger
(represented as 𝑂
superscript indicates Hermitian conjugate, or the complex
ˆ
conjugate transpose. Also recall that 𝑒 𝑖𝜃 𝐴 is a unitary operator
which rotates by an angle 𝜃 about the direction of 𝐴ˆ . Then
in our switch to the rotating frame of reference, the new
Hamiltonian and new wavefunction representation we get
are
ˆ ˆ
𝑖𝜔𝑅 𝑡 𝐼ˆ𝑧
ˆ
𝐻(𝑡)
↦−→ 𝐻ˆ 𝑅 (𝑡) = 𝑒 −𝑖𝜔𝑅 𝑡 𝐼𝑧 𝐻(𝑡)𝑒

𝜓(𝑡) ↦−→ 𝜓 𝑅 (𝑡) = 𝑒

−𝑖𝜔𝑅 𝑡 𝐼ˆ𝑧

(2.40a)

𝜓(𝑡)

(2.40b)

with an effective Schrödinger equation given now by

𝜕
𝜓 𝑅 (𝑡) = −𝑖~[−(𝜔0 − 𝜔𝑅 )𝐼ˆ𝑧 − 𝜔1 𝐼ˆ𝑥 ] 𝜓 𝑅 (𝑡)
𝜕𝑡
≡ −𝑖~𝐻ˆ eff (𝑡) 𝜓 𝑅 (𝑡)
(2.41)
In the rotating frame, not that the initial wavefunction is
generic: 𝜓 𝑅 (0) = 𝑐 𝛼 𝑒 𝑖𝜙 𝛼 |𝛼i + 𝑐 𝛽 𝑒 𝑖𝜙𝛽 𝛽 .
Assuming the pulse is on-resonance ( 𝜔𝑅 = 𝜔0 , meaning that
𝐻ˆ eff = −𝜔1 𝐼ˆ𝑥 ) and of length 𝑡 𝑝 , then from Equation (2.40b)
we have

𝜓 𝑅 (𝑡 𝑝 ) = 𝑐 𝛼 𝑒
+ 𝑐𝛽 𝑒

−𝑖𝜙 𝛼

−𝑖𝜙𝛽





𝜔1 𝑡 𝑝



cos
2


𝜔1 𝑡 𝑝


cos

2

|𝛼i + 𝑖 sin
𝛽 + 𝑖 sin



𝜔1 𝑡 𝑝



2


𝜔1 𝑡 𝑝



𝛽


|𝛼i

2
(2.42)

Consider the special case where the pulse is applied for a
time 𝑡180 such that 𝜔1 𝑡180 = 𝜋 (or 180◦ ). Then substituting
this into Equation (2.42), we get



𝜓 𝑅 (𝑡180 ) = 𝑖 𝑐 𝛼 𝑒 −𝑖𝜙 𝛼 𝛽 + 𝑐 𝛽 𝑒 𝑖𝜙𝛽 |𝛼i



from which we can see that h𝜇ˆ 𝑧 i𝜓𝑅 = ~𝛾 𝜓 𝑅 𝐼ˆ𝑧 𝜓 𝑅
~𝛾 2
2 (𝑐 𝛽

𝑐 2𝛼 )

=

−
following the same logic as Equation (2.36).
Note, however, that in this case, this result is the negative
of Equation (2.36). This indicates that 𝑀 𝑧 has been inverted,
which complies with physical intuition following a 180◦
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pulse.
Consider also the case of a 90◦ pulse. The pulse is turned on
for a time 𝑡90 such that 𝜔1 𝑡90 = 𝜋2 (or 90◦ ). Substituting this
into Equation (2.42), we get
1
𝜓 𝑅 (𝑡90 ) = √ [(𝑐 𝛼 𝑒 −𝑖𝜙 𝛼 +𝑖𝑐 𝛽 𝑒 −𝑖𝜙𝛽 ) |𝛼i+(𝑐 𝛽 𝑒 −𝑖𝜙𝛽 +𝑖𝑐 𝛼 𝑒 −𝑖𝜙 𝛼 ) 𝛽 ]
2
For a single spin, after working out the math, we find that

h𝜇ˆ 𝑥 i𝜓𝑅 = ~𝛾𝑐 𝛼 𝑐 𝛽 cos(𝜙𝛽 − 𝜙 𝛼 )
~𝛾
h𝜇ˆ 𝑦 i𝜓𝑅 = − (𝑐 2𝛼 − 𝑐 𝛽2 )
2
h𝜇ˆ 𝑧 i𝜓𝑅 = ~𝛾𝑐 𝛼 𝑐 𝛽 sin(𝜙𝛽 − 𝜙 𝛼 )
When averaging over ensembles, periodic terms will become
0:

h𝜇ˆ 𝑥 i 𝜓𝑅 = 0
h𝜇ˆ 𝑦 i 𝜓 = −
𝑅

~𝛾 2
(𝑐 𝛼 − 𝑐 𝛽2 )
2

h𝜇ˆ 𝑧 i 𝜓𝑅 = 0
In other words, the macroscopic magnetization which was
before pointing along the + 𝑧 -direction (Equation (2.36)) is
now pointing along the −𝑦 -direction, exactly what would
happen following a 90◦ pulse applied along the + 𝑥 -axis. What
this shows is that a 90◦ equalizes the probabilities between
the |𝛼i and 𝛽 states (hence h𝜇ˆ 𝑧 i 𝜓𝑅 = 0) and also induces
a phase coherence between these states as well, generating
transverse magnetization.
It is worth noting that, physically, we should not picture two
populations of spins, such that one is purely spin-up and the
other is purely spin-down. That is to say, it is wrong to assume
there are 𝑁𝛼 spins with a wavefunction given by 𝜓 𝛼 = |𝛼i
and 𝑁𝛽 spins with a wavefunction given by 𝜓𝛽 = 𝛽 such
𝑁𝑘
that 𝑐 2𝑘 = 𝑁𝛼 +𝑁
for 𝑘 ∈ {𝛼, 𝛽}. This incorrectly implies that
𝛽

each 𝑐 2𝑘 is the respective probability of a spin being in the |𝑘i
state. The system described here is an example of a statistical
mixture of states, which is not observed physically. Rather, a
real system is described as a group of 𝑁 spins, each of which
P
has a generic wavefunction given by 𝜓 = 𝑘∈{𝛼,𝛽} 𝑐 𝑘 𝑒 𝑖𝜙 𝑘 |𝑘i ,
which is a linear superposition of the different states. Note
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that this still does not imply 𝑐 2𝑘 is related to the probability
of being entirely in the |𝑘i state. If this were the case, then 𝑐 𝑘
would be 0 or 1 for every spin in the system. This would mean
that during polarization, h𝜇ˆ 𝑥 i = ~𝛾𝑐 𝛼 𝑐 𝛽 cos(𝜔0 𝑡 + Δ𝜙) and
h𝜇ˆ 𝑦 i = −~𝛾𝑐 𝛼 𝑐 𝛽 sin(𝜔0 𝑡 + Δ𝜙) would always be 0 since 𝑐 𝛼 𝑐 𝛽
would always be 0. This would be for each spin, not solely
for the ensemble average. Thus, there would be no transverse
components to bring into coherence following a 90◦ pulse
and no signal would ever be generated. In a real NMR
experiment, the system is described by a statistical mixture
of spins, each of which is described by a linear superposition
of states. This means that there are 𝑁 spins, each of which
with a wavefunction 𝜓 𝑘 = 𝑐 𝛼 𝑘 𝑒 𝑖𝜙 𝛼 𝑘 |𝛼i + 𝑐 𝛽 𝑘 𝑒 𝑖𝜙𝛽 𝑘 𝛽 ( 𝑘 =
1 , 2 , · · · , 𝑁 ), where every 𝑐 𝛼 𝑘 , 𝑐 𝛽 𝑘 , 𝜙 𝛼 𝑘 , and 𝜙𝛽 𝑘 is a real
constant and 𝑐 2𝛼 𝑘 + 𝑐 𝛽2 = 1.
𝑘

2.4 Chemical Shift Effects
Chemical shift was introduced briefly in the context of electronic shielding (Equation (2.24)). Chemical shift in NMR
reveals many properties about the sample, not simply in terms
of shielding but also general physical properties like state of
matter, and physiological properties like pH and temperature. Intramolecular shielding is also only one component.
There is also chemical shift which arises from interactions of
intermolecular shielding between NMR-visible nuclei and
paramagnetic species which produce their own local magnetic fields. This latter type will be explored in subsequent
chapters, focusing on the sodium-23 (23 Na) nucleus in the
presence of paramagnetic lanthanide-based agents. However,
the remainder of this section will focus on both the chemical shift arising from intramolecular and intermolecular
effects.

Intramolecular Effects
Chemical shift is an easily made observable measurement in
®0 which enables
the presence of an external magnetic field 𝐵
probing the electronic shielding within a molecule, which
cannot be measured directly. In the most general case, both
these quantities are anisotropic, and therefore require tensorial descriptions. A relationship between tensors for chemical
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Molecule (CH3 X)

𝜀𝑋 (Paulings)

𝛿 (ppm)

CH4
CH3 I
CH3 Br
CH3 Cl
CH3 OH
CH3 F

2.1
2.5
2.8
3.1
3.5
4.0

0.23
2.16
2.68
3.05
3.4
4.26

shift 𝜹 and electronic shielding 𝝈 is given by[225]

𝜹 = 𝜎iso 1 − 𝝈

(2.43)

where 1 is the 3 × 3 identity matrix, and 𝜎iso is the absolute
isotropic chemical shift, which is the trace of the shielding
tensor for the NMR reference standard. Usually, this is chosen to be 0 as well for convenience. For in vitro 1 H NMR,
two common reference standards used are Si(CH3 )4 (tetramethylsilane, TMS) or Si(CH3 )3 CH2 CH2 COOH (trimethylsilylpropanoic acid, TSP) due to the relative insensitivity of
their peaks to external factors like temperature and ionic
composition of the solution being studied.
Electronegativity ( 𝜀) was one aspect of shielding and chemical shift that was discussed earlier. Electronic motion around
the nucleus produces small magnetic fields which, when
®0 . When
time-averaged, oppose the applied external field 𝐵
the nucleus of interest is either directly or closely bound
to a highly electronegative atom, this serves to de-shield
the nucleus and affect chemical shift. Consider the values
shown in Table 2.2. These values demonstrate how increased
electronegativity de-shields the C atom to a greater degree,
and the electron clouds surrounding the H atoms are pulled
toward C atom to compensate, ultimately exposing the 1 H
®0 to a greater extent. These de-shielding effects
nuclei to 𝐵
are cumulative, so a larger number of electronegative atoms
results in even more de-shielding, as seen in Table 2.3. Therefore, de-shielding produced by highly electronegative atoms
plays a significant role in the chemical shifts observed. Overall, we see the net magnetic field experienced by the nuclei
®0 and the local chemical
of interest is a superposition of 𝐵
environment determined by the electron density.

Table 2.2: Electronegativities and
chemical shifts for monosubstituted methane derivatives.
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Molecule
CH4
CH3 Cl
CH2 Cl2
CHCl3

Table 2.3: Chemical shifts for
methane derivatives with different degree of chloride substitution.

𝛿 (ppm)
0.23
3.05
5.3
7.27

Seminal work by Norman Ramsey expanded on the theory
of the shielding tensor[225]. In his formalism, he Taylorexpanded the energy 𝐸 of the molecules being studied with
®0 and the magnetic moment 𝜇
® of the nuclei of
respect to 𝐵
interest[226]. The components of the shielding tensor 𝜎𝜆𝜌
represent the coefficients of this bilinear expansion of 𝐸 in the
Ramsey formalism, and are hence the second mixed partial
derivatives of energy, i.e.,

𝜎𝜆𝜌 =

𝜕2 𝐸
®𝜌
𝜕 𝐵®0 𝜕𝜇

(2.44)

𝜆

Ramsey arrived at explicit expressions for 𝝈 by applying
Hartree-Fock perturbation theory. However, the physics of
shielding can also be recast by considering the interaction of
® with the current density ®𝐽ind (®𝑟 ) induced by 𝐵®0 . From this,
𝜇
®ind can very easily be
the shielding-induced magnetic field 𝐵
calculated by the Biot-Savart Law:
1
𝐵®ind (®𝑟 ) =
𝑐

®𝐽ind (®𝑟 ) × 𝑟®

∫
molecule

𝑟®

𝑑3 𝑟®

(2.45)

3

where integration is performed over the whole volume. Equiv®ind will also be thought of as a response to 𝐵®0 with
alently, 𝐵
the shielding tensor facilitating the description of this response:

𝐵®ind𝜆 = −

3
X

𝜌=1

𝜎𝜆𝜌 𝐵®0𝜌

(2.46)

®ind and ®𝐽ind will be pertinent to both perspectives
Both 𝐵
outlined above.
®0 in its ground
Consider a molecule in a magnetic field 𝐵
state electronic configuration. Let 𝜓0 be its wavefunction.
By Maxwell’s equations, the induced current density ®𝐽ind (®𝑟 )
is

®𝐽ind (®𝑟 ) = 𝑖 [h∇𝜓0 |𝜓0 i − h𝜓0 |∇𝜓0 i] − 1 h𝜓0 |𝜓0 i 𝐴®
2
𝑐

(2.47)
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where 𝑐 is the speed of light (2.998 × 108 m/s) and 𝐴® is a
®0 , i.e. 𝐵®0 = ∇ × 𝐴®. To calculate
magnetic vector potential of 𝐵
𝐵®ind (Equation (2.45)) from this ®𝐽ind (Equation (2.47)), the
ground-state wavefunction 𝜓0 must be formulated. For a
®0 , the Hamiltonian 𝐻ˆ
molecule with 𝑁𝑒 electrons in a field 𝐵
is

𝐻ˆ =

𝑁𝑒
𝑝ˆ 2𝑗
X

−

2

𝑗=1

𝐴® · 𝑝ˆ 𝑗
2𝑐

!

𝐴® · 𝐴®
+
+𝑉
2𝑐 2

(2.48)

where 𝑗 indexes the electrons, 𝑝ˆ 𝑗 is the momentum operator
for the 𝑗 th electron, and 𝑉 is the aggregate potential energy
for the electron-nucleus and electron-electron interactions.
Since 𝐴® is not unique, the Coulomb gauge is chosen for
®0 × 𝑟®, for which ∇ · 𝐴® = 0 without loss of
convenience: 𝐴® = 12 𝐵
generality. This Hamiltonian can be expanded perturbatively
as 𝐻ˆ = 𝐻ˆ (0) + 𝐻ˆ (1) similar to Ramsey, where 𝐻ˆ (1) contains
the 𝐴® · 𝑝ˆ 𝑗 interaction term between the magnetic field and the
electronic momentum. Using the position-space definition
of the momentum operator 𝑝ˆ = −𝑖∇, we find
1
𝑖
𝐻ˆ (1) = − (𝐵®0 × 𝑟®) · ∇ ≡ 𝐵®0 · 𝐿ˆ
2𝑐
2𝑐

(2.49)

where 𝐿ˆ is the angular momentum operator for the electron.
Likewise, the ground-state wavefunction can be expanded
as
E
E
(0)
(1)
®
𝜓 0 = 𝜓 0 + 𝑖 𝐵0 · 𝜓 0 + · · ·
(2.50)
and the induced current density can be expanded as

®
®𝐽ind (®𝑟 ) = ®𝐽 (0) (®𝑟 ) + 𝐵®0 · 𝜕 𝐽(®𝑟 ) + · · ·
𝜕𝐵®0

(2.51)

The first term in Equation (2.51) is a natural current density
in the absence of any applied magnetic field, which goes
to 0 for molecules lacking a permanent magnetic moment
(i.e., non-magnetic materials). Furthermore,
the first-order
E
(1)

perturbation of the wavefunction 𝜓0

is normally expanded

in the basis of the unperturbed system’s excited states:
(1)

𝜓0

E

=

X
𝑛≠0

® 𝑛(1) 𝜓(𝑛0)
𝐾

E
(2.52)

Employing the perturbation in Equation (2.50), the second
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term in Equation (2.51) becomes

h
E
E
𝜕®𝐽(®𝑟 )
𝑖
(0)
(1)
= 𝐵®0 𝜓0
𝐵®0 ·
∇ · 𝜓0
2
𝜕 𝐵®0
(1)

− 𝜓0

E

(0)

∇ · 𝜓0

1
− h𝜓0 |𝜓0 i 𝐴®
𝑐

E


(2.53)

With these linearizations in place, the Biot-Savart Law (Equation (2.45)) stipulates that the shielding tensor is now given
as a function of nuclear position 𝑟®𝑁 by

𝑟 · 𝑟®𝑁 )1 − 𝑟®𝑁 ⊗ 𝑟® (0)
1
(0) (®
𝝈(®𝑟 𝑁 ) = 2 𝜓0
𝜓0
2𝑐
|®𝑟 𝑁 | 3


𝐿ˆ
2
(0)
(0)
𝜓0
𝜓
−
𝑐
|®𝑟 𝑁 | 3 0





(2.54)

Substituting the expansion in Equation (2.52) into this expression for the electronic shielding tensor (Equation (2.54))
yields

𝑟 · 𝑟®𝑁 )1 − 𝑟®𝑁 ⊗ 𝑟® (0)
1
(0) (®
𝝈(®𝑟 𝑁 ) = 2 𝜓0
𝜓0
2𝑐
|®𝑟 𝑁 | 3

 D
E
2X
𝐿ˆ
1
(0)
(0) ˆ
(0)
(0)
−
𝜓0
⊗
𝜓
𝐿
𝜓
𝜓
𝑛
𝑛
0
𝑐 𝑛≠0 𝐸𝑛 − 𝐸0
|®𝑟 𝑁 | 3



≡ 𝝈𝒅 (®𝑟 𝑁 ) + 𝝈𝒑 (®𝑟 𝑁 )



(2.55)

where 𝝈𝒅 (®𝑟 𝑁 ) and 𝝈𝒑 (®𝑟 𝑁 ) respectively represent the diamagnetic and paramagnetic terms to the chemical shift. This is
the form for the shielding tensor that was also expressed by
Ramsey, however the analysis here took more a quantum
electrodynamic approach of the shielding phenomenon. Although application of Equation (2.55) requires knowledge of
the complete set of wavefunctions and their corresponding
energies, approximate solutions can be determined using
computational methods like density function theory. Also
in complete basis, the result is gauge-invariant, so any other
choice of the vector would not affect the results[227]. This
justifies the use of the Coulomb gauge in this analysis.
The first term in Equation (2.55) is the diamagnetic contribution to the electronic shielding, and the second term is
the paramagnetic contribution. Note that from the nature of
Equation (2.55), it is evident that the diamagnetic portion of
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electronic shielding depends solely on the nuclear-electron
Coulombic interactions based on the positions of the electrons and the nucleus. The paramagnetic portion, on the other
hand, includes the angular momentum which results from
®0 (Equation (2.49)).
nuclear and electronic interactions with 𝐵
It has been shown that for a variety of molecules, the paramagnetic contribution to shielding is a stronger determinant
of the chemical shift. For instance, Saika and Slichter demonstrated that 𝝈𝒑 played a bigger role in 19 F chemical shifts
and bond characteristics for fluorinated molecules[228]. In
general, the fractional changes in 𝝈𝒅 caused by bond variations are smaller than fractional changes in 𝝈𝒑 for atoms
other than hydrogen[229]. Dickinson conducted simulations
of the Ramsey equations for various atoms which showed
that the contribution of outer electrons to 𝝈𝒅 comprised less
of an overall percentage as atomic number increased[230].
This is significant for bonding and chemical environments
since outer electrons are involved in forming molecules. He
concluded that changes in chemical environment for H atom
is roughly reflect the change in magnitude of the shielding
of protons, but outer electrons in Xe (i.e., 5 𝑝 ) comprise only
0.075% of 𝝈𝒅 . As a result, the diamagnetic contribution to Xe
chemical shift is small.
−2
Also, for both 𝝈𝒅 and 𝝈𝒑 , there is a clear 𝑟 𝑁
(i.e., inversesquare) dependence on the nuclear positions and nuclearelectronic distances (although the denominator contains a
−3
𝑟𝑁
term, the numerator also contains 𝑟 𝑁 to the first power).
However, Jameson and Gutowsky found that 1 H chemical
shift and electronic shielding variations arising from changes
in chemical environment would instead scale according
−3
to 𝑟 𝑁
[229], with experimental correlations between this
quantity and observed chemical shifts for several atoms
confirming this[231]. This discrepancy can be attributed to
the theoretical Ramsey equations not explicitly taking into
account interactions between different electrons and their
®0 [232]. However, this
effect on shielding in the presence of 𝐵
incongruity between theory and experiment do not detract
from some of the main points to be taken away from the
previous derivations and results.

Overall, this analysis provides a detailed look at the mechanisms behind electronic shielding and their ultimate effect
on the chemical shift observed. Paramagnetic effects play a
significant role for many NMR-visible X-nuclei, including
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23

Na. While intramolecular shielding plays a significant role
for atoms which frequently participate in covalent bonds,
metals are less likely to be coordinated to any one particular
molecule long enough for intramolecular shielding effects
to take effect. For metals (like sodium), chemical shifts will
arise less from electrons and more from the presence of
paramagnetic species, which will now be explored.

Intermolecular Effects
Most endogenous biological metals – like sodium (Na+ ),
potassium (K+ ), and calcium (Ca2+ ), among others – play
critical roles in vivo in creating physiologically relevant electrochemical potential differences and facilitating a multitude
of bioenergetic processes. While the following discussion focuses on Na+ , it can readily apply to other metallic cations.
Na+ , like other biological cations, remains in ionic form in
vivo and does not form covalent bonds with other molecules
in which it shares electrons with other atoms in order to
fill up its valence shell. For this reason, Na+ usually acts
as a counterion to balance negatively charged moieties on
other species in vivo but does so only transiently with the
potential to be displaced by other cations, and does not
formally compose any molecule. To this end, there are two
distinct states in which Na+ may be found: ionically bound to
negatively charged domains on other molecules, or aqueous
and unbound as part of the bulk electrolyte. Moreover, there
is constant exchange happening between these two Na+ pools.
The existence of this pair of distinct physical states for Na+ as
well as continuous physical interconversion between the two
has interesting consequences for their magnetic properties
and ultimately what is seen on the NMR spectrum.
The aqueous, unbound state obeys the same principles of
magnetic moment outlined in detail earlier. Recall that the
gyromagnetic ratio for sodium-23 is 𝛾Na = 11.26 MHz/T( Ta®0 , unbound Na+ nuclei
ble 2.1). For a particular external field 𝐵
resonate with the Larmor frequency 𝜔0 = 𝛾Na 𝐵0 , without
any electronic shielding effects producing different chemical
shifts. Thus, there is a single frequency in a population of free,
aqueous Na+ . Moreover, relaxation is often undisturbed for
this pool of Na+ , but produces different observed relaxation
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®0
rates 𝑅 1 and 𝑅 2 (as defined in Section 2.2) with different 𝐵
strengths[233–236].
Bound Na+ , on the other hand, exhibits different magnetic
properties. For the small amount of time Na+ spends bound
to another species (𝜏𝑚 , the lifetime of bound Na+ ), it will
experience lower translational and rotational mobility, as
measured by molecular correlation time 𝜏𝑐 and rotational
correlation time 𝜏𝑅 , respectively. However, if the species is
non-magnetic, then it will not show an appreciable change
in resonance frequency because it ultimately experiences the
®0 that unbound Na+ experience as well. Therefore,
same 𝐵
during the course of an NMR experiment, it will polarize
®1 in much the same way as unbound Na+ .
and be excited by 𝐵
The difference between bound Na+ and unbound Na+ will
then arise in the relaxation dynamics. Bound Na+ will relax
much more quickly than unbound Na+ provided that 𝜏𝑚 is
appreciable on the NMR timescale, because the increased
𝜏𝑐 and 𝜏𝑅 will allow spin-spin interactions to enhance the
rate at which individual 23 Na spins de-phase, resulting in a
faster loss of transverse phase coherence, i.e., a larger 𝑅 2 . This
results in bound Na+ producing a much broader 23 Na NMR
peak compared to unbound Na+ (Equation (2.25)). This is
seen in a variety of studies, where a larger concentration of
agents which can attract free Na+ will exhibit larger relaxation
rates[236, 237]. Also, in vivo, intracellular Na+ has often
been shown to have altered relaxation dynamics due to an
abundance of intracellular proteins with negatively charged
moieties which have an affinity for Na+ [238–240].
It is also interesting to consider the case where the agent
interacting with Na+ itself is paramagnetic. In this case, not
only will relaxation be affected, but the intrinsic magnetic
®int produced by such an agent will affect the resonance
field 𝐵
frequency of bound Na+ . The change in 23 Na relaxation will
also be a cumulative effect of binding as well as the change
in magnitude of the net magnetic field at Na+ binding sites.
Lanthanide ion (Ln3+ )-based agents are widely used in 23 Na
NMR to induce chemical shift and relaxation differences in
bound Na+ . The lanthanides all have stable isotopes and + 3
oxidation states, with an electronic configuration of [Xe]4 𝑓 𝑛
(𝑛 = 0 , 1 , · · · , 14) – except promethium (Pm) which is radioactive[241]. Because these 4 𝑓 electrons are covered by the
5 𝑠 and 5 𝑝 electrons, it is not feasible for Ln3+ to form direct
covalent bonds. However, the lanthanides are strong Lewis
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acids and can therefore coordinate to ligands with strongly
electronegative moieties. Most ligands for these lanthanidebased agents are derivatives of 1,4,10-tetraazacyclododecane
(cyclen, Figure 2.5a). Cyclen itself has no donor sites with
which Ln3+ ions can spontaneously coordinate, and are often
functionalized on each of the nitrogens with aliphatic groups
referred to as the pendant arms. The simplest such ligand is
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA4− ,
Figure 2.5b), in which acetate pendant arms are affixed to
the nitrogen atoms on cyclen. From DOTA4− , many other
ligands can be formed such as 1,4,7,10-tetraazacyclododecane1,4,7,10-tetrakis(methylacetate) (DOTMA4− , Figure 2.5c), in
which each acetate pendant arm is methylated, and 1,4,7,10tetraazacyclododecane-1,4,7,10-tetra(methylenephosphonate)
(DOTP8− , Figure 2.5d), in which each acetate is replaced by a
phosphonate. LnDOTP5− complexes, for example, have been
studied extensively as agents due to the magnetic properties
they confer on NMR-visible nuclei like 1 H and 23 Na[242–
244].

(a) Cyclen

(b) DOTA4−

(c) DOTMA4−

(d) DOTP8−
Figure 2.5: Chemical structures of common chelates used for lanthanide-based NMR contrast agents.(a)
1,4,7,10-tetraazacyclododecane, also known as cyclen. (b) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate,
also known as DOTA4− . It is similar to cyclen but has a carboxylate pendant arm attached to each nitrogen
on the cyclododecane ring. (c) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylacetate), also known as
DOTMA4− . It is identical to DOTA4− , except each carboxylate pendant arm has a methyl group at the H6 proton
position. (d) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylene phosphonate), also known as DOTP8− . It
is identical to DOTA4− except each pendant arm contains a phosphonate group instead of a carboxylate group.
This gives it double the negative charge.

The induced chemical shift 𝛿 on a nucleus coordinated to
such a paramagnetic agent is composed of several parts[241]:
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𝛿 = 𝛿 𝜒 + 𝛿 𝑑 + 𝛿 𝑝𝑐 + 𝛿 𝑐

(2.56)

where 𝛿 𝜒 is the shift from changes in the bulk magnetic
susceptibility (BMS), 𝛿 𝑑 is the diamagnetic shift, 𝛿 𝑝𝑐 is the
pseudocontact shift, and 𝛿 𝑐 is the contact shift. Using the
Ramsey formalism of chemical shift described earlier for
shielding (Equation (2.55)), 𝛿 𝜒 does not arise due to electronic
activity but from the non-perturbed 𝐻ˆ (0) through alteration
of the magnetic vector potential by presence of the intrinsic
®int (Equation (2.48)). The diamagnetic shift 𝛿 𝑑
magnetic field 𝐵
clearly is a consequence of the diamagnetic shielding tensor
𝝈𝒅 , while 𝛿 𝑝𝑐 and 𝛿 𝑐 are paramagnetic shifts emanating
from 𝝈𝒑 . The BMS shift is the same for all nuclei throughout
the sample and is dependent on neither identity of the
coordinated nuclei nor the Ln3+ -based complex employed.
Corsi and colleagues demonstrated that this BMS shift is
given by[245]


4000𝜋𝑐 𝜇eff 2
𝛿𝜒 =
(2.57)
3𝑇
2.84
where 𝑐 is the molar concentration of the Ln3+ ion, 𝑇 is the absolute temperature, and 𝜇eff is the effective magnetic moment
of the Ln3+ ion. Usually, 𝛿 𝜒 contributions are canceled by
inclusion of a reference standard and/or frequency-locking
the NMR spectrometer. Furthermore, the 𝛿 𝑑 contributions
are small, unless the lanthanide metal used is lanthanum
(La), lutetium (Lu), or ytterbium (Y) which are diamagnetic
due to very few or no unpaired 4 𝑓 electrons[246]. These
diamagnetic shifts can arise from inductive effects or conformational changes that result from coordination with nuclei.
The 𝛿 𝑐 shift is produced by the transfer of unpaired spin
polarization from the Ln3+ ion’s 4 𝑓 orbital to the coordinated
nuclei of interest by direct delocalization of the spins[241],
and is given by

𝛿𝑐 =

𝜇𝐵 h𝜇ˆ 𝑧 i
𝐴
× 106 ·
~
3 𝑘 𝐵 𝑇𝛾 2

where 𝐴/~ is the hyperfine coupling constant, 𝜇𝐵 =

(2.58)
~𝑒
2𝑚 𝑒

=

9.27 × 10−21 C·m/s2 is the Bohr magneton, and h𝜇ˆ 𝑧 i is
the ensemble-average of the polarization as described earlier (Equation (2.37)). Golden and Halton[247], and later
Pinkerton[248] and Autillo[249], have computationally determined h𝑆ˆ 𝑧 i = h𝜇ˆ 𝑧 i/𝛾 (Equation (2.27)) using various Hartree-
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Fock methods. For gadolinium (Gd) and larger atomic numbers, their calculations for h𝑆ˆ 𝑧 i have been more in agreement
than for europium (Eu) and smaller atomic numbers. The 𝛿 𝑐
magnitude drops sharply as more bonds separate the Ln3+
ion and nucleus of interest[246].
The pseudocontact, or dipolar, shift 𝛿 𝑝𝑐 arises from anisotropic
magnetic susceptibility caused by crystal field effects that
break the spherical symmetry around the Ln3+ ion. The
effects are non-negligible for nuclei within 40Å of the paramagnetic Ln3+ ion, except Gd3+ whose spherical symmetry
does not experience crystal field effects[250]. Due to the
involvement of anisotropy, 𝛿 𝑝𝑐 calculations become tensorial
in nature, with a dependence on different components of the
magnetic susceptibility tensor 𝝌 [251, 252]:
𝛿 𝑝𝑐 =

106
12𝜋𝜌3

h



(3 cos2 𝜙 − 1) 𝜒𝑧𝑧 −

𝜒𝑥𝑥 +𝜒 𝑦𝑦
2



+ 32 (𝜒𝑥𝑥 − 𝜒 𝑦 𝑦 ) sin2 𝜙 cos(2𝜃)

i

(2.59)
where 𝜌, 𝜃 , and 𝜙 are the distance, polar, and azimuthal spherical coordinates, respectively. Further assumptions made by
Bleaney[252] that crystal field splitting effects are small compared to 𝑘 𝐵 𝑇 and approximating unpaired electrons as point
charges result in a more straightforward expression for the
pseudocontact shift:

𝛿 𝑝𝑐 =

𝐶Ln 𝜇0 𝜇2𝐵
60 𝑘 𝐵2 𝑇 2 𝜌3

[𝛽 20 (3 cos2 𝜙 − 1) + 𝛽 22 sin2 𝜙 cos(2𝜃)] (2.60)

where 𝐶Ln is a constant specific to the Ln3+ used in the agent,
𝜇0 = 4𝜋 × 10−7 T·m/A is the permeability of free space, and
𝛽20 and 𝛽 22 are second-order crystal field coefficients. However,
certain studies do not support Bleaney’s assumptions[253,
254], since some crystal field splitting values can be larger
than 𝑘 𝐵 𝑇 [255] and assuming point charges for unpaired
electrons might not be valid since certain Ln3+ ions have
prolate and oblate 4 𝑓 electron densities[256].
Paramagnetic agents will also alter relaxation rates as mentioned earlier. These enhancements in both longitudinal
and transverse relaxation rates are a combination of both
inner-sphere and outer-sphere effects. The diamagnetic contribution to this enhancement is mainly caused by the Na+
binding, and can be separated empirically by interpolating
between relaxation contributions from the corresponding
La3+ - and Lu3+ -based complexes and subtracting this from
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the overall result[246]. What remains is the paramagnetic
contribution, mainly composed of mechanisms from dipolar
and Curie magnetic susceptibility effects[257]. The former
results from fluctuations in the local field caused by molecular motion, and can be adapted from the theory by Solomon,
Bloembergen, and Morgan (SBM)[258–260]:

!

𝑅 1dip

2 𝛾𝐼2 𝜇2eff  𝜇0  2
3𝜏𝑐
7𝜏𝑐
=
+
6
2
2
4𝜋
15𝑟
1 + 𝜔𝐼 𝜏𝑐 1 + 𝜔𝑆2 𝜏𝑐2

𝑅 2dip

2 𝛾 2 𝜇2  𝜇0  2
3𝜏𝑐
13𝜏𝑐
4𝜏𝑐 +
= 𝐼 6eff
+
4𝜋
15𝑟
1 + 𝜔𝐼2 𝜏𝑐2 1 + 𝜔𝑆2 𝜏𝑐2

(2.61a)

!

(2.61b)
where 1/𝜏𝑐 = 1/𝑡𝑎𝑢𝑅 + 1/𝜏𝑚 + 𝑅 𝑖 𝑒 , and 𝑅 𝑖 𝑒 ( 𝑖 = 1 , 2) is the
longitudinal ( 𝑖 = 1) or transverse ( 𝑖 = 2) relaxation rate of
the electron. Furthermore, the subscripts 𝐼 and 𝑆 refer to the
coordinated nucleus and its electrons, respectively, and 𝑟 is
the distance between the nucleus and the Ln3+ ion. Realistically, 𝜏𝑚  𝜏𝑅  𝑅 −𝑖 𝑒1 , which simplifies Equation (2.61) to

𝑅 𝑖dip

4 𝛾𝐼2 𝜇2eff  𝜇0  2
= 6
3𝑟 𝑅 𝑖 𝑒 4𝜋

(2.62)

for 𝑖 = 1 , 2. These results, however, only hold upon the
assumption that molecular reorientation is both geometrically
and magnetically isotropic.
The Curie magnetic susceptibility mechanism also contributes
to the relaxation enhancement and is a product of the nuclear
spin interacting with the electronic system’s thermal-average
spin state[261]. It is the dominant contribution at large magnetic fields. This mechanism is described by

𝑅1Cur =
𝑅2Cur =

6 𝜔𝐼2 𝜇2eff
5𝑟 6 (3 𝑘

𝐵

𝑇)2

𝜔𝐼2 𝜇2eff

 𝜇 2
0

4𝜋

 𝜇 2
0

5𝑟 6 (3 𝑘 𝐵 𝑇)2 4𝜋

𝜏𝑅
1 + 𝜔𝐼2 𝜏𝑅2
4𝜏𝑅 +

!
(2.63a)
3𝜏𝑅

1 + 𝜔𝐼2 𝜏𝑅2

!
(2.63b)

Equation (2.63) assumes that 𝝌 is isotropic and that the
electronic Zeeman interaction dominates over the zero-field
splitting. This Curie contribution becomes more intricate
upon relaxation of these assumptions[262–264]. Suturina
and colleagues recently cast some simple equations describing both the dipolar and Curie mechanisms taking into
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account relaxation anisotropy[265]. They rely on the electronic shielding tensor 𝝈 (Equation (2.55)) in the canonical
Cartesian frame, and its first- and second-rank invariants,
respectively termed Δ2𝜎 and Λ2𝜎 , defined by
2
2
Δ2𝜎 ≡𝝈𝑥𝑥
+ 𝝈 𝑦2 𝑦 + 𝝈𝑧𝑧
− 𝝈𝑥𝑥 𝝈 𝑦 𝑦 − 𝝈 𝑦 𝑦 𝝈𝑧𝑧 − 𝝈𝑥𝑥 𝝈𝑧𝑧


3
(𝝈𝑥 𝑦 + 𝝈 𝑦𝑥 )2 + (𝝈𝑥𝑧 + 𝝈𝑧𝑥 )2 + (𝝈 𝑦𝑧 + 𝝈𝑧 𝑦 )2
4
(2.64a)

Λ2𝜎 ≡(𝝈𝑥𝑦 − 𝝈 𝑦𝑥 )2 + (𝝈𝑥𝑧 − 𝝈𝑧𝑥 )2 + (𝝈 𝑦𝑧 − 𝝈𝑧 𝑦 )2

(2.64b)

Moreover, in the following Suturina equations, 𝑟ˆ is a unit
vector pointing along the direction between the Ln3+ and
coordinated nucleus, and 𝐺(𝜔) is the spectral density function, which is the Fourier Transform of the autocorrelation
function. With these definitions, the Suturina equations are

𝑅 1dip
𝑅 1dip
𝑅 1Cur

2 𝛾𝐼2  𝜇0  2
= 6
𝐺(𝜔𝐼 ) Tr[(3𝑟ˆ 𝑟ˆ𝑇 − 1)2 ]
(2.65a)
3𝑟 4𝜋
𝛾𝐼2  𝜇0  2
[𝐺(0) + 𝐺(𝜔𝐼 )] Tr[(3𝑟ˆ 𝑟ˆ𝑇 − 1)2 ] (2.65b)
= 6
3𝑟 4𝜋
Λ2𝜎 𝜔𝐼2 𝜏𝑅
2Δ2𝜎 𝜔𝐼2 𝜏𝑅
=
+
(2.65c)
2(1 + 9 𝜔𝐼2 𝜏𝑅2 ) 15(1 + 𝜔𝐼2 𝜏𝑅2 )

𝑅1Cur =

Λ2𝜎 𝜔𝐼2 𝜏𝑅
4(1 +

9 𝜔𝐼2 𝜏𝑅2 )

+

Δ2𝜎 𝜔𝐼2
45

4𝜏𝑅 +

3𝜏𝑅
1 + 𝜔𝐼2 𝜏𝑅2

!
(2.65d)

The previous discussions highlighted the chemical shift and
line broadening effects on NMR spectra of biological cations
like Na+ bound to paramagnetic agents and free as part of the
bulk electrolyte. There is one more phenomenon to consider
in this picture, and that is the interconversion between these
bound and free states, termed chemical exchange. If M is any
such metal in the presence of a paramagnetic agent P, then
MP will represent the bound state. The exchange reaction is
described by
k𝑓

−−
−⇀
M+P−
↽
−− MP

(2.66)

k𝑟

The equilibrium binding constant is then

𝐾=

𝑘𝑓
[MP]
=
𝑘𝑟
[M][P]

(2.67)
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Furthermore, the differential rate equations for the binding
of M are

𝑑[M]
= −𝑘 𝑓 [M][P] + 𝑘 𝑟 [MP]
𝑑𝑡
𝑑[MP]
= 𝑘 𝑓 [M][P] − 𝑘 𝑟 [MP]
𝑑𝑡


Solve Equation (2.68a) for [MP] [MP] =

(2.68a)
(2.68b)

𝑑[M]
𝑑𝑡 +𝑘 𝑓 [M][P]

𝑘𝑟


and

subsitute into Equation (2.68b):

𝑑
𝑑𝑡

𝑑[M]
𝑑𝑡

+ 𝑘 𝑓 [M][P]
𝑘𝑟

!
= 𝑘 𝑓 [M][P] − 𝑘 𝑟

𝑑[M]
𝑑𝑡

+ 𝑘 𝑓 [M][P]

!

𝑘𝑟

𝑑[M]
𝑑[M]
𝑑 2 [M]
+ 𝑘 𝑓 [P]
= −𝑘 𝑟
2
𝑑𝑡
𝑑𝑡
𝑑𝑡
2
𝑑 [M]
𝑑[M]
=⇒
=0
+ (𝑘 𝑓 [P] + 𝑘 𝑟 )
2
𝑑𝑡
𝑑𝑡

=⇒

This demonstrates how fluctuations in M from its equilibrium
concentration decay exponentially at a combined rate of
𝑘 0 = 𝑘 𝑓 [P] + 𝑘 𝑟 . Analogous steps when solving for [M] and
𝑑 2 [MP]

𝑑[MP]

substituting also results in 𝑑𝑡 2 + 𝑘 0 𝑑𝑡 = 0. This shows
how fluctuations in both species interconvert at the same
rate, suggesting 𝑘 0 is related to the exchange between these
two species.
Moreover, Harden McConnell amended the traditional Bloch
equations (Equation (2.11)) to account for situations in which
two species are exchanging[266]. In the picture described
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here, the Bloch-McConnell equations are

𝑑𝑀 𝑥𝑢
= −𝑅 2𝑢 𝑀 𝑥𝑢 + cos(𝜔𝑢 𝑡)𝑀 𝑦𝑢 − 𝑘 𝑓 [P]𝑀 𝑥𝑢 + 𝑘 𝑟 𝑀 𝑥𝑏
𝑑𝑡
(2.69a)
𝑑𝑀 𝑥𝑢
= −𝑅 2𝑢 𝑀 𝑦𝑢 − sin(𝜔𝑢 𝑡)𝑀 𝑥𝑢 − 𝑘 𝑓 [P]𝑀 𝑦𝑢 + 𝑘 𝑟 𝑀 𝑦𝑏
𝑑𝑡
(2.69b)
𝑑𝑀 𝑥𝑏
= −𝑅 2𝑏 𝑀 𝑥𝑏 + cos(𝜔𝑏 𝑡)𝑀 𝑦𝑏 + 𝑘 𝑓 [P]𝑀 𝑥𝑢 − 𝑘 𝑟 𝑀 𝑥𝑏
𝑑𝑡
(2.69c)
𝑑𝑀 𝑥𝑏
= −𝑅2𝑏 𝑀 𝑦𝑏 − sin(𝜔𝑏 𝑡)𝑀 𝑥𝑏 + 𝑘 𝑓 [P]𝑀 𝑦𝑢 − 𝑘 𝑟 𝑀 𝑦𝑏
𝑑𝑡
(2.69d)
(2.69e)
where subscripts 𝑏 and 𝑢 refer to bound and unbound M.
These can be consolidated into matrix form employing the
same complex time-domain notation as Equation (2.22):

𝑑
𝑑𝑡



e 𝑥 𝑦𝑢
𝑀
e 𝑥 𝑦𝑏
𝑀

=⇒



®
e
𝑑𝑀
𝑥𝑦
𝑑𝑡


= (𝜿 − 𝛀)

e 𝑥 𝑦𝑢
𝑀
e 𝑥 𝑦𝑏
𝑀

®
e
= (𝜿 − 𝛀) 𝑀
𝑥 𝑦 (𝑡)



(2.70)

−𝑘 𝑓 [P] 𝑘 𝑟
𝑅 2𝑢 + 𝑖𝜔𝑢
0
where 𝜿 ≡
and 𝛀 ≡
,
𝑘 𝑓 [P] −𝑘 𝑟
0
−𝑅 2𝑏 + 𝑖𝜔𝑏
and which has a simple exponential solution:







®
®
(𝜿−𝛀) e
e
𝑀
𝑀 𝑥 𝑦 (0)
𝑥 𝑦 (𝑡) = 𝑒



(2.71)

and this illustrates how NMR line broadening is induced by
𝑘 𝑓 and 𝑘 𝑟 through the 𝜿 matrix.
In terms of chemical shift, we look to the equilibrium conditions (Equation (2.67)). Let 𝐶M = [M] + [MP] be the total
concentration of M, which is a constant. Likewise, define
𝐶P = [P] + [MP]. Then the fraction 𝑓 of M bound is given by
[MP]
[M]
𝑓 = [M]+[MP] = 𝐶M . With these terms, Equation (2.67) can be
rewritten as

𝐾=

𝑓 𝐶M
𝑓 𝐶M
=
(𝐶M − 𝑓 𝐶M )(𝐶P − 𝑓 𝐶M ) (1 − 𝑓 )𝐶M (𝐶P − 𝑓 𝐶M )

which is an expression that is quadratic in 𝑓 and can therefore
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be solved easily:

𝑓 =

𝐶M + 𝐶P +

1
𝐾

−

q

𝐶M + 𝐶P +


1 2
𝐾

− 4𝐶M 𝐶P

2𝐶M

(2.72)

When exchange is fast (as it is for Na+ in the presence of
paramagnetic agents), the observed chemical shift 𝛿 obs is
weighted average between the totally bound shift 𝛿 𝑏 and the
totally unbound shift 𝛿 𝑢 :

𝛿obs = 𝑓 𝛿 𝑏 + (1 − 𝑓 )𝛿 𝑢

(2.73)

In these ways, intermolecular effects all come together to
affect the NMR spectra.

2.5 Overview of Medical Applications
NMR has found success through a variety of modalities
like magnetic resonance spectroscopy (MRS), imaging (MRI),
and spectroscopic imaging (MRSI) [also known as chemical
shift imaging (CSI)]. The discussion up until this point has
been essentially a detailed analysis of MRS, which is defined
by the use of NMR to generate spectra in frequency space.
We have seen already that taking the Fourier Transform of
the Bloch equations (Equation (2.23)) results in Lorentzian
functions of frequency which are plotted to yield the NMR
spectrum where the chemical dimension is represented with
the frequency domain. There are a few additional applicationspecific considerations to consider in MRS which will be
touched upon in this section. MRI, on the other hand, uses
NMR to produce an image, which fundamentally is a 2D array
of signal intensities visualized together where the spatial
dimension is represented with the frequency domain. Lastly,
MRSI combines these two concepts to produce a 2D array of
local spectra which can provide chemical information across
the spatial dimension.

Magnetic Resonance Spectroscopy
From an application standpoint, MRS encompasses the practice of analyzing spectroscopic features like chemical shift and
linewidth to analyze the sample of interest. The set of peaks
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Figure 2.6: In Vivo 23 Na MRS.
Sample 23 Na MRS spectra of gerbil leg muscles after infusion of
a contrast agent, and before (top)
and after (bottom) introduction
of ouabain. Peak A refers to intracellular sodium, while Peak
B refers to extracellular. This
demonstrates the ability of in vivo
23
Na MRS to elucidate physiological changes with minimal invasion. Modified from[267].

and chemical shifts observed provide information about the
structure and type of the molecules present, in terms of bond
characteristics and exchange, all of which we have seen have
an effect on the relaxation dynamics and net magnetic fields
experienced by nuclei that ultimately manifest in the spectra.
Furthermore, the initial magnetization is proportional to the
spin concentration ( 𝑁/𝑉 in Equation (2.6)). Consequentially,
when there are multiple peaks present due to chemical shift
effects, each pool of nuclei with those specific resonance
frequencies will have their own initial magnetizations, which
can yield information regarding concentrations of different
pools. Spectroscopically, the displayed absorption spectra,
which are Lorentzian functions, can be integrated:

∫

∞

−∞

𝑀0 𝑅 2
𝜔
=
𝑀
arctan
0
𝑅2
𝑅22 + (Δ − 𝜔)2 𝑑𝜔



∞

= 𝑀0 𝜋

−∞

Therefore, ultimately, these integrals are proportional to
the spin concentrations, and integrating peaks on the same
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NMR spectra provide valuable information about relative
concentrations of one pool of nuclei versus another. For
example, Naritomi used the contrast agent DyTTHA3− (explained in more detail below) to separate 23 Na intracellular
and extracellular signals before and after introduction of the
Na+ /K+ -ATPase toxin ouabain and demonstrated how the
integrals of the intracellular and extracellular peaks changed
(Figure 2.6). In these ways, MRS is a powerful application
which can identify various species in samples which manifest themselves through distinct chemical shifts, as well as
determine their relative concentrations when these peaks are
integrated.
There are a number of practical considerations to account for
in an MRS experiment which need not be addressed when discussing theory only. Physical spectroscopic measurements,
for example, will always exhibit noise at the baseline due to
intrinsic properties of the experiment like heat generated by
the coils or other instrumentation-related phenomena. With
sufficiently strong signal, however, the spectral peaks will be
visible and with an amplitude far exceeding the noise level.
This ratio between the peak amplitude and average noise amplitude(Figure 2.7) is termed the signal-to-noise ratio (SNR).
Mathematically, noise is generated by a departure from true
sinusoidal behavior near the end of the FID (Equation (2.22)),
causing random variations in the spectrum subsequently
generated by the Fourier Transform. Apodization is a spectral processing technique which can semi-artificially improve
the SNR of the acquired spectrum. Prior to Fourier Transformation, the FID is multiplied by an exponentially decaying
or by a Gaussian function which decreases the contribution
from the noise-producing end of the FID and enhances the
contribution of the true signal[268, 269].
Figure 2.7: Signal-to-noise ratio
in different spectra. A demonstration of signal-to-noise ratio
(SNR) where the NMR spectrum
on the left has superior SNR due
to the fact that the average noise
amplitude at baseline is much
smaller compared to the average
noise amplitude at baseline for the
spectrum on the right. For this reason, despite similar peak amplitudes, the spectrum on the right
exhibits poor SNR. Modified from
[267].
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Furthermore, it is only an idealization that a pulse will be a
complete 𝜋/2-pulse or that it will be entirely on-resonance.
Practical limitations of the RF hardware used may introduce
initial phases in the transverse coherence which the aforementioned did not address. The problem with this initial
phase is that taking the real part of the Fourier Transform will
not purely be the absorption spectrum but rather a mixture
between the absorption and dispersion spectra[270, 271]. To
rectify this, phasing is often applied to the post-processed
spectrum in order to counteract these initial phases. Computationally, this amounts to multiplying the entire spectrum
by a phase factor 𝑒 𝑖𝜙 . When 𝜙 is only some constant 𝜙0 , this
is referred to as a zeroth-order phase correction. Phasing
can also be done in a frequency-specific manner, in which the
case phase correction for a particular frequency 𝜔 is given
by 𝜙(𝜔) = 𝜙0 + 𝜙1 (𝜔 − 𝜔0 ), for constants 𝜙0 and 𝜙1 . This
is referred to as a first-order phase correction. Higher-order
phase corrections are feasible in this same manner but are
not usually employed in MRS practice.
MRS has found a number of crucial biomedical applications.
It has been shown to non-invasively quantify changes in in
vivo metabolite levels, of which there can be up to 20,000[272],
and provide accurate clinical diagnoses[273–275]. Of course,
detectability requires concentrations large enough (usually 1
mM and above) to produce sufficient SNR, as was discussed
earlier. In the brain, there are many metabolites detectable by
1
H MRS such as choline (Cho), creatine (Cr), and 𝑁 -acetyl
aspartate (NAA)[276–278], which have respective chemical
shifts of 3.19, 3.03, and 2.01 ppm[279]. Cr intensity is usually
constant, and reduction of a peak at the Cr position would
signify an impairment of Cr generation, like in guanidinoacetate methyltransferase disorders[280–283], 𝐿-arginine
glycine amidinotransferase disorders[284], or a failure of
the Cr transporters[285]. Other brain metabolites include
myoinositol (mIns, at 3.61 ppm) and glycine (Gly, at 3.55
ppm)[280]. Brain tumors also exhibit general changes in
these metabolite concentrations, such as decreases in Cr[286]
and NAA[287–289], and increases in Cho[290]. However, this
is not true for all varieties for brain tumors, as Cho levels are
more uncorrelated in glioblastoma (GBM)[291, 292], which
was discussed extensively in Chapter 1. Furthermore, MRS is
able to measure oncometabolites like D-2-hydroxyglutarate
(D-2-HG) which was also discussed in Chapter 1. Other diseases like Systemic Lupus Erythematosus (SLE) and multiple
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sclerosis (MS) are also detectable with 1 H MRS, typified by
decreased NAA/Cr signal intensity ratios [293–297]. In addition to physiological disorders, behavioral and psychiatric
disorders have also been diagnosed with MRS by looking at
alterations in these same metabolite levels[298–301].
MRS has played invaluable roles in science and medicine.
The ability to detect metabolite levels non-invasively has
helped confer many favorable clinical prognoses to patients
which otherwise would not have been possible with more
invasive probes. While the previous discussion focused on
1
H MRS, spectroscopy of any nucleus follows the same
principles. Carbon-13 (13 C) MRS is also highly useful for
tracking metabolism of compounds enriched with 13 C such as
glucose[302, 303]. Subsequent chapters will also demonstrate
the utility and feasibility of 23 Na spectroscopy, which is the
focus of my thesis.

Magnetic Resonance Imaging
While the goal of MRS was to produce a spectrum from the
NMR signal of the region of interest (ROI) within an organ,
the goal of MRI is to produce an image beyond the ROI to
encapsulate the entire organ. An image here is defined as an
𝑚 × 𝑛 rectangular grid (i.e., 2D representation) of squares
known as pixels. Associated with each pixel is an intensity,
and the arrangement of these pixels in the proper order
produces the image. The 3D analogs of pixels are known as
voxels, and are relevant for 3D imaging.
Since the prior theoretical discussion revolved around spectroscopy, additional insight is needed to understand how
the FID signal can ultimately be converted into an image.
This is achieved primarily through the use of gradient magnetic fields, which are magnetic fields whose magnitudes are
varied across the sample. Since resonance frequencies are
directly related to magnetic field strengths, applications of
gradient fields create a frequency-position constraint such
that positions are encoded in the detected frequencies (i.e.,
gradients enable different Larmor frequencies across the sample). Varying these gradients the full image can be formed.
One striking difference between spectroscopy and imaging
regards the sectioning of the ROI. In MRS, there is one signal
representative of the entire sample. In MRI, however, the
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sample must be partitioned into a 2D or 3D array of voxels,
and each voxel must be treated as its own individual ROI
producing its own signal. Looking at Equation (2.22), the
time-dependence is found only in the exponential term, while
the magnitude (which is magnetization) remains constant
since there is only one signal. When dealing with imaging, the
exponential phase factor will still exhibit time-dependence,
but now both magnitude and phase must exhibit spatial
dependence, and the signal 𝑆 consists of the sum (or integral)
of these voxel-wise signals over the entire spatial region:

𝑆(𝑡) =

∫ ∫ ∫
𝑥

𝑦

e 0 (𝑥, 𝑦, 𝑧)𝑒 −𝑖𝜙(𝑥,𝑦,𝑧,𝑡) 𝑑𝑥 𝑑𝑦 𝑑𝑧
𝑀

𝑧

(2.74)

® = 𝐺 𝑥 (𝑡)𝑥ˆ + 𝐺 𝑦 (𝑡) 𝑦ˆ +
In the presence of a gradient field 𝐺(𝑡)
𝐺 𝑧 (𝑡)ˆ𝑧 , the magnitude of the net magnetic field 𝐵® is given by
® 𝑟 , 𝑡) = 𝐵®0 + 𝐺(𝑡)
® · 𝑓® = 𝐵0 + 𝐺 𝑥 𝑥 + 𝐺 𝑦 𝑦 + 𝐺 𝑧 𝑧
𝐵(®

(2.75)

and the spatiotemporal phase function from Equation (2.74)
is

𝜙(𝑥, 𝑦, 𝑧, 𝑡) =

∫

𝑡

𝜔(𝑥, 𝑦, 𝑧, 𝜏) 𝑑𝜏 = 𝛾

∫

0

𝑡

𝐵(𝑥, 𝑦, 𝑧, 𝜏) 𝑑𝜏

0

= 𝛾𝐵0 𝑡 + 𝛾

∫

𝑡

[𝐺 𝑥 (𝜏)𝑥 + 𝐺 𝑦 (𝜏)𝑦 + 𝐺 𝑧 (𝜏)𝑧] 𝑑𝜏

0

(2.76)
Therefore, the signal (Equation (2.74)) can now be rewritten
as

𝑆(𝑡) = 𝑒

−𝑖𝛾𝐵0 𝑡

∫ ∫ ∫
𝑥

𝑦

𝑧

e 0 (𝑥, 𝑦, 𝑧)𝑒 −𝑖𝛾
𝑀

∫𝑡
0

[𝐺 𝑥 (𝜏)𝑥+𝐺 𝑦 (𝜏)𝑦+𝐺 𝑧 (𝜏)𝑧] 𝑑𝜏

(2.77)
The
can be disregarded for the remainder of this
discussion since it can easily be phased out as was mentioned
prior. Equation (2.77) describes the measured NMR signal of
a sample over all of its voxels.

𝑒 −𝑖𝛾𝐵0 𝑡

e 0 (𝑥, 𝑦, 𝑧).
As an aside, consider the Fourier Transform of 𝑀
This is not a function of time, but rather a function of space.
The Fourier conjugate of time 𝑡 is temporal frequency 𝜔 .
Likewise, the Fourier conjugates of 𝑥 -, 𝑦 -, and 𝑧 -coordinates
are the spatial frequencies 𝑘 𝑥 , 𝑘 𝑦 , and 𝑘 𝑧 . Therefore, the
e 0 (𝑥, 𝑦, 𝑧), called 𝑊0 , would be written
Fourier Transform of 𝑀

𝑑𝑥 𝑑𝑦 𝑑𝑧
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as

∫ ∫ ∫

𝑊0 (𝑘 𝑥 , 𝑘 𝑦 , 𝑘 𝑧 ) =

𝑥

𝑦

𝑧

e 0 (𝑥, 𝑦, 𝑧)𝑒 −𝑖 2𝜋(𝑘 𝑥 𝑥+𝑘 𝑦 𝑦+𝑘 𝑧 𝑧) 𝑑𝑥 𝑑𝑦 𝑑𝑧
𝑀

(2.78)
Comparing Equation (2.77) and Equation (2.78), this means
that the NMR signal during an MRI is directly related to the
spatial Fourier Transform of the magnetization:

𝑆(𝑡) = 𝑊0



𝛾
2𝜋

∫
0

𝑡

𝛾
𝐺 𝑥 (𝜏) 𝑑𝜏,
2𝜋

∫
0

𝑡

𝛾
𝐺 𝑦 (𝜏) 𝑑𝜏,
2𝜋

∫

𝑡

𝐺 𝑧 (𝜏) 𝑑𝜏

0

(2.79)
From Equation (2.79), since the gradients can be turned
on/off during the course of the experiment, the signal is
received during the amount of time the gradients are turned
on. Each value of the spatial frequency is directly related
to the integral of the gradient over time. Given this crucial
fact, the way that the image from an MRI is formed is by
registering signals from all possible ( 𝑘 𝑥 , 𝑘 𝑦 , 𝑘 𝑧 ) triples, and
then performing the inverse Fourier Transform to convert
that signal back to (𝑥, 𝑦, 𝑧) space which is more informative.
The set of all (𝑘 𝑥 , 𝑘 𝑦 , 𝑘 𝑧 ) triples represents a spatial frequency
space known as 𝑘 -space. Gradient fields, therefore, are used
to traverse 𝑘 -space and form the image via inverse Fourier
Transform.
Practically speaking, it is cumbersome (if not impossible)
to sample the full 𝑘 -space to generate the image. For most
applications, however, it is not required to determine 𝑘 -space
in its entirety. This is because information regarding the main
features of the image is mainly found in regions of low spatial
frequency, close to the origin of 𝑘 -space, whereas information
about minute, fine details are found in the outer edges of
𝑘 -space. Therefore, as long as the gradients are operated in
such a way that a sufficient amount of the central region
of 𝑘 -space is covered, enough information can be gleaned
from the image formed. Design of 𝑘 -space trajectories as
well sampling of each line of 𝑘 -space is a vast area of MRI
research, with the goal being to optimize 𝑘 -space sampling
in as little time as possible[304, 305].
The development of MRI has unquestionably left an indelible
mark in the world of healthcare and medicine. MRIs are
ordered ubiquitously by doctors for their patients, and radiologists are specially trained to interpret MRIs and scope
anomalies which the imaging can reveal. Clinical MRI se-
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quences are traditionally 𝑇1 - or 𝑇2 -weighted, which means
that imaging parameters are optimized to highlight differences in 𝑇1 or 𝑇2 between different tissues in the ROI. 𝑇1 or
𝑇2 are the relaxation times, the reciprocals of the relaxation
rates 𝑅 1 and 𝑅 2 . To that end, they serve as the time constants
in the Bloch equations (Equation (2.11)). A common sequence
employed clinically is 𝑇2 -weighted fluid-attenuated inversion recovery (𝑇2 -FLAIR), in which the signal from bodily
fluids, such as cerebrospinal fluid (CSF), is stifled before
the conventional 𝑇2 -weighted pulse sequence is employed.
Normally, fluids are bright in 𝑇2 -weighted images because
nuclei in liquids freely diffuse so there is less opportunity
for spin-spin de-phasing to occur. An example of clinical
23
Na MRI is depicted in Figure 2.8, where the images obtained with standard pulse-acquire and inversion recovery
sequences enabled total sodium concentration quantification
in the brain[305].
Figure 2.8: In vivo 23 Na MRI. A
demonstration of 23 Na MRI used
clinically to determine sodium levels. Images shown are generated
by (A) standard pulse-acquire and
(B) inversion recovery sequences
based on the 23 Na MRI signal, and
(C) a 1 H MRI of the gray matter.
Poor resolution in the 23 Na images compared to the 1 H image
is attributed to superior in vivo
SNR of the latter nucleus. Modified from[305].

These relaxometric MRI methods are also further enhanced
by including contrast agents, which are designed to enhance
𝑅 1 and 𝑅 2 (i.e., shorten 𝑇1 and 𝑇2 ). Through these effects,
they will affect the appearance of 𝑇1 - and 𝑇2 -weighted images
to brighten and darken lesions, respectively. The majority
of contrast agents are Gd-based, and because of this have
more of an effect on 𝑅 1 than on 𝑅 2 . However, iron (Fe)based agents termed superparamagnetic iron oxide (SPIO)
strengthen 𝑅 2 very effectively. Dynamic contrast-enhanced
(DCE) MRI is also an imaging tool made possible by the inclusion of Gd-based contrast agents. It uses rapid 𝑇1 -weighted
imaging to follow and model the uptake of Gd3+ following
a bolus intravenous injection by monitoring the regions of
𝑇1 enhancement, akin to tracer kinetic modeling[306]. Since
it is intravenous, the input to the DCE model will be the
arterial input function (AIF), which measures [Gd3+ ] over
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time within vessels. DCE analysis can be parametric and
quantitative or non-parametric and qualitative[307]. The latter choice is often employed clinically, in which changes in
the raw signal intensity over time are followed to gain better
understanding of the vascular network, but cannot provide
quantitative information. Parametric analysis, on the other
hand, requires fitting the AIF and other relaxometric data in
the ROI to a pharmacokinetic model, such as the Tofts model,
or two-compartment exchange model (2CXM):

𝑣𝑝

𝑑𝐶 𝑝

= 𝑃𝑆(𝐶 𝑒 − 𝐶 𝑝 ) + 𝐹𝑝 (𝐶 𝑎 − 𝐶 𝑝 ) (2.80a)
𝑑𝑡
𝑑𝐶 𝑒
𝑣𝑒
= 𝑃𝑆(𝐶 𝑒 − 𝐶 𝑝 )
(2.80b)
𝑑𝑡
𝐶𝑡 = 𝑣 𝑝 𝐶 𝑝 + 𝑣 𝑒 𝐶 𝑒
(2.80c)
𝑃𝑆 =

𝐹𝑝 𝐾 trans
(2.80d)

1 − 𝐾 trans

which relates the changes in contrast agent concentration 𝐶
and volume fraction 𝑣 to flow rate 𝐹 and the permeabilitysurface product 𝑃𝑆 , where the subscript ‘ 𝑝 ’ refers to plasma,
‘ 𝑒 ’ to extracellular, ‘ 𝑎 ’ to arterial, and ‘𝑡 ’ to total. 𝐾 trans is the
volume transfer coefficient dependent on both the plasma
flow 𝐹𝑝 and vascular permeability 𝑃𝑆 . Other models exist but
are essentially derived from this 2CXM. Perfusion can also
be assessed in the lesion using a method known as dynamic
susceptibility contrast (DSC), which utilizes a similar infusion
protocol but relies on changes in 𝑅 2 .
Clinical 1 H MRI methods have also been developed to probe
water diffusion, mainly typified by the apparent diffusion coefficient (ADC) of water within voxels[308]. Pulse sequences
which exploit differences in water diffusivity comprise the
diffusion-weighed imaging (DWI) modality. Diffusion gradient fields are used to saturate and then re-focus 1 H nuclei
after a certain time delay Δ. The pulse is characterized a
𝑏 -value, given by

𝑏=𝛾

2

𝐺2 𝑡 𝑑2



𝑡𝑑
Δ−
3


(2.81)

where 𝐺 is the diffusion gradient strength, and 𝑡 𝑑 is the
duration of the applied gradient. This 𝑏 -value is related to
ADC similarly to how 𝑅 2 is related to time - namely that the
FID sinusoid falls off exponentially between the product of 𝑏
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and ADC:

𝑀(𝑥, 𝑦, 𝑧, 𝑡) = 𝑀0 (𝑥, 𝑦, 𝑧, 𝑡)𝑒 −ADC·𝑏

(2.82)

As mentioned earlier, nuclei freely diffuse in liquids, meaning
that they will exhibit high ADC values. Tumors, on the other
hand, which are highly cellular, represent more restricted
regions where ADC values can be abnormally low. This
makes ADC and DWI part of the standard cancer imaging
regimen[309].
The development of MRI has been instrumental in a multitude of areas in the healthcare sector, including drug development and disease diagnosis. The clever use of gradient
magnetic fields to encode spatial information into the NMR
resonance frequencies has enabled MRI to be an efficacious
method to provide clinically relevant information. Imaging
altogether, including other clinical modalities like CT and
PET, has created platforms for efficient tracking of traceable
molecules, monitoring of drug efficacy, and overall patient
health.

Magnetic Resonance Spectroscopic Imaging
It was mentioned previously that MRS determines NMR
spectra from the entire sample or ROI within the sample,
while in MRI the sample is partitioned into voxels, each
of which is handled like an individual magnetization and
generates a signal intensity, and all these intensities are
arranged to form an image. MRSI weds these two concepts
together by partitioning the sample into voxels just as in MRI,
but retrieving for each voxel not only a signal intensity, but
an entire FID. This is not different from MRI, where a voxel
still has its own FID (Equation (2.77)). However, in MRI, the
maximum value of the signal is taken in order to form an
image, whereas in MRSI this FID is Fourier transformed into a
spectrum. Thus, there is an additional dimension of chemical
information in MRSI data compared to MRI. The result is
an array of different NMR spectra where the signal from
each spectrum comes from each voxel, enabling mapping
spectral properties in order to observe spatial heterogeneity
in a manner that neither whole-sample MRS nor MRI can
accomplish. For instance, 1 H MRSI was of greater diagnostic
utility than ordinary 1 H MRI in the context of fatty liver
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disease[310–312]. Moreover, 23 Na-MRSI was used by Alhulail
and colleagues to visualize spatial variations of [Na+ ] in the
calf muscle by incorporating phantoms with different known
[Na+ ] and interpolating the 23 Na-MRSI signal from the calf
to the signals from the phantoms (Figure 2.9)[313].

Figure 2.9: In vivo 23 Na MRSI.
An attempt at [Na+ ] quantification using 23 Na MRSI on the
calf muscle (indicated on figure)
to produce concentration maps.
Below the depicted slice of the
muscle are tubes with standard,
known [Na+ ] concentrations (A is
the highest concentration and D
is the lowest) and the [Na+ ] in the
muscle was calculated by interpolating the muscular 23 Na MRSI
signal between the 23 Na MRSI
signals from the tubes, assuming
a one-to-one correspondence between signal and concentration.
Modified from [313].

Endogenous protons for in vivo 1 H MRSI are generally the
same as those discussed in the general MRS section: NAA,
Cho, Cr, etc. There are other 1 H spectroscopy signals found
in the body like lactate, among others[314]. It should be
reiterated that sufficient concentrations of metabolites are
necessary to have adequate SNR. In ordinary MRS, the
concentration of metabolites over the whole sample provided
the SNR in the spectrum. Conversely, in MRSI, the SNR for a
particular metabolite in each spectrum will be determined by
the metabolite concentration only in the voxel associated with
the spectrum. In this way, spatial variations of metabolites
can be observed and analyzed.
Since chemical shift is at the heart of MRSI, paramagnetic
shift-inducing agents have started to play a crucial role in
evolving MRSI-based research and the range of information
it can divulge. A recently developed 1 H MRSI method which
uses paramagnetic lanthanide-based agents (as discussed
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prior) is Biosensor Imaging of Redundant Deviations in Shifts
(BIRDS)[315–317]. The method differs from the discussion of
intermolecular chemical shifts caused by coordinated nuclei
outlined earlier, in that BIRDS does not rely on measuring
endogenous 1 H chemical shifts but rather measures protons
on the paramagnetic complex itself. The agent most commonly used for BIRDS studies is the thulium(III) (Tm3+ )
salt of DOTP8− , termed TmDOTP5− , whose conformation
is very sensitive to pH and temperature. These conformational changes likewise alter the chemical environment and
electronic shielding experienced by the protons on the agent,
making the chemical shifts of these exogenous protons functions of temperature and pH. Establishment of the relationship between chemical shift, temperature, and pH allows the
latter two to be determined by chemical shift, which has been
demonstrated many times in the brain[318–323]. Specifically,
BIRDS with TmDOTP5− has revealed crucial information
about glioblastoma regarding extracellular acidosis even after therapy[319, 322, 324], and more recently hepatocellular
carcinoma in the liver[325]. It is interesting to note that these
results from Huang, Coman, and colleagues show how the
acidotic regions produced by the tumor are actually larger
than the tumor boundary delineated by 𝑅 2 enhancement of
water protons by the presence of TmDOTP5− , which is what
traditional MRI would reveal. Other agents have also been
employed for BIRDS, like TmDOTMA− which shows greater
temperature sensitivity[315]. A great advantage to the BIRDS
method is that it depends solely on the presence of a peak at
a particular chemical shift and not on the amplitude, which
makes it a generally concentration-independent method, as
long as enough of the paramagnetic agent has reached the
ROI to produce a visible peak with sufficient SNR.
MRSI has proven to be a very powerful application of NMR
with the potential to reveal a great amount of information
non-invasively, both preclinically and clinically. It combines
the spectral characteristics of MRS taking into account the
spatial variations made possible by gradient fields in MRI
to arrive at a versatile technique whose applications range
from measuring spatial heterogeneity in metabolite levels
in vivo to mapping the pH of the brain non-invasively. The
examples given so far have relied on 1 H MRSI, but X-nuclei
also have the capability to be spectroscopically imaged. The
focus of this project was to explore the power of 23 Na MRSI.
The following discussion will briefly provide an overview of
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23

Na spectroscopy.

Overview of Sodium Imaging and Spectroscopy
While the majority of preclinical and clinical applications of
MRS, MRI, and MRSI have been based on the 1 H NMR signal,
23
Na has also been used for spectroscopy and imaging. Of
the X-nuclei, 23 Na provides the strongest signal in vivo after
1
H, but since it does not form covalent bonds, all nuclei will
be magnetically indistinguishable since endogenous shielding effects will not take place. As discussed in Chapter 1,
sodium imbalances between different physiological in vivo
compartments are often implicated in a variety of diseases,
particularly cancer. Thus, compartmentalization of 23 Na signals depends on being able to alter the net magnetic field
experienced by only some 23 Na nuclei. Intravenous introduction of paramagnetic lanthanide-based agents in vivo is one
solution, as these agents advantageously extravasate into the
extracellular space of some organs while being barred from
entry into the intracellular space by the plasma membrane
due to their large size. Therefore, intravascular and extracellular sodium ions will experience a change in resonance
frequency brought about by the presence of these paramagnetic agents while intracellular ions will resonate at the
natural, agent-free Larmor frequency.
One of the earliest attempts of this phenomenon[326] was conducted by the group of Charles Springer Jr. where Na+ efflux
was measured in yeast cells with the dysprosium(III) (Dy3+ )
salt of nitrilotriacetic acid (N(CH2 CO2 )33− , abbreviated NTA3− ,
see Figure 2.10a), i.e., DyNTA3− . A series of 23 Na NMR spectra were measured over time in a suspension of yeast cells
containing DyNTA3− , and two peaks were observed: one at 0
ppm (intracellular) and the other at 2.75 ppm (extracellular).
Initially, the former peak was larger than the latter in both
terms of integral as well as amplitude. As time passed, the
pattern reversed, suggestive of Na+ efflux contributing to
larger extracellular and lower intracellular sodium concentrations. Around the same time, Gupta and Gupta performed
a similar experiment in a suspension of frog skeletal muscle cells with dysprosium tripolyphosphate (DyPPP72− ) as
the paramagnetic agent[327]. From their findings, they concluded that extracellular sodium concentrations were much
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larger than intracellular, which is well-known. More importantly, however, they also demonstrated that the extracellular
23
Na NMR peak is shifted by the agent in a concentrationdependent manner. Several years later, Naritomi applied
these same principles in vivo in gerbil brains, using the Dy3+
salt of 3,6,9,12-tetrakis(carboxymethyl)-triethylenetetramineN,N,N’,N”,N”’,N”’-hexaacetate (TTHA6− , see Figure 2.10b),
i.e., DyTTHA3− [267]. Before DyTTHA3− infusion, one peak
was observed on the 23 Na NMR spectrum at 0 ppm, and a
few hours after injection, there were clearly two peaks, with
a larger shifted peak now close to 5.5 ppm (extracellular) in
addition to a smaller remnant peak at 0 ppm (intracellular).
After injection of ouabain, the amplitudes of the two peaks
equalized, suggesting intracellular sodium retention.

(a)
Nitrilotriacetic (b) Triethylenetetraminehexaacetic
acid (H3 NTA)
acid (H6 TTHA)

These earlier interrogations of 23 Na compartmentalization
used Dy3+ -based compounds as the paramagnetic agent
used to induce chemical shifts. TmDOTP5− soon came to
also be used for these purposes. Although TmDOTP5− has a
higher tendency to disrupt living systems than an agent like
DyTTHA3− due to higher affinity for endogenous metals like
Mg2+ or Ca2+ [328, 329], it is able to induce larger chemical
shifts so smaller doses can be used. Moreover, Dy3+ salts are
relatively less stable which leads to free Dy3+ often circulating,
which is toxic. Bansal and colleagues demonstrated that
TmDOTP5− can be safely infused into rats to separate and
quantify compartmental 23 Na signals in the brain[330] and
the liver[242, 331]. Furthermore, they characterized sodium
imbalances as well the effect of chemotherapy in the 9L
gliosarcoma using TmDOTP5− as well[332, 333], though the
tumor was planted subcutaneously and not in situ.
Following these early MRS experiments, much of the research
gravitated toward purely 23 Na MRI techniques, with an emphasis on filtering certain 23 Na compartments by exploiting

Figure 2.10: Early NMR chelates.
Chemical structures of (a) nitrilotriacetic acid and (b) triethylenetetraminehexaacetic acid (TTHA),
which have been used as early
NMR contrast agents to induce
23
Na chemical shift differences
when complexed with dysprosium.
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differences in relaxation behavior between extracellular and
intracellular sodium. The previous theoretical discussion focused mainly on a spin-1/2 (𝐼 = 12 ) nucleus with only two 𝐼ˆ𝑧
eigenstates (2𝐼 + 1 = 2, 𝑚 = ±1/2) and therefore only one energy transition between them. Because 23 Na is spin-3/2, there
are actually four 𝐼ˆ𝑧 eigenstates (2𝐼 + 1 = 4, 𝑚 = ±1/2 , ±3/2):
one central transition between 𝑚 = ±1/2, like a spin-1/2
nucleus, and two single-quantum satellite transitions between 𝑚 = +1/2 ↔ +3/2, and between 𝑚 = −1/2 ↔ −3/2.
There are also two possible double-quantum transitions between 𝑚 = +1/2 ↔ −3/2 and between 𝑚 = −1/2 ↔ +3/2,
and one triple-quantum transition between 𝑚 = ±3/2. Note
that for the central and satellite transitions, Δ𝑚 = 1, whereas
for the double- and triple-quantum transitions, Δ𝑚 = 2 and
3, respectively. Bound sodium is more likely to undergo
these non-central transitions and exhibits shorter 𝑇2 values,
whereas aqueous sodium almost always experiences the central transition and exhibits larger 𝑇2 values. Because bound
sodium corresponds to intracellular sodium, and aqueous
to extracellular, double-quantum filtering (DQF) and triplequantum filtering (TQF) sequences have been designed to
weigh the signal towards a particular compartment[334, 335].
These sequences still lack complete specificity, as not all intracellular sodium is bound, nor is all extracellular sodium
freely aqueous.

2.6 Conclusion
This chapter provided a detailed and in-depth overview of
the NMR phenomenon from both the classical and quantum
physics perspectives, as well as the chemistry of paramagnetic agents and how they affect the physical properties of
coordinated nuclei. These fundamentals set the stage for appreciating the clinical and biomedical applications of NMR in
both medicine and research, mainly through the use of MRS,
MRI, and MRSI. The discussion on sodium spectroscopy
provides adequate background for the results described in
this study. While a myriad of paramagnetic agents was used
to induce compartmental separation of 23 Na signals, a rigorous biomedical model that examines the mechanism of
the shifting has not been adequately developed. The next
chapter (Chapter 3) will focus on the novel design of such
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a model with predictive power for many possible paramagnetic agents. Furthermore, the spectroscopy techniques used
thus far have employed whole-sample or whole-organ MRS,
leaving much to be desired in terms of spatial variations only
achievable by MRI or MRSI. As discussed earlier, however,
23
Na MRI techniques have not yet been fully refined to quantify individual compartments. Chapter 4 discusses a novel
23
Na MRSI method in the context of gliomas which demonstrates interesting properties about sodium imbalances in
several glioma cell lines. Chapter 5 then describes several
future directions which the crucial results from this study
establish.
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which depends on aqueous free sodium ions (Na+ ) exchang3.5 Discussion . . . . . . . . 103
ing with LnChe𝑛− . We analyzed 23 Na shiftability and broad3.6 Conclusion . . . . . . . 106
ening due to hyperfine and bulk magnetic susceptibility
(BMS) effects that arise from LnChe𝑛− designs using selective Ln3+ ions (i.e., thulium, Tm3+ ; gadolinium, Gd3+ ;
europium, Eu3+ ) and macrocyclics derived from 1,4,7,10tetraazacyclododecane (cyclen) [i.e., with phosphonate (DOTP8− )
and carboxylate (DOTMA4− ) arms] and 1,4,7-triazacyclononane
(TACN) [i.e., with phosphonate (NOTP6− ) arms]. All macrocyclic complexes of LnChe𝑛− showed downfield shifts, but
Gd3+ and Tm3+ agents, respectively, were dominated by
bulk magnetic susceptibility and hyperfine effects, and in
good agreement with theory. While 23 Na shiftability and
broadening were minimally affected by pH and competing
cations (K+ , Ca2+ , Mg2+ ) within physiological ranges, the
23
Na shiftability and broadening were most sensitive for
LnChe𝑛− concentration in relation to interstitial Na+ level
in vivo. The greatest 23 Na shiftability and broadening were
obtained with Tm3+ and Gd3+ agents respectively, with the
net anionic charge 𝑛 of LnChe𝑛− being a key component. The
results indicate that the Na+ exchange rate with LnChe𝑛−
also depends on the ionic radii and magnetic moment of
Ln3+ . Given biological importance of resolving extracellular
and intracellular Na+ signals with 23 Na-NMR in vivo, as
Na+ distributions across biological membranes are tightly
regulated, future macrocyclic designs of LnChe𝑛− should be
sought for biomedical sensor applications.

3.1 Introduction
Nuclear magnetic resonance (NMR) is a versatile method
to non-invasively probe physical, chemical and biological
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phenomena alike, e.g., within intact tissue in vivo. Its most
common application is clinically, as it underlies the phenomenon of magnetic resonance imaging (MRI). The vast
majority of biomedical applications relies on detection of
the proton (1 H) nuclear spin (𝐼 = 1/2)[336]due to its large
gyromagnetic ratio ( 𝛾H = 42.57 MHz/T). Moreover, there is
an overabundance of 1 H in biological samples, resulting in an
excellent signal-to-noise ratio (SNR)[337]. Sodium-23 (23 Na),
which has 100% natural abundance, is also NMR-visible (𝐼 =
3/2) and provides the next-strongest SNR among biological
ions[335]. Its gyromagnetic ratio ( 𝛾Na = 11.26 MHz/T) is 1/4
that of 1 H, but with shorter longitudinal (𝑇1 ) and transverse
(𝑇2 ) relaxation times, so under idealized situations SNR for
23
Na-MRI may potentially be comparable.
One limitation of traditional 23 Na-NMR is that signals from
different pools overlap, and additional techniques must be
utilized to differentiate among them. Employing 23 Na-NMR
toward compartmental Na+ discrimination broadly depends
on intrinsic and extrinsic approaches. Intrinsic approaches
use complex pulse sequences to weigh the signal towards
compartments of interest[338]. Most of these exploit differences in the degree of Na+ binding, which affect 23 Na
relaxation times. While these methods have set the stage,
techniques with greater compartmental specificity and more
accurate quantification are desirable[305, 335, 339].
Extrinsic methods primarily rely on using paramagnetic
agents to induce spectroscopic chemical shift differences
between compartments[239]. The agents usually consist of
linear and/or macrocyclic chelates (Che(𝑛+3)− ) complexed
with a lanthanide ion (Ln3+ ) at its core to form an anionic lanthanide complex (LnChe𝑛− )[244, 329, 340–344]. Such agents
have been used with 23 Na-NMR to spectroscopically discriminate between 23 Na signals and enable quantification[242, 267,
330, 332], although more rigorous experimentation is needed.
Prior experiments attempted to quantify 23 Na chemical shift
using LnChe𝑛− agents versus parameters like pH, temperature and other cations, but they did not consider relevant in
vivo conditions nor did they consider line broadening[345].
LnChe𝑛− consists of macrocyclic chelates conjugated with
Ln3+ which have different atomic radii, unpaired electrons,
and magnetic moments. These collectively induce an overall shift/broadening of NMR peaks via the diamagnetic,
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hyperfine, and bulk magnetic susceptibility (BMS) mechanisms, where the latter two are paramagnetic consequences
of LnChe𝑛− . The hyperfine shift can be due to contact (i.e.,
scalar) or pseudo-contact (i.e., dipolar) mechanisms, whereas
the BMS shift depends on the degree of alignment between
the magnetic moment (of Ln3+ ) and the static magnetic field,
so it is important to separate the dominant shifting/broadening mechanisms of NMR spectra[329, 346]. Here, we probe
the mechanism and propose a model for 23 Na peak shiftability and broadening effects induced by various LnChe𝑛−
designs, where the Ln3+ and Che(𝑛+3)− are in use for in vivo
preclinical studies – using 1 H-NMR to measure properties
like temperature[323, 347, 348], pH[316, 318, 319, 321, 322,
325, 349–351], and tumor hypoxia[352, 353] – with preference
towards macrocyclic complexes because of their thermodynamic and kinetic stability over linear complexes[354].
The Ln3+ used were thulium (Tm3+ ), gadolinium (Gd3+ ), and
europium (Eu3+ ), whereas the Che(𝑛+3)− used were based on
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonate)
(DOTP8− ), 1,4,7-triazacyclononane-1,4,7-tris(methylenephosphonate)
(NOTP6− ), and 1,4,7,10-tetraazyacyclododecane-1,4,7,10-tetrakis(methylacetate)
(DOTMA− ) ( Figure 3.1a-c). We deliberately selected these
Ln3+ ions based on atomic radii [Eu3+ (112 pm) > Gd3+ (110.7
pm) > Tm3+ (105.2 pm)], unpaired electrons [Gd3+ (7) > Eu3+
(6) > Tm3+ (2)], and magnetic moment [Gd3+ (7.9-8.0) > Tm3+
(7.1-7.5) > Eu3+ (3.3-3.5)][355]. Each possible pair between
Ln3+ and Che(n+3)- was employed in this study, encompassing an assay of nine different agents in vitro. Crucially,
we examined 23 Na shiftability and broadening in relation
to temperature, pH, and competing cations (Na+ , K+ , Ca2+ ,
Mg2+ ) within physiological levels. The in vitro results reveal
a strong dependence on the concentration and charge of the
LnChe𝑛− in relation to Na+ , but where the magnetic moment
of the Ln3+ also plays a role.
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Figure 3.1: Structures and
charges of macrocyclic chelates,
with schematic of experimental
design. Chemical structures of
various chelates (Che): (A) 1,4,7,10tetraazacyclododecane-1,4,7,10tetrakis(methylenephosphonate)
(DOTP8− ),
(B)
1,4,7triazacyclononane-1,4,7tris(methylenephosphonate)
(NOTP6− ), and (C) 1,4,7,10tetraazacyclododecane1,4,7,10-tetrakis(methylacetate)
(DOTMA4− ). Conjugation with
different lanthanide (Ln3+ ) metals
(Tm3+ , Eu3+ , or Gd3+ ) results
in anionic lanthanide-chelate
complexes (LnChe𝑛− ) with (A) -5,
(B) -3 and (C) -1 charges. Because
of the negative charges, they
will attract Na+ and shift the
23
Na-MRSI signal.

3.2 Theory
Interactions between Na+ ions and LnChe𝑛− can be described
by[345]
k𝑓

−−−
−⇀
nNa+ + LnChe𝑛− ↽
−− Na𝑛 LnChe
k𝑟

with an equilibrium binding constant 𝐾 given by

𝐾=

𝑘𝑓
[Na𝑛 LnChe]
=
𝑘𝑟
[Na+ ]𝑛 [LnChe𝑛− ]

(3.1)

This reaction is driven to a large extent by the negative
charge 𝑛 , since the larger anionic charge on LnChe𝑛− will
attract Na+ ions more intensely due to electrostatic affinity.
In other words, the weakly bound Na+ fraction increases
with negative charge 𝑛 on LnChe𝑛− (Figure 3.2). In terms of
𝑛[Na𝑛 LnChe]
this equilibrium fraction 𝑓 , defined by 𝑓 ≡
where
𝐶Na
+
+
𝐶Na ≡ [Na ] + 𝑛[Na𝑛 LnChe] is the total Na concentration,
then Equation (3.1) can be rewritten as

𝐾=

(1 −

𝑓 𝐶Na
𝑛
𝑓 )𝑛 𝐶Na (𝑛𝐶LnChe

− 𝑓 𝐶Na )

(3.2)
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where 𝐶LnChe = [LnChe𝑛− ]+[Na𝑛 LnChe] is the total LnChe𝑛−
concentration. Due to their different ionic environments, the
weakly bound and free Na+ ions experience different chemical shifts, namely 𝛿 𝑏 and 𝛿 𝑢 [in ppm] respectively. The
observed 23 Na chemical shift Δ𝛿 is a weighted average:

Δ𝛿 = 𝑓 𝛿 𝑏 + (1 − 𝑓 )𝛿 𝑢

(3.3)

which simplifies to Δ𝛿 = 𝑓 𝛿 𝑏 because 𝛿 𝑢 is at 0 ppm[356].
The weakly bound shift 𝛿 𝑏 arises from the Ln3+ ion’s intrinsic
®int which augments the static magnetic field
magnetic field 𝐵
𝐵®0 that the nucleus experiences, and results in a chemical
shift for the weakly bound Na+ ions given by

𝛿𝑏 =
=

𝛾Na | 𝐵®0 + 𝐵®int | − 𝛾Na | 𝐵®0 |
𝜔𝑏 − 𝜔𝑢
=
𝜔𝑢
𝛾Na | 𝐵®0 |
| 𝐵®0 + 𝐵®int |
| 𝐵®int |
−1≈
| 𝐵®0 |
| 𝐵®0 |

(3.4)

where 𝜔𝑏 and 𝜔𝑢 are the resonance frequencies of the weakly
bound and free Na+ , respectively, and the final approximation is made since 𝐵int  𝐵0 . The magnetic moment,
electronic configuration, and ionic radius of Ln3+ are impor®int | , and thus Δ𝛿 in this model is a
tant determinants of | 𝐵
result of complex interplay between the choice of Ln3+ used
(through 𝛿 𝑏 ) and the charge on LnChe𝑛− (through 𝑓 ).
The Δ𝛿 term in Equation (3.3) is a total chemical shift comprised of diamagnetic Δ𝛿 𝑑 and paramagnetic Δ𝛿 𝑝 contributions. The latter is the sum of the hyperfine shift Δ𝛿 ℎ 𝑓 and
the bulk magnetic susceptibility shift Δ𝛿 𝜒 . In other words,

Δ𝛿 = Δ𝛿 𝑑 + Δ𝛿 𝑝 = Δ𝛿 𝑑 + Δ𝛿 ℎ 𝑓 + Δ𝛿 𝜒

(3.5)

Δ𝛿 ℎ 𝑓 refers to the chemical shift induced by interaction of
LnChe𝑛− with Na+ , as described above. Δ𝛿 𝜒 , which has
been extensively studied prior[329, 346], is induced by the
presence of LnChe𝑛− assuming no interaction with Na+ , and
is dependent on the phantom’s orientation with respect to
𝐵®0 . Theoretically, Δ𝛿 𝜒 is given by[346]



4𝜋𝐶𝑆 𝜇eff 2
Δ𝛿 𝜒 =
𝑇
2.84

(3.6)

where 𝐶 is the agent concentration in mM, 𝑆 = +1/3 for ori-
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Figure 3.2: Mechanism of Na+ exchange for 23 Na peak shiftability and broadening effects. A shift agent is
composed of a paramagnetic lanthanide ion (Ln3+ ) complexed with a negatively charged cyclic chelating agent
(Che(𝑛+3)− ) to form a polyanionic lanthanide complex (LnChe𝑛− ). The Na+ ions (black circles) directly linked to
the Ln3+ ion (white circle) exchange with bulk electrolyte composed of free Na+ ions, where the exchange rate
( 𝑘 𝑒 𝑥 ) transmits the paramagnetic effect of the Ln3+ ion to the surrounding milieu. Efficacy of this process depends
on the number of Na+ ions bound to the Ln3+ ion, which in part is dictated by shape of the cyclic chelating
agent (Che(𝑛+3)− , shown in gray) because this manifests the overall negative charge (𝑛 ) on LnChe𝑛− . The light
gray portion of the chelate represents the region where the anionic charge resides and allows Na+ coordination.
The dark grey portion signifies the closed-off regions where anionic charge is not concentrated and Na+ would
not bind. The scenarios for 𝑛 = 1 , 3 , 5 are shown from left to right. Many factors dictate 𝑘 𝑒𝑥 , including the ionic
radius, magnetic moment, and electronic configuration of the Ln3+ ion as well as the rotational correction time
(𝜏𝑅 ) of LnChe𝑛− .

®0 , −1/6 for orientations perpendicular,
entations parallel to 𝐵
and 0 for spherical geometries, 𝑇 is the absolute temperature
and 𝜇eff is the effective magnetic moment for the particular
Ln3+ .
Compared to free Na+ ions in the bulk electrolyte, the Na+
ions in the vicinity of LnChe𝑛− will experience enhanced
relaxation due to the paramagnetic field of the Ln3+ ion.
However, these weakly bound Na+ ions also exchange with
the free Na+ ions in the bulk electrolyte with an exchange
rate 𝑘 𝑒 𝑥 , defined as the reciprocal of the mean lifetime 𝜏𝑚
any single Na+ ion spends in the weakly bound state, i.e.,
𝑘 𝑒 𝑥 = 1/𝜏𝑚 ( Figure 3.2). The cooperative exchange between
weakly bound and free Na+ ions dictates that 𝜏𝑚 is inversely
dependent on the negative charge (𝑛 ) of the paramagnetic
LnChe𝑛− , and thus the exchange rate 𝑘 𝑒 𝑥 , has direct effects on
the 23 Na linewidth. This type of chemical exchange broadens
the 23 Na linewidth by contributing to the observed transverse
relaxation rate 𝑅 ∗2𝑜𝑏𝑠 :

𝑅 ∗2𝑜𝑏𝑠 = 𝑅 ∗20 + Δ𝑅∗2 (𝑘 𝑒 𝑥 )

(3.7)

where 𝑅 ∗20 is the 23 Na transverse relaxation rate in the absence of LnChe𝑛− , and Δ𝑅 ∗2 (𝑘 𝑒 𝑥 ) represents the exchange
contribution. Since measured linewidth (Γ𝑜𝑏𝑠 ) of a resonance
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is directly related to 𝑅 ∗2𝑜𝑏𝑠 , we have

Γ𝑜𝑏𝑠 =

𝑅 ∗2𝑜𝑏𝑠
𝜋

=

𝑅 ∗20 + Δ𝑅 ∗2 (𝑘 𝑒 𝑥 )
𝜋

= Γ0 + ΔΓ(𝑘 𝑒 𝑥 )

(3.8)

with natural (i.e., agent-free) linewidth Γ0 corresponding to
𝑅 ∗20 and ΔΓ is the exchange contribution to the linewidth,
directly related to Δ∗2 .
The model depicted by Equation (3.3) (shiftability) and Equation (3.8) (broadening) lends predictive power when aspects
about LnChe𝑛− are varied, such as the Ln3+ ion and/or the
LnChe𝑛− chelate charge (𝑛 ), which can ultimately affect 𝑓 and
𝑘 𝑒 𝑥 . A greater LnChe𝑛− charge (𝑛 ), for example, produces
greater attraction for Na+ + ions, increasing 𝑓 but reducing
𝜏𝑚 for any particular Na+ . Consequentially, as 𝑘 𝑒 𝑥 increases,
so does the exchange contribution ∗20 (𝑘 𝑒 𝑥 ), and ultimately
Γ𝑜𝑏𝑠 (Equation (3.8)). The Ln3+ can also be changed for a
given Che(𝑛+3)− , leading to variations in ionic radius, electron configuration and magnetic moment (e.g., number of
total and unpaired electrons) which can affect 𝑓 and 𝑘 𝑒 𝑥 .
Differences in ionic radius affect the dipolar distance (𝑟LnNa )
between the Ln3+ and coordinated Na+ ions, as can the
numbers of both total and unpaired 𝑓 -block electrons. These
factors all work in a multifaceted manner to affect 𝑘 𝑒 𝑥 as well
®int . In addition, the rotational correlation time (𝜏𝑅 ) of
as 𝐵
LnChe𝑛− would also be a factor Figure 3.2. Thus, there is
need for empirical examinations.

3.3 Materials and Methods
LnChe𝑛− Synthesis
All chemicals and solvents were reagent-grade and used
as received without additional purification. The complexes
TmDOTP5− , TmDOTMA− and the protonated ligands H8 DOTP,
H6 NOTP, and H4 DOTMA were purchased from Macrocyclics Inc. (Plano, TX, USA). Thulium(III) chloride hydrate
(TmCl3 · 𝑥 H2O, 99.99%) was received from Alfa Aesar (Ward
Hill, MA). Europium(III) chloride (anhydrous EuCl3 , 99.99%)
and gadolinium(III) chloride (anhydrous GdCl3 , 99.99%)
were purchased from Sigma Aldrich (St. Louis, MO).
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All LnDOTP5− , LnNOTP3− , and LnDOTMA− were synthesized by adding equimolar concentrations of the Ln(III) salt
to an aqueous solution of the protonated ligand in deionized
H2 O (10 mL, 500 𝜇mol each). The resulting suspension was
transferred to a round-bottom flask and heated to 60 ◦ C with
stirring. The pH was adjusted to 7 by adding 1 N KOH dropwise and the reaction mixture was stirred overnight. After
cooling to room temperature, the reaction pH was increased
to 8 by adding additional KOH. The solution was then passed
through a 500 nm syringe filter, and the pH of the filtrate
was adjusted to 7 using 1 N HCl. Free metal was not found
in the filtrate. Finally, solutions were lyophilized (LabConco
Freezone Plus 4.5-Liter Cascade Benchtop System) at –80 ◦ C.
The synthesized complex was characterized using 1 H-NMR
on a Bruker Avance III HD 500 vertical-bore spectrometer
(Bruker, Billerica, MA, USA) interfaced with Bruker TopSpin
v3.2 software.

23

Na Spectra Acquisition

In vitro experiments were performed using concentric NMR
tubes (spherical and cylindrical; Wilmad-LabGlass, Vineland,
NJ, USA). One compartment (inner) contained 150 mM NaCl
and the other (outer) contained the same but with varying
amounts of LnChe𝑛− and 10% v/v 2 H2 O to lock the spectrometer frequency using the 2 H2 O signal. Sodium chloride
and 2 H2 O were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Each solution was pH-adjusted using HCl or
KOH to give 5 different pH values.
23

Na-NMR spectra were collected on the same Bruker system
as for 1 H-NMR. A single 23 Na square pulse was used to
globally excite the volume of interest (repetition time 𝑇𝑅 =
275 ms) collecting 2048 FID points in the time domain with an
acquisition time 𝑡 𝑎𝑞 = 38.9 ms, averaged 1024 times. Spectra
were analyzed applying 10-Hz line broadening and manual
zeroth- and first-order phasing. The chemical shift and line
width of the shifted peak were measured using the ’peakw’
function on TopSpin.
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3.4 Results
Three selected Ln3+ ions (Tm3+ , Eu3+ and Gd3+ ) have varying
trends in their atomic radii, unpaired electrons, and magnetic
moment. Of the three Ln3+ metals, Tm3+ -based agents (Figure 3.3) provided the strongest chemical shifts compared to
Eu3+ -based (Figure 3.4) and Gd3+ -based (Figure 3.5) agents
and these latter two were mostly broadened. For 10 mM
concentrations of each LnDOTP5− spectrum in the coaxial
tubes parallel to the magnetic field which accentuate the
BMS effects, TmDOTP5− shifted 150 mM Na+ by 20.79 ppm
(Figure 3.3a), whereas EuDOTP5− caused a shift of 0.587
ppm (Figure 3.4a) and GdDOTP5− induced a shift of 0.520
ppm (Figure 3.5a). Similarly, superior shifts caused by Tm3+
compared to Eu3+ and Gd3+ were also seen for the LnNOTP3−
(Figure 3.3b, Figure 3.4b, Figure 3.5b) and LnDOTMA− (Figure 3.3c, Figure 3.4c, Figure 3.5c) complexes. Therefore, given
a particular chelate, Tm3+ -induced 23 Na chemical shifts were
greater than those prompted by Eu3+ and Gd3+ , which were
comparable to each other. When comparing paramagnetic
agents with the same Ln3+ metal, there is a clear trend that
more negative LnChe𝑛− charges (𝑛 ) produce larger 23 Na
chemical shifts. Moreover, higher LnChe𝑛− concentrations
resulted in larger shifts as well. This is evident across all
concentrations for Tm3+ -based (Figure 3.3d), Eu3+ -based
(Figure 3.4d), and Gd3+ -based (Figure 3.5d) agents. The
slope of each best-fit line represents the sensitivity of the
23
Na chemical shift to the concentration of the corresponding
LnChe𝑛− , and is termed the concentration shiftability 𝑠 𝑐 of
the complex (Table 3.1). Line broadening also occurred in
the presence of LnChe𝑛− agents, and in general followed the
same trends. Larger negative charges (𝑛 ) and higher concentrations generally resulted in broader spectra for Tm3+ -based
(Figure 3.3e), Eu3+ -based (Figure 3.4e), and Gd3+ -based (Figure 3.5e) agents just like for chemical shift. Similar to 𝑠 𝑐 , a
quantity called the concentration broadening potential 𝛽 𝑐
can be defined to reflect the sensitivity of 23 Na linewidth to
LnChe𝑛− concentration (Table 3.1).
Table 3.1 presents measured 𝑠 𝑐 and 𝛽 𝑐 values for the nine
LnChe𝑛− designs, although the BMS effects were fully measured for three of these agents. Compared to shiftability/broadening in the spherical phantom in the DOTP8−
agents, the total shift was enhanced by 2.5% for Tm3+ , 20%
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Chelate
Metal
Tm3+

Eu3+

Gd3+

®0
Phantom Orientation to 𝐵

DOTP8−

⊗
||
⊥
⊗
||
⊥
⊗
||
⊥
TmDOTP5− :
EuDOTP5− :
GdDOTP5− :

2.03
2.08
1.98
0.035
0.042
0.03
0.04
0.0546
0.03
|| BMS=
|| BMS=
|| BMS=

NOTP6−

DOTMA4−

0.042

0.568

0.018

0.162

0.0024

0.0054

0.00792

0.0052

0.0072

0.0005

0.036

0.0435

0.0117

0.0382

0.0043

+2.5%,
+20%,
+36.5%,

⊥ BMS=
⊥ BMS=
⊥ BMS=

−2.5%
−14.3%
−25%

for Eu3+ , and 36.5% for Gd3+ when the coaxial tubes were
parallel to the magnetic field, whereas the total shift was
reduced by 2.5% for Tm3+ , 14.3% for Eu3+ , and 25% for Gd3+
when the coaxial tubes were perpendicular to the magnetic
field. Collectively, these suggest that the hyperfine shift terms
dominate for TmDOTP5− giving rise to high shiftability (i.e., 2
ppm/mM), whereas the BMS effects dominate for EuDOTP5−
(i.e., 0.01 ppm/mM) and GdDOTP5− (i.e., 0.04 ppm/mM)
for large broadening, but with minor shifting. Given the reasonably higher measured sc values for Tm3+ complexes with
NOTP6− and DOTMA4− (Table 3.1), these could potentially
be useful given their overall orientation-dependent 𝑠 𝑐 values
of 0.5 ppm/mM and 0.2 ppm/mM, respectively (Table 3.1).
These numerical values for 𝑠 𝑐 confirm the aforementioned
trends in charge, concentration and the superior shiftability
of Tm3+ -based agents (Table 3.1). The highest and lowest 𝑠 𝑐
values were for TmDOTP5− and EuDOTMA− , respectively.
The measured 𝛽 𝑐 values illustrate the trends that larger
concentrations of any LnChe𝑛− results in broader spectra,
and more negative charges for a given Ln3+ also broaden
spectra more (Table 3.1). The highest and lowest 𝛽 𝑐 values
were for TmDOTP5− and EuDOTMA− , respectively. It should
also be noted that for a given chelate, broadening by Tm3+ and
Gd3+ were comparable, as evidenced by similar 𝛽 𝑐 values. In
addition, they both broadened 23 Na spectra more than Eu3+ .
This can be attributed to similar magnetic moments between
Tm3+ and Gd3+ , which are larger than that of Eu3+ .
From all these spectra in Figure 3.3-Figure 3.5, and 𝑠 𝑐 and 𝛽 𝑐
values in Table 3.1, Eu3+ was the least effective in separating
the 23 Na signals between different compartments in terms
of both chemical shift and linewidth. Meanwhile, Tm3+
exhibited the strongest capability to both shift and broaden
the 23 Na signal in a single compartment. Gd3+ , however,

Table 3.1: Concentration shiftability ( 𝑠 𝑐 ) and broadening potential (𝛽 𝑐 ) values (left and
right, respectively) for different
LnChe𝑛− agents employed. Values reported in ppm/mM agent.
LnDOTP5− complexes were assessed in spherical ( ⊗ ), parallel
( || ), and perpendicular (⊥) orientations. BMS contributions calculated using Equation (3.6).
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displayed interesting properties. While it was not particularly
efficacious for shifting (low 𝑠 𝑐 values for GdChe𝑛− agents),
it had similar line broadening capabilities (i.e., 𝛽 𝑐 ) as Tm3+ .
Furthermore, pH was also considered as a potential confound
for the observed 23 Na chemical shift and linewidth. However,
the sensitivity to pH pales in comparison to the sensitivity
for agent concentration. This was shown for all chelates
conjugated to Tm3+ (Figure 3.6d-e), Eu3+ (Figure 3.7d-e),
and Gd3+ (Figure 3.8d-e). Therefore, pH was not considered
a relevant factor which significantly affected our putative
binding model (Equation (3.3) and Equation (3.8)). However,
concentration and charge of LnChe𝑛− play significant roles.
The presence of other cations can potentially confound the
measured 𝑠 𝑐 and 𝛽 𝑐 values for in vivo settings, as they could
compete with Na+ for attraction to LnChe𝑛− . We tested the
individual and collective effects of the presence of Ca2+ , Mg2+ ,
and K+ on 23 Na shiftability and line broadening using the
same in vitro setup. CaCl2 , MgCl2 , and KBr salts were added
at concentrations of 2 mM, 2 mM, and 10 mM, respectively, to
a solution containing 150 mM NaCl and 2 mM TmDOTP5− in
the external compartment to roughly reflect the physiological
amounts of these species in the in vivo extracellular space[357–
359]. TmDOTP5− was chosen as the candidate LnChe𝑛−
because it exhibited the highest 𝑠 𝑐 (Table 3.1). We found
that, with these cationic concentrations, changes in 23 Na
chemical shift and linewidth were negligible (Figure 3.9a).
Chemical shift decreased by only 3% (Figure 3.9b), whereas
linewidth decreased by only 6% (Figure 3.9c). These small
changes verify that in vivo 23 Na-MRSI results would not be
compromised by the presence of other cations in the Na+ -rich
extracellular space.
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Figure 3.3: Concentration and charge effects of Tm3+ -based agents on 23 Na chemical shift. 23 Na spectra are
displayed for concentric tubes parallel to magnetic field, where the LnChe𝑛− added to the outer compartment in
the phantom was (A) TmDOTP5− , (B) TmNOTP3− , or (C) TmDOTMA− . Spectra are shown for 10 (blue), 7.5
(golden), 5 (green), and 3 (red) mM, and 0 ppm corresponds to the natural, unshifted 23 Na resonance of the inner
compartment to which no LnChe𝑛− was added. The 23 Na chemical shifts clearly display a dependence on both
the concentration and charge of the LnChe𝑛− , with larger shifts corresponding to both higher concentrations and
larger negative charges. These trends are summarized in (D), where TmDOTP5− displays the highest shiftability,
followed by TmNOTP3− , and then TmDOTMA− . The addition of LnChe𝑛− also induces line broadening in
23
Na spectra due to 𝑇2 shortening, which follows similar patterns of dependence on [LnChe𝑛− ] and charge
and is summarized in (E). See Figure 3.4 and Figure 3.5 for similar data from Eu3+ - and Gd3+ -based agents,
respectively. See Figure 3.6 for pH variations from these same Tm3+ -based agents.
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Figure 3.4: Concentration and charge effects of Eu3+ -based agents on 23 Na chemical shift. 23 Na spectra are
displayed for concentric tubes parallel to magnetic field, where the LnChe𝑛− added to the outer compartment
in the phantom was (A) EuDOTP5− , (B) EuNOTP3− , or (C) EuDOTMA− . Spectra are shown for 10 (blue), 7.5
(golden), 5 (green), and 3 (red) mM, and 0 ppm corresponds to the natural, unshifted 23 Na resonance of the
inner compartment to which no LnChe𝑛− was added. The 23 Na chemical shifts display a dependence on both
the concentration and charge of the LnChe𝑛− much like Tm3+ -based agents, although to a much lesser extent.
These trends are summarized in (D), where EuDOTP5− displays the highest shiftability, followed by EuNOTP3− ,
and then EuDOTMA− . The line broadening trends are summarized in (E), and also follow these same patterns.
See Figure 3.3 and Figure 3.5 for similar data from Tm3+ - and Gd3+ -based agents, respectively. See Figure 3.7 for
pH variations from these same Eu3+ -based agents.
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Figure 3.5: Concentration and charge effects of Gd3+ -based agents on 23 Na chemical shift. 23 Na spectra are
displayed for concentric tubes parallel to magnetic field, where the LnChe𝑛− added to the outer compartment
in the phantom was (A) GdDOTP5− , (B) GdNOTP3− , or (C) GdDOTMA− . Spectra are shown for 10 (blue),
7.5 (golden), 5 (green), and 3 (red) mM, and 0 ppm corresponds to the natural, unshifted 23 Na resonance of
the inner compartment to which no LnChe𝑛− was added. The 23 Na chemical shifts display a dependence on
both the concentration and charge of the LnChe𝑛− much like Tm3+ -based agents, although to a much lesser
extent. These trends are summarized in (D), where GdDOTP5− displays the highest shiftability, followed by
GdNOTP3− , and then GdDOTMA− . These Gd3+ -based agents produced significant line broadening, and trends
are summarized in (E), also following these same patterns. See Figure 3.3 and Figure 3.4 for similar data from
Tm3+ - and Eu3+ -based agents, respectively. See Figure 3.8 for pH variations from these same Gd3+ -based agents.
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Figure 3.6: pH effects of Tm3+ -based agents on 23 Na chemical shift. 23 Na spectra are displayed for concentric
tubes parallel to magnetic field, where the LnChe𝑛− added to the outer compartment in the phantom was
(A) TmDOTP5− , (B) TmNOTP3− , or (C) TmDOTMA− . Spectra are shown for pH 6 (blue), 7(golden), and 8
(green), and 0 ppm corresponds to the natural, unshifted 23 Na resonance of the inner compartment to which
no LnChe𝑛− was added. The 23 Na chemical shifts do not display a significant dependence on the pH of the
environment. These trends are summarized in (D). The line broadening also does not exhibit pH dependence
(E). See Figure 3.7 and Figure 3.8 for similar data from Eu3+ - and Gd3+ -based agents, respectively. See Figure 3.3
for concentration and charge effects from these same Tm3+ -based agents.

99

3 Comparison of Lanthanide Macrocyclic Complexes as 23 Na
NMR Sensors

Figure 3.7: pH effects of Eu3+ -based agents on 23 Na chemical shift. 23 Na spectra are displayed for concentric
tubes parallel to magnetic field, where the LnChe𝑛− added to the outer compartment in the phantom was (A)
EuDOTP5− , (B) EuNOTP3− , or (C) EuDOTMA− . Spectra are shown for pH 6 (blue), 7(golden), and 8 (green), and
0 ppm corresponds to the natural, unshifted 23 Na resonance of the inner compartment to which no LnChe𝑛− was
added. The 23 Na chemical shifts do not display a significant dependence on the pH of the environment. These
trends are summarized in (D). The line broadening also does not exhibit pH dependence (E). See Figure 3.6 and
Figure 3.8 for similar data from Tm3+ - and Gd3+ -based agents, respectively. See Figure 3.4 for concentration and
charge effects from these same Eu3+ -based agents.
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Figure 3.8: pH effects of Gd3+ -based agents on 23 Na chemical shift. 23 Na spectra are displayed for concentric
tubes parallel to magnetic field, where the LnChe𝑛− added to the outer compartment in the phantom was (A)
GdDOTP5− , (B) GdNOTP3− , or (C) GdDOTMA− . Spectra are shown for pH 6 (blue), 7(golden), and 8 (green),
and 0 ppm corresponds to the natural, unshifted 23 Na resonance of the inner compartment to which no LnChe𝑛−
was added. The 23 Na chemical shifts do not display a significant dependence on the pH of the environment.
These trends are summarized in (D). The line broadening also does not exhibit pH dependence (E). See Figure 3.6
and Figure 3.7 for similar data from Tm3+ - and Eu3+ -based agents, respectively. See Figure 3.5 for concentration
and charge effects from these same Gd3+ -based agents.
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Figure 3.9: Effect of cation competition on 23 Na chemical shift and line width induced by 2 mM TmDOTP5− .
(A) 23 Na-NMR spectra for 150 mM NaCl solutions containing 2 mM TmDOTP5− alone (blue), and in the presence
of 2 mM Ca2+ (golden), 2 mM Mg2+ (green), 10 mM K+ (red), and all three of these ions (purple). All 23 Na
spectra were acquired from concentric tubes parallel to magnetic field (similar to Figure 3.3-Figure 3.5). Ca2+ ,
Mg2+ , and K+ were introduced as the salts CaCl2 , MgCl2 , and KBr, respectively. These concentrations were all
chosen to represent physiological concentrations in the extracellular space. The changes in 23 Na (B) chemical
shift and (C) line width were negligible, suggesting overall higher affinity for Na+ given the aforementioned
amounts. Chemical shift ranged between 2.433 ppm (B, alone, blue) and 2.352 ppm (B, all, purple), representing
only a 3% change in the presence of all competing cations. Line width ranged between 0.2433 ppm (C, alone,
blue) and 0.2285 ppm (C, all, purple), representing only a 6% change in the presence of all competing cations.
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3.5 Discussion
Comparison of these nine LnChe𝑛− agents reveals that Tm3+ based agents (hyperfine shift-dominated) exhibited superior
shiftability, but Gd3+ -based agents (BMS shift-dominated)
showed sufficient line broadening. This makes Tm3+ - and
Gd3+ -based agents promising candidates for in vivo 23 Na compartmental signal separation. To date, no specific in vivo or in
vitro studies have used Gd3+ -based agents for 23 Na compartmental signal separation. However, numerous studies have
demonstrated that infusion of TmDOTP5− in vivo resulted in
separated (i.e., chemically shifted) 23 Na NMR peaks which
could be quantified individually to yield physiologically
relevant results[242, 330]. This method has proven crucial
for probing the tumor microenvironment[332, 333]. Because
TmDOTP5− would extravasate easily into the tumoral extracellular space while still being barred from the intracellular
compartment, different concentrations of TmDOTP5− would
be found across different physiological compartments, which
we have shown[356]. Given that agent concentration would
never reach the same level as Na+ concentration in any compartment, these 𝑠 𝑐 and 𝛽 𝑐 values measured in vitro should be
translatable in vivo. As demonstrated in this study, LnChe𝑛−
agents induce shiftability and broadening in a concentrationdependent manner. Therefore, there would be a different
23
Na peak observed for each compartment in vivo based on
Na+ concentration and the integrals of these peaks would
be directly related to the compartmental Na+ concentrations,
suggesting perturbed Na+ biodistribution across healthy
tissue and lesions.
The results demonstrate that TmDOTP5− is the most effective
out of the three TmChe𝑛− agents (TmDOTP5− , TmNOTP3− ,
and TmDOTMA− ) in inducing 23 Na chemical shifts. Furthermore, when compared to same ligand complexed with
different Ln3+ ions; neither EuDOTP5− nor GdDOTP5− would
cause shifts to the same extent as TmDOTP5− . However, Tm3+ based agents are not approved for clinical use, but Gd3+ -based
agents are ubiquitous in clinical 1 H MRI scans[306, 360–362],
as they shorten 1 H 𝑇1 relaxation times which results in signal enhancement in lesions. As confirmed by this study,
GdChe𝑛− agents also provide substantial 23 Na line broadening, comparable to that caused by TmChe𝑛− agents. Therefore,
there is potential to use an agent like GdDOTP5− in vivo to
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yield peaks with different 23 Na linewidths, from which Na+
concentrations could be extrapolated, albeit qualitatively.
The model (Equation (3.3) and Equation (3.8)) describing the
mechanism of Na+ exchange to induce 23 Na peak shiftability
and broadening effects aligned with the in vitro results quite
well. The bound fraction 𝑓 of Na+ coordinated to LnChe𝑛−
agents is a crucial determinant for the chemical shift and depends on the negative charge (𝑛 ) since Na+ will have a higher
electrostatic affinity for more negatively charged species. We
see these trends illustrated across all TmChe𝑛− (Figure 3.3d),
EuChe𝑛− (Figure 3.4d), and GdChe𝑛− (Figure 3.5d) agents,
and in their 𝑠 𝑐 values ( Table 3.1). Moreover, comparing across
different Ln3+ metals, we found Tm3+ to have consistently the
highest 𝑠 𝑐 given any chelate, followed by Gd3+ and then Eu3+ .
The increasing 𝑠 𝑐 with decreasing ionic radii explains how
ionic radius affects 𝑓 and 𝑠 𝑐 through the intrinsic magnetic
field. This is likely a consequence of Tm3+ having the smallest
ionic radius among the three metals studied[241], resulting
®int in Equation (3.4))
in a stronger intrinsic magnetic field (𝐵
which increases 𝑓 .
Another component of the model involves line broadening of
23
Na spectra by inclusion of paramagnetic LnChe𝑛− agents.
The spectral linewidth is ultimately affected by the exchange
rate 𝑘 𝑒 𝑥 (Equation (3.8)) between Na+ bound to LnChe𝑛− and
free Na+ found in the bulk. Most notably, for agents with
the same Ln3+ metal, more negatively charged species produced larger linewidths, suggesting that 𝑘 𝑒 𝑥 is larger when
𝑛 is larger due to strong electrostatic attraction between
LnChe𝑛− and Na+ , and reduced mean lifetime (𝜏𝑚 ) means
fast exchange with the free Na+ pool. We see these trends
illustrated across all TmChe𝑛− (Figure 3.3e), EuChe𝑛− (Figure 3.4e), and GdChe𝑛− (Figure 3.5e) agents, and in their 𝛽 𝑐
values (Table 3.1). Similarly, comparing different Ln3+ metal
cores across a particular chelate, Tm3+ and Gd3+ showed
similar broadening capabilities (comparable 𝛽 𝑐 values) and
were both superior to Eu3+ . Line broadening results from
changes in 23 Na 𝑇2 relaxation (Equation (3.8)) caused by fluctuations in the local magnetic field experienced by Na+ ions.
The local magnetic field is determined by interplay between
the dipolar coupling and magnetic moment interactions between the weakly bound Na+ and the Ln3+ . The dipolar
coupling is affected primarily by the distance between Na+
and Ln3+ (𝑟LnNa ), which is related to the ionic radii of the two
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species. Larger 𝑟LnNa would decrease paramagnetic effects
and affinity between Na+ and the LnChe𝑛− , ultimately reducing 𝑘 𝑒 𝑥 . Thus, we would expect line broadening to follow
Eu3+ < Gd3+ < Tm3+ . While the experimental results concur
with our expectation of Eu3+ , Gd3+ broadening was closer to
the level of Tm3+ broadening. We attributed this to the fact
that 𝑅 2 strongly affects the linewidth, and this 𝑅 2 effect is directly related to the magnetic moment of the agent[363]. The
strong magnetic moment and overall paramagnetic nature
of Tm3+ are responsible for its broadening capability (𝛽 𝑐 )
being similar to an ion like Gd3+ which has a larger radius
but similar magnetic properties. With respect to the model,
the exchange contribution Δ𝑅 ∗20 is larger for Ln3+ nuclei with
a larger number of unpaired electrons.
Assessment of the effect of other cations at physiological
concentrations demonstrated that 23 Na chemical shift and
line width are relatively unaffected when compared to the
effects of LnChe𝑛− concentration and charge (Figure 3.9a-c).
Specifically, for the extracellular space, Na+ dominates K+
by an order of magnitude, and dominates Ca2+ and Mg2+
by more than two orders of magnitude. Therefore, in vivo,
LnChe𝑛− would exhibit very high affinity for Na+ which
would be relatively unperturbed by the presence of competing cationic species. Although higher cationic concentrations
will affect 23 Na chemical shift more drastically[345], such
scenarios are not relevant for in vivo studies.
The BMS contribution to Δ𝛿 (Equation (3.5)) and to the
measured 𝑠 𝑐 values are important. According to previous
rigorous studies[346], Δ𝛿 𝜒 contributions increase when the
®0 , and decrease when the
sample orientation is parallel to 𝐵
orientation is perpendicular (Equation (3.6)). TmDOTP5−
exhibited a very small Δ𝛿 𝜒 since the chemical shifts in all
three orientations were negligibly different. On the other
hand, the chemical shift induced by GdDOTP5− observed in
our studies (i.e., parallel orientation) was almost entirely due
to Δ𝛿 𝜒 , whereas EuDOTP5− had intermediate Δ𝛿 𝜒 contributions. We expect these effects to scale accordingly for the
less-negatively-charged LnNOTP3− and LnDOTMA− complexes.
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3.6 Conclusion
This study probed the mechanisms underlying shiftability
and line broadening phenomena in paramagnetic 23 Na-NMR
spectroscopy using combinations of Ln3+ ions (Tm3+ , Eu3+ ,
and Gd3+ ) and macrocyclic chelates (DOTP8− , NOTP6− , and
DOTMA4− ). Overall, we have crucially characterized the
dependencies of 23 Na chemical shifts and linewidths in the
presence of paramagnetic agents on charge and chemical
structures of these agents, and confounding effects like pH,
temperature, and other physiological cations. BMS effects
on different LnChe𝑛− designs were also critically considered. These observations together allow us to establish a
reliable model that provides the basis for future designs of
LnChe𝑛− .
Chemical shift is a consequence of the binding between
Na+ ions and the paramagnetic LnChe𝑛− agent, primarily
affected by the equilibrium fraction 𝑓 of Na+ that is bound
to LnChe𝑛− . Line broadening occurs due to the kinetics of
exchange between Na+ bound to LnChe𝑛− and free in the bulk
electrolyte, encapsulated by the exchange rate constant 𝑘 𝑒 𝑥 .
TmDOTP5− shifted and broadened 23 Na-NMR spectra more
effectively than TmNOTP3− , which did so more effectively
than TmDOTMA− . Identical patterns were seen for EuChe𝑛−
and GdChe𝑛− agents. This confirmed that larger negative
charges (𝑛 ) ultimately resulted in larger values for 𝑓 and 𝑘 𝑒 𝑥 ,
in agreement with the model’s predictions. Across metals,
Tm3+ shifted more than Eu3+ , which shifted more than Gd3+ .
In terms of broadening, Tm3+ and Gd3+ were comparably
effective while Eu3+ was not. These trends are explained by
differences in different Ln3+ metals, but also shape of the
chelate (Che(𝑛+3)− ).
Tm3+ agents can be used presently in preclinical studies. We
have previously demonstrated the use of LnChe𝑛− agents
in compartmentalizing 23 Na magnetic resonance spectroscopic imaging (MRSI) signals in gliomas in vivo to reveal
abnormally strong transendothelial and weak transmembrane Na+ gradients in tumors[356]. However, Gd3+ agents
are approved for clinical use, and in this study have shown
to provide sufficient 23 Na line broadening in a concentrationdependent manner. Therefore, there is some potential for
Gd3+ agents to be used in vivo to identify compartmental
Na+ concentrations based on differences in line broadening.

106

3 Comparison of Lanthanide Macrocyclic Complexes as 23 Na
NMR Sensors

The proposed model will serve to make 23 Na-NMR spectroscopic methods a more viable option which can reveal critical
information regarding altered ion distributions.
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Imaging the Transmembrane and
Transendothelial Sodium Gradients in Gliomas

The following chapter is taken from my published work in Nature Scientific Reports[356]. Under normal conditions, high
+
sodium (Na+ ) in extracellular (Na+
e ) and blood (Nab ) com+
+
partments and low Na in intracellular milieu (Nai ) produce
strong transmembrane (ΔNa+
mem ) and weak transendothe+
lial (ΔNaend ) gradients respectively, to signify cell membrane potential (𝑉𝑚 ) and blood-brain barrier (BBB) integrity.
We developed a sodium (23 Na) magnetic resonance spectroscopic imaging (MRSI) method using an intravenouslyadministered paramagnetic polyanionic agent to measure
ΔNa+mem and ΔNa+end . In vitro 23 Na-MRSI established that the
23
Na signal is intensely shifted by the agent compared to
biological factors. In vivo 23 Na-MRSI showed Na+
i remained
+
+
unshifted and Nab was more shifted than Nae , and these
+
together revealed weakened ΔNa+
mem and enhanced ΔNaend
in rat gliomas (vs. normal tissue). RG2 and U87 tumors maintained weakened ΔNa+
mem (i.e., depolarized 𝑉𝑚 ) implying an
aggressive state for proliferation, whereas RG2 tumors displayed elevated ΔNa+
suggesting altered BBB integrity. We
end
anticipate that 23 Na-MRSI will allow biomedical explorations
of perturbed Na+ homeostasis in vivo.

4.1 Introduction
Sodium (Na+ ) concentration is normally low intracellularly
(10 mM) and high in blood and extracellular spaces (150
mM)[364–366], producing a strong transmembrane Na+ gra+
dient (ΔNa+
mem ≈ 140 mM) and a weak transendothelial Na
gradient (ΔNa+
≈ 0 mM). The ΔNa+mem is coupled to the
end
cell membrane potential (𝑉𝑚 ), nerve signaling[364], muscle
activity[367] and osmoregulation[368], while the ΔNa+
imend
pacts bicarbonate and proton transport between extracellular
and blood spaces[365, 369–371] and signifies blood-brain
barrier (BBB) integrity[372, 373].
The sodium-potassium pump transports Na+ against its
electrochemical gradient by consuming adenosine triphos-
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phate generated through oxidative phosphorylation[374]. In
glioblastoma (GBM), glycolysis is upregulated in relation to
oxidative phosphorylation even with sufficient oxygen[375].
Aerobic glycolysis generates excessive amounts of hydrogen
ions and lactate, which are extruded into the extracellular
milieu, lowering the pH of the tumor microenvironment[317].
Since both the cell membrane and BBB regulate the ionic
composition of the extracellular fluid[364, 365], we posited
+
that maintaining ΔNa+
mem and ΔNaend becomes unsustainable in the tumor neurovascular unit. Since cancer cells are
generally non-excitable, activity of voltage-gated sodium
channels on the cell membrane helps regulate proliferation,
migration, and invasion rather than excitability[156]. Similar
to pH dysregulation in cancer, electrolyte imbalance also
has a role in tumorigenesis[376, 377]. Thus, being able to
measure [Na+ ] across different compartments in vivo could
be considered as an important biomarker.
Hyperpolarized 𝑉𝑚 corresponds to quiescent cell cycle stages
(𝐺0 phase), and depolarized 𝑉𝑚 to proliferative/replicative
stages ( 𝑀 phase)[199, 378, 379]. Therefore, ΔNa+
mem is a
biomarker for tumorigenicity and tumor aggressiveness. Determining [Na+ ] in the extracellular milieu usually involves
inserting microelectrodes through the skull and reading
voltage differences across cellular compartments[380]. In
addition to issues of accurate microelectrode positioning
and tissue penetration, such invasive techniques challenge
human translation.
Angiogenesis is a crucial part of tumor growth[381]. Unlike
normal tissues, the immature tumor vasculature exhibits
saccular formations, hyperbranching, and twisted patterns
that cause the BBB to be leaky. Prior cancer research avoided
measuring [Na+ ] in blood presumably due to microhemorrhage concerns from ruptured blood vessels with microelectrodes. But given the gamut of anti-angiogenic therapies for
GBM[382], measuring ΔNa+
non-invasively is desirable.
end
Nuclear magnetic resonance (NMR) detects the isotope
sodium-23 (23 Na), a spin-3/2 quadrupolar nucleus. 23 Na
is 100% abundant and provides the second-strongest endogenous NMR signal in vivo, next to hydrogen (1 H) which
is a spin-1/2 non-quadrupolar nucleus[336]. 23 Na magnetic resonance imaging (MRI) has greatly impacted stroke
and ischemia research[233, 383], but reflects total sodium
+
23
(Na+
T )[335, 384] because Na-MRI signals from blood (Nab ),
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+
extracellular (Na+
e ), and intracellular (Nai ) compartments
are difficult to separate. 23 Na-MRI methods based on apparent diffusion coefficient (ADC), inversion recovery, and
multiple quantum filtering (MQF) attempt to separate Na+
i
and Na+
signals
and
their
volume
fractions,
but
suffer
from
e
low sensitivity. Moreover, diffusion methods necessitate large
magnetic field gradients due to low gyromagnetic ratio ( 𝛾Na )
and short longitudinal/transverse relaxation times (𝑇1 /𝑇2 )
for 23 Na. These 23 Na-MRI methods are somewhat limited for
probing the Na+
i signal because they cannot fully suppress
major contributions from Na+
and Na+
e , both of which domb
inate the Na+
signal[305,
335,
339].
Thus,
quantification of
T
+
+
+
transmembrane (ΔNamem = Nae − Nai ) and transendothelial
(ΔNa+
= Na+b − Na+e ) gradients has been challenging with
end
23
Na-MRI. While detecting Na+T is useful clinically, ΔNa+
end
and ΔNa+
may
help
reveal
relevant
information
about
BBB
mem
viability and cellular proliferative/oncogenic potential.

Another approach to separate Na+ signals in vivo involves
intravenous administration of an exogenous paramagnetic
but polyanionic contrast agent (paraCA𝑛− ). The paraCA𝑛−
consists of a lanthanide(III) cation core bound to an anionic macrocyclic chelate[329, 346]. Since the paraCA𝑛− extravasates into extracellular space of most organs but does
+
not enter cells, only Na+
e and Nab will be attracted to the
𝑛−
paraCA and experience a shift in the 23 Na resonance frequency (depending on degree of paraCA𝑛− extravasation in
each compartment) to separate the 23 Na magnetic resonance
spectroscopic imaging (MRSI) signals between Na+
, Na+
e and
b
+
Nai . While these paramagnetic effects will also shorten relaxation times slightly, the peak’s integral remains unaffected
if data are acquired under fully relaxed conditions, and the
peak’s shift can still be precise when there is marginal line
broadening although integral bands will need to be widened
so as to accurately estimate concentration. Proof-of-concept
for this has been demonstrated in situ for the heart[338] and
liver[238]. Given the compromised BBB in tumors relative
to healthy tissue, the 23 Na-MRSI technique in conjunction
with paraCA𝑛− is particularly efficacious in studying brain
tumors.
The most effective paraCA𝑛− for compartmental 23 Na separation is[330] the thulium(III) cation (Tm3+ ) complexed with
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonate)
(DOTP8− ) to form TmDOTP5− (Figure 4.1a). TmDOTP5− has
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many applications in animal models, both with 1 H-NMR[315,
316, 319, 321] and 23 Na-NMR[238, 385], demonstrating that
these Tm3+ agents are non-toxic at the doses used. Particularly, TmDOTP5− has been infused intravenously to induce
23
Na compartmental signal separation in healthy[330, 331]
and tumor-bearing rats[332]. However, these studies only
detected non-localized 23 Na signals, and thus could not
differentiate between Na+ across tissues. Our goal was to
+
investigate ΔNa+
mem and ΔNaend in brain tumors and normal
tissues in 3D using 23 Na-MRSI with TmDOTP5− at high
spatial resolution.
In vitro studies established that the 23 Na chemical shift is more
sensitive to [TmDOTP5 ] than other biological factors such as
changes in pH (i.e., 0.4 difference between tumor and healthy
tissue[319] and/or temperature variations (at most 0.5 ◦ C
difference across regions[315] (Figure 4.1b-g; Section 4.2).
Upon in vivo administration of TmDOTP5− , three peaks were
+
+
observed, corresponding to Na+
, Na+
e , and Nai . Nab was
b
shifted the most, while Na+
i remained unshifted. Our in
vivo results, consistent with prior studies of tumor cells in
vitro[199], demonstrated a significantly weakened ΔNa+
mem
and strengthened ΔNa+
within
tumor
tissue
relative
to
end
+
healthy tissue as consequences of elevated Nab and lowered
23
Na+
e , respectively. The Na vascular results showed similar
patterns to traditional vascular imaging by 1 H-based dynamic
contrast-enhanced MRI (1 H-DCE-MRI)[306]. We describe the
nuances of these novel measurements of disrupted Na+
homeostasis in cancer and their implications.
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Figure 4.1: Shifting mechanism of the 23 Na resonance in vitro. (a) Chemical structure of sodium thulium(III)
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonate) (Na5 TmDOTP). The TmDOTP5 complex
consists of the Tm3+ ion chelated with DOTP8− . Each phosphonate-containing pendant arm on TmDOTP5−
has electron-donating groups on the oxygen atoms (red) to stabilize the Tm3+ conjugation with DOTP8− .
The -5 charge simultaneously attracts five Na+ ions(purple), which experience a shift in the observed 23 Na
resonance that is dependent on [TmDOTP5 ]. (b) In vivo, prior to TmDOTP5 administration (left), the 23 Na
+
spectrum yields only a single peak representing the total sodium (Na+
T ) comprising blood (Nab ), extracellular
+
+
5
(Nae ), and intracellular (Nai ) compartments. Following TmDOTP administration (right), the peaks become
spectroscopically separable based on [TmDOTP5 ] in each compartment. Integrals of these peaks will be
representative of [Na+ ] in each compartment. (c) A two-compartment coaxial cylinder tube setup was employed
for in vitro observation of the chemical shift separation scheme (Figure 4.2). The inner tube (smaller volume)
was filled with 150 mM NaCl, while the outer tube (larger volume) was filled with the same solution in addition
to various amounts of TmDOTP5 , each subject to different pH conditions. Thus, all 23 Na spectra from this
phantom setup displayed a small unshifted peak from the inner compartment and a larger shifted peak. The
outer-to-inner volume ratio was 8.6, explaining the difference in sizes. Exemplary traces of 23 Na spectra show
that the shift is much more sensitive to [TmDOTP5 ] (2.77 ppm/mM) than to variations in pH (0.25 ppm/pH
unit) or temperature (0.03 ppm/◦ C). The downfield peaks in the red, blue, and/or black spectra are shifted
differently due to varying TmDOTP5 concentrations, and these shifts exceed those caused by pH, but all of
these shifts are detectable independent of broadening caused by TmDOTP5 (see also Figure 4.2). Plots (d) and
(e) show that temperature, pH, and [TmDOTP5 ] all contribute to variations of the 23 Na chemical shift. However,
these plots depict ranges of pH and temperature that are unlikely for in vivo settings (i.e., changes over 2 full
pH units and temperature changes over 15 ◦ C). Moreover, [Na+ ] in vivo (150 mM in blood and extracellular
space) is extremely high compared to [TmDOTP5 ]. Therefore, variations in 23 Na chemical shift are primarily
dependent on [TmDOTP5 ]/[Na+ ] thereby rendering (f) pH and (g) temperature dependencies negligible. Data
points were fit to Chebyshev rational polynomials using TableCurve 3D v4.0.05 (Systat Software, San Jose, CA,
USA; https://systatsoftware.com/products/tablecurve-3d/).
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4.2 Theory
Complexation of Tm3+ with DOTP8− stably[244] forms TmDOTP5−
(Figure 4.1a), which attracts Na+ effectively due to its high
negative charge. When intravenously injected, TmDOTP5−
resides in Na+ -rich blood and extracellular compartments
([Na+ ]b ≈ [Na+ ]e ≈ 150 mM). Without loss of generality, the
+
narrative below is with regard to Na+
e , but also applies to Nab .
5−
However, Na+
(Figure 4.1b).
i is not affected by TmDOTP
The total 23 Na chemical shift depends on cumulative effects
of diamagnetic and paramagnetic terms. The former has
intramolecular and intermolecular contributions (e.g., ring
currents, chemical exchange), but the latter is affected by
proximity of the nuclear spin to unpaired electrons[386, 387].
Electrostatic attraction forces Na+
e close to the paramagnetic
3+
Tm core, whose unpaired electrons generate an intrinsic
®int augmenting the static field 𝐵®0 . This results
magnetic field 𝐵
®0 |
in a shift of the 23 Na resonance frequency from 𝜔0 = 𝛾Na | 𝐵
+
®0 + 𝐵®int | for Nae , where 𝛾Na = 11.26 MHz/T
to 𝜔 = 𝛾Na | 𝐵
and the chemical shift 𝛿 ≡ (𝜔 − 𝜔0 )/𝜔0 is in units of parts
per million (ppm).
Introducing paraCA𝑛− creates a fast-exchange equilibrium
between bound and unbound Na+
e [388], thereby producing
a single resonance detected between the two extremes. If
the unbound and bound Na+
e pools have the chemical shifts
𝛿 𝑢 and 𝛿 𝑏 with respect to a reference frequency, then the
observed 23 Na peak has a chemical shift 𝛿 given by the
weighted average of 𝛿 𝑢 and 𝛿 𝑏 :

𝛿 = 𝑓𝑏 𝛿 𝑏 + 𝑓𝑢 𝛿 𝑢

(4.1)

where 𝑓𝑏 and 𝑓𝑢 are the respective fractions of Na+
e bound
5−
and unbound to TmDOTP ( 𝑓𝑏 + 𝑓𝑢 = 1). The reference
frequency is usually defined as that of natural (unbound)
sodium ( 𝛿 𝑢 → 0). In vivo, the chemical shift caused by
binding shows dependencies on temperature (𝑇 ), pH and
[paraCA𝑛− ][316, 345]:

𝜕𝛿
𝜕𝛿
𝛿(𝑇, pH , [paraCA ]) =
Δ𝑇 +
ΔpH
𝜕𝑇
𝜕pH
𝑛−









𝜕𝛿
Δ[paraCA𝑛− ]
+
𝜕[paraCA𝑛− ]
(4.2)
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These partial derivatives, or shiftability terms ( 𝑠 𝑓 ≡

𝜕𝛿
),
𝜕𝑓

reflect the sensitivity of 23 Na chemical shift to variations in
their respective factors:

𝛿(𝑇, pH , [paraCA𝑛− ]) = 𝑠𝑇 Δ𝑇+𝑠pH ΔpH+𝑠 [paraCA𝑛− ] Δ[paraCA𝑛− ]
(4.3)
where 𝑠𝑇 , 𝑠 pH , and 𝑠 [paraCA𝑛− ] are the respective shiftabilities
for changes in temperature, pH, and [paraCA𝑛− ] (Figure 4.1c).
Equation (4.3) is based on shift changes for small variations to
approximate linear limits of cation-anion binding models. In
vitro tests reveal that [paraCA𝑛− ] has the greatest contribution
to 𝛿 (Figure 4.1d,e) when considering realistic pH and/or
temperature ranges experienced in vivo (Figure 4.1f,g). If
we examine the 23 Na chemical shift dependence on relative
concentration [paraCA𝑛− ]/[Na+ ] as expected in vivo (i.e. 2
mM vs. 150 mM), then Equation (4.3) simplifies even further
to
𝛿([paraCA𝑛− ]) ≈ 𝑠[paraCA𝑛− ] Δ[paraCA𝑛− ]
(4.4)
Note that 23 Na-MRSI shiftability reflected in Equation (4.4) (in
units of ppm per mM) is analogous to the 1 H MRI relaxivity
𝑟 of a contrast agent (in units of rate enhanced per mM). Integrating the shifted peaks enables Na+ quantification under
fully relaxed conditions. TmDOTP5− induces a chemical shift
in the Na+
and Na+
e signals, with the former hypothesized to
b
be shifted more than the latter based on [paraCA𝑛− ] in each
compartment[315, 316]. The integral of the shifted Na+
peaks
b
+
+
reflects [Na ]b , and likewise the shifted Nae and unshifted
+
+
Na+
i peaks, respectively, reflect [Na ]e and [Na ]i .

4.3 Materials and Methods
In vitro characterization
In vitro experiments were performed using a 2-compartment
coaxial cylindrical 7-inch NMR tube setup from WilmadLabGlass (Vineland, NJ, USA). One compartment contained
150 mM NaCl and the other contained the same but with
varying amounts of TmDOTP5− (1–10 mM) and 10% v/v
2
H2 O to lock the spectrometer frequency using the 2 H2 O
signal (Figure 4.2). NaCl and 2 H2 O were purchased from
Sigma-Aldrich (St. Louis, MO, USA), and TmDOTP5− was
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purchased as the sodium salt Na5 TmDOTP from Macrocyclics (Plano, TX, USA). The 5-mm opening of the NMR
tube permitted an insert (the inner compartment) whose
50-mm-long tip had inner and outer diameters of 1.258 and
2.020 mm, respectively. The outer-to-inner volume ratio between the two compartments was 8.6. The geometry of the
setup allowed 645 𝜇L total in the outer compartment to fill
around the tip. Each solution was pH-adjusted using HCl or
NH4 OH to give 5 different pH values.

Figure 4.2: Depiction of the in vitro experimental setup. A diagram of the two-compartment coaxial tube
setup used for in vitro experiments (left). The overall tube length was 7 inches, with a 5-mm body in which the
second compartment (inner/outer diameter = 1.258/2.020 mm) was inserted. The length of the tip within the
excitable volume was 50 mm. The outer-to-inner volume ratio was 8.6. A confirmatory study was conducted in
which the inner compartment contained 150 mM NaCl and no TmDOTP5− and the outer contained 150 mM
NaCl with 5 mM Na5 TmDOTP (right, red). The pH was set to 7.4, and the temperature in the spectrometer was
300 K. The outer compartment also contained D2 O for frequency locking of the spectrometer. The resulting
unshifted peak at 0 ppm and shifted peak at 12.5 ppm were consistent with reported apparent shiftability ( 𝑠 app )
of 2.77 ppm/mM. Integration of the spectra yielded a shifted-to-unshifted integral ratio of 10, which reflects
the ratio of moles between the two compartments (not 8.6 due to the addition of extra Na+ with the agent).
The contents of the compartments were switched (right, blue) and the resulting spectrum showed the peaks
having interchanged positions and an inverted integral ratio, i.e. 0.1. Both compartments displayed broader
peaks with TmDOTP5− than without. This illustrates that TmDOTP5− caused the observed shift effects and that
only the difference in compartment volume was responsible for the size of the peak. See Figure 4.1 for more
example of representative data from this phantom setup. Comparison of the Outer red (+TmDOTP5− ) and
Outer blue (no TmDOTP5− ) peaks and/or the Inner red (+TmDOTP5− ) and Inner blue (no TmDOTP5− ) shows
that there is minor broadening due to TmDOTP5− , but these broadening effects do not confound the chemical
shifts observed.
23

Na NMR spectra were collected on a Bruker Avance III
HD 500 MHz vertical-bore spectrometer (Bruker, Billerica,
MA, USA) interfaced with Bruker TopSpin v2.1 software.
We used a Bruker 500 MHz TBO liquid broadband probe
with 𝑧 -gradient in all frequencies and an inner coil was used
to detect X-nuclei. A single 23 Na square pulse (50 𝜇s) was
used to globally excite the volume of interest (repetition
time 𝑇𝑅 = 275 ms) collecting 2048 free induction decay (FID)
points in the time domain with an acquisition time 𝑡aq = 38.9
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ms, averaged 4096 times. Each set of scans was repeated at
a series of temperatures: 27, 30, 34, 37, and 40 ◦ C. Spectra
were analyzed using 10 Hz line broadening (for improved
delineation of major peaks and reduction of baseline noise)
and manual zeroth- and first-order phasing. Data points were
fit to Chebyshev rational polynomials using TableCurve 3D
v4.0.05 (Systat Software, San Jose, CA, USA).

In vivo studies
The in vivo protocol was approved by the Institutional Animal
Care & Use Committee of Yale University, and all procedures
were performed in accordance with these enforced guidelines and regulations, and in compliance with the ARRIVE
guidelines. Rats (athymic/nude and Fischer 344) were purchased through Yale University vendors. U251, U87 and RG2
GBM cell lines were purchased from American Type Culture Collections (Manassas, VA, USA). The U251, U87, and
RG2 cells were cultured and grown in a 5% CO2 incubator
at 37 ◦ C in either low-glucose (U251 cells) or high-glucose
(U87 and RG2 cells) Dulbecco’s Modified Eagle’s Medium
(DMEM) (Thermo Fisher Scientific, Waltham, MA, USA) with
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
Cells for tumor inoculation were harvested upon reaching at least 80% confluence and were prepared in FBS-free
DMEM. Athymic/nude rats were injected intracranially with
2 − −5 × 106 tumor cells either from the U251 (𝑛 = 6) or
the U87 (𝑛 = 8) cell line (5-𝜇L aliquot) while placed in a
stereotactic holder on a heating pad. Fischer 344 rats were
injected with 1.25 × 103 RG2 cells (𝑛 = 8). During the procedure, animals were anesthetized via isoflurane (Isothesia)
inhalation (34%), purchased from Covetrus (Portland, ME,
USA). Dissection was performed to the cranium, and a hole
was drilled into the skull to allow for stereotactic needle
insertion. Injections were performed using a 10-𝜇L Hamilton
syringe with a 26G needle into the right striatum for majority
of the experiments, 3 mm to the right of the bregma and
3 mm below the dura. The cells were injected steadily at 1
𝜇L/min over 5 minutes and the needle was left in place for
an additional 5 minutes post-injection. The syringe was then
gradually removed to preclude any backflow of cells. The
hole in the skull was sealed with bone wax, and the incision
site was sutured after removal of the syringe. Animals were
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given bupivacaine (2 mg/kg at incision site) and carprofen
(5 mg/kg, subcutaneously) during the tumor inoculation to
relieve pain. Carprofen was subsequently given once per day
for two days post-inoculation.
Rats were weighed daily and kept on a standard diet of
rat chow and water. Tumor growth was monitored every
3-4 days using 1 H-MRI under isoflurane anesthesia. When
the tumor had reached a minimum mean diameter of 3
mm at 20-24 days post-injection, each animal was imaged
using 1 H-MRI and 23 Na-MRSI. An infusion line was first
established through cannulation of the tail vein as a means to
administer fluids and the paraCA𝑛− . During the cannulation
procedure, the rat was placed on a heating pad to maintain
physiological body temperature. A 30G needle, fitted onto a
PE-10 line, was inserted into the tail vein while the animal
was under anesthesia (also isoflurane 2-3%). The animal was
then given Puralube Vet Ointment (Dechra, Overland Park,
KS, USA) over the eyes and then situated in a prone position
underneath an in-house built 23 Na/1 H quad surface coil
before being placed in the magnet. The 2.5-cm 23 Na coil was
placed directly on top of the head, and the two 5-cm 1H
coils flanked the head on the left and right sides. Breathing
rate was measured by placement of a respiration pad under
the torso, and temperature was monitored through a rectal
fiber-optic probe thermometer.
Imaging was conducted on a 9.4T horizontal-bore Bruker
Avance system (Billerica, MA), interfaced with Bruker ParaVision v6.0.1 software running on CentOS. Rats weighed 200260 g at the time of imaging. Positioning and power optimizations for 1 H signals were performed using Bruker-defined
gradient-echo (GE) and fast spin-echo (FSE) sequences. Shimming was done on the 1 H coils using an ellipsoid region
(12 × 7 × 11 mm3 ) to bring the water linewidth to less than 30
Hz using 𝐵0 mapping with second-order shim corrections.
Pre-contrast 1 H anatomical MRI was first performed using a
spin-echo sequence with 9 axial slices (FOV: 25 × 9 × 25 mm3 ,
128 × 128 in-plane resolution) over 10 echo times 𝑇𝐸 (10100 ms)
with 𝑇𝑅 = 4 s). The multiple echo times enabled voxel-wise
calculations of 1 H 𝑇2 values. 23 Na power optimizations were
then performed using a 2-ms 90◦ Shinnar-Le Roux (SLR) RF
pulse over a 4096 Hz bandwidth (𝜈0Na = 105.9 MHz at 9.4 T),
where the optimal 90◦ pulse power was achieved using no
more than 8 W.
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23

Na-MRSI in 3D was performed without slice selection using
an SLR pulse, where the FOV was 25 × 19 × 25 mm3 using a
nominal voxel size of 1.0 × 1.0 × 1.0 mm3 (i.e., point-spread
function was 2.24 × 2.24 × 2.24 mm3 )[318], with 𝑇𝑅 = 300
ms, and phase encoding (gradient duration = 1 ms, sweep
width = 8 kHz, encoding steps = 1027, 𝑘 -space radius factor
= 0.55) was done in all three spatial dimensions to avoid
chemical shift artifacts caused by slice-selective RF pulses. A
preliminary 23 Na-MRSI scan (same parameters/conditions)
was run before administering paraCA𝑛− . The in vivo 1 H-MRI
delineated the tumor and brain boundary and permitted
co-registration with 23 Na-MRSI data, both before and after
infusion of paraCA𝑛− , enabling anatomical localization of
23
Na-MRSI spectra at the voxel level. All spectra were linebroadened by 10 Hz and magnitude-corrected.
The animals were then given 1 𝜇L/g BW probenecid using
a syringe pump (Harvard Apparatus, Holliston, MA, USA)
for 10 minutes followed by a 20-minute waiting period. Then
Na5 TmDOTP (1 𝜇mol/g BW) was co-infused with probenecid
(same dose) at a rate of 15 𝜇L/min. This infusion protocol
with probenecid has been shown to increase TmDOTP5−
retention in vivo without the need for renal ligation, and
yielded 0.1 𝜇mol TmDOTP5− /g BW in the cortex and subcortex[321]. Moreover, the slow infusion rate allows TmDOTP5−
diffusion/clearance into other tissue during the infusion,
and therefore TmDOTP5− does not accumulate and remain
exclusively in the vasculature. Post-contrast 23 Na-MRSI was
performed 30 minutes after the start of infusion and repeated
subsequently thereafter during the infusion. The imaging
session was concluded with post-contrast 1 H-MRI under
identical conditions. Rats were sacrificed following imaging
by isoflurane inhalation overdose (5%) while the animal was
already unconscious during imaging. Death was ensured by
inducing bilateral pneumothorax.
1

H-MRI and 23 Na-MRSI results were processed and analyzed
using home-written code in MATLAB (MathWorks, Natick,
MA, USA). Voxel-wise 𝑇2 values for 1 H were calculated by
fitting MRI voxel intensities versus the series of 𝑇𝐸 values to a
monoexponential curve 𝑒 𝑇𝐸 /𝑇2 . Pre-contrast and post-contrast
1
H 𝑇2 values were used to qualitatively ascertain the success of
paraCA𝑛− infusion. 3D 23 Na-MRSI data were reconstructed
using Fourier transformation in all spatial and temporal
dimensions after 10-Hz line-broadening. Individual 23 Na
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peaks were identified and integrated in MATLAB, guided
by the changes observed in 𝑅 2 maps from the 1 H-MRI data
which is roughly proportional to [TmDOTP5− ]. Due to line
broadening induced by TmDOTP5− , the integration range
was different for each compartment to capture majority of
the integral. Integration bandwidths were chosen based on in
vitro results and amount of peak separation. The shift for each
23
Na peak was based on the amount of TmDOTP5− present in
each compartment, i.e., most shifted and broadest for blood
compartment compared to the extracellular compartment,
whereas the intracellular compartment was unshifted and
narrowest. For significant overlap between adjacent peaks,
we used peak amplitudes∫instead. The∫ ΔNa+
mem values were
+
+
calculated by∫ subtracting∫ Nai from Nae , and ΔNa+
by
end
+
+
subtracting Nae from Nab .

1

H-DCE-MRI Studies

To measure vascular parameters [𝐾 trans (volume transfer
coefficient, min−1 ), 𝐹𝑝 (plasma flow rate, min−1 ), 𝑣 𝑒 (extracellular volume fraction, unitless), 𝑣 𝑝 (plasma volume fraction,
unitless)] from a two-compartment exchange model (2XCM),
1
H-DCE-MRI was performed on a subset of RG2 (9.4T), U87
(11.7T) and U251 (11.7T) tumors. 1 H-DCE-MRI data used a
1
H volume-transmit (8-cm)/surface-receive (3.5-cm) coil.
Baseline images for 𝑇1 mapping were acquired using a rapid
acquisition with relaxation enhancement (RARE) sequence
with six 𝑇𝑅 values (0.4, 0.7, 1, 2, 4, 8 s). Seven 1-mm slices
covering the extent of the tumor were chosen and images
were acquired with a 25 × 25 mm FOV, 128 × 128 matrix
and 𝑇𝐸 of 10 ms. 1 H-DCE-MRI acquisition consisted of a
dynamic dual-echo spoiled GE sequence with a temporal
resolution of 5 s. Images were acquired with 𝑇𝑅 = 39.1 ms,
𝑇𝐸 = 2.5/5 ms, flip angle=15◦ , and one average. Three central
slices of the tumor were chosen with identical positioning,
FOV (25 × 25 mm), and matrix (128 × 128) to be co-registered
to the 𝑇1 data. The sequence was repeated every 5 s over a
22 min period with 0.25 𝜇mol/g gadobutrol (Bayer, AG),
a gadolinium (Gd3+ )-containing contrast agent, injected 2
min after the start of the sequence and then flushed with
100 𝜇L heparinized saline. The multi-𝑇𝑅 𝑇1 sequence was
then repeated at the end of the 1 H-DCE-MRI acquisition to
serve as a post-Gd3+ 𝑇1 mapping which was used to delineate
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tumor boundaries. Quantitative 𝑇1 maps were generated by
fitting voxel-level data to a monoexponential function in
MATLAB.
Measurements from 𝑇1 -weighted images before Gd3+ injection were used to transform time-intensity curves into timeconcentration curves after the bolus injection. The region of
interest (ROI) was placed inside the tumor area, including
the rim, as determined by the region of contrast enhancement/uptake. All analysis, including masking the ROI, was
performed in MATLAB using the same home-written code.
The arterial input function (AIF) was measured by collecting
arterial blood samples at discrete time points post-injection.
The raw AIF was fit to a bi-exponential curve with a linear
upslope during injection of Gd3+ . Plasma [Gd3+ ] was derived
from the blood [Gd3+ ] using a hematocrit of 0.45. The time
resolution and duration interval used downstream in the
analysis pipeline were adjusted manually.
The exchange-model parameters were estimated by fitting
each voxel using Levenberg-Marquardt regression. Because
𝐾 trans fitting often converged on local minima instead of the
desired global minimum, multiple starting values were used,
ultimately choosing the one with the smallest residual. Other
variables were less sensitive to the initial condition so a single
starting value sufficed.

Statistics
All statistical comparisons were performed in MATLAB using a 2-sample Student’s 𝑡 -test (i.e., data passed normality
tests with Prism in GraphPad, San Diego, CA) whose null hypothesis claimed there was no difference between the means
of the two populations being tested. The populations in our
analysis were compartmental and gradient 23 Na signal values
(i.e., means and standard deviations of voxel-wise integrals)
between tumor and normal tissue and between cohorts of
different tumors. For 1 H-DCE-MRI studies, the populations
were different parameter values between different tumors.
In all cases, a significance level of 0.05 was used.
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4.4 Results
In Vitro Studies for Mechanistic Separation of
23
Na Peaks
The goal of these studies was to separate the total Na+
+
signal (Na+
T ) into distinct signals for blood (Nab ), extracel+
lular (Na+
e ), and intracellular (Nai ) pools (Figure 4.1b). The
shifting mechanism induced by exogenous TmDOTP5− and
endogenous biological factors on the 23 Na chemical shift in
vitro is shown in Figure 4.1c-g. A two-compartment coaxial
cylinder NMR tube setup in vitro was used to mimic Na+ in
extracellular/intracellular pools in vivo Figure 4.2. The inner
(smaller) and outer (larger) compartments both contained
150 mM NaCl while the latter also contained TmDOTP5− at
various concentrations. The whole setup was subjected to
several different pH and temperature conditions. The inner
compartment, which lacked TmDOTP5− to represent the intracellular space in vivo, produced a small, unshifted peak at
0 ppm. The larger peak was shifted downfield by TmDOTP5− ,
with the difference in peak integrals stemming from different compartment volumes Figure 4.2. To demonstrate the
feasibility of this approach to quantify Na+ signals from
different compartments, the contents of the compartments
were switched and the above measurements were repeated
(Figure 4.2).
In vitro 23 Na spectra revealed that the chemical shift is most
sensitive to [TmDOTP5− ], compared to pH and temperature (Figure 4.1c). The 23 Na shiftability for TmDOTP5−
( 𝑠 [paraCA𝑛− ] = 2.77 ppm/mM; Equation (4.3)) was 11.1×
larger than the shiftability for pH ( 𝑠 pH = 0.25 ppm/pH
unit) and 92.3× larger than the shiftability for temperature
( 𝑠𝑇 = 0.03 ppm/◦ C). This means that addition of 1.1 mM
TmDOTP5− would induce a 3 ppm shift in the 23 Na peak.
Conversely, a maximal change of 0.4 in pH units, which is
seen between normal and tumor tissues[319], would induce
only a 0.1 ppm shift. A similar shift by temperature would
require a 3.3 ◦ C change, which is unlikely in vivo. Based on
the pH and temperature ranges observed in vivo (including
tumors), the effect from TmDOTP5− dominates the chemical shift (Equation (4.2)) by 95%. Therefore, [TmDOTP5− ]
is several orders of magnitude more sensitive in shifting
the 23 Na resonance than typical in vivo factors. The 23 Na
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shiftability arising from [TmDOTP5− ] and pH/temperature
effects is much larger than 𝑇2 broadening from TmDOTP5−
(Figure 4.1c and Figure 4.2). Consequently, 23 Na spectra displayed dependence mostly on [TmDOTP5− ] (Figure 4.1d-e).
However for in vivo scenarios the ranges shown for pH (2 full
pH units) and temperature (15 ◦ C interval) are overestimated,
and where [Na+ ] far exceeds [TmDOTP5− ] based on prior
experiments[316]. In blood and extracellular spaces, [Na+ ]
is 30 − 100× greater than [TmDOTP5− ][315]. This suggests
that the relative amount of TmDOTP5− is the primary factor
affecting 23 Na chemical shift (Equation (4.4)).

In Vivo Separation of 23 Na Peaks Indicates
Compartmentalized Na+ Pools
Interrogating individual voxels in the brain before and after
TmDOTP5− administration ( 1 𝜇mol/g body weight (BW))
revealed clear 23 Na signal separation, although to varying
extents depending on the degree of TmDOTP5− extravasation
from blood to the extracellular space. 23 Na-MRSI data overlaid on 1 H-MRI anatomy (Figure 4.3a) of rat brains bearing
U251 tumors showed spectra in tumor and healthy tissue
voxels (Figure 4.3b-c), with candidate voxels inside/outside
the tumor before and after TmDOTP5− . Before TmDOTP5−
delivery, there was a single 23 Na peak at 0 ppm corresponding to Na+
T , observed ubiquitously both inside and outside
the tumor. Upon TmDOTP5− delivery, compartmental 23 Na
peak separation was achieved. Within the tumor, the compromised BBB permitted greater TmDOTP5− extravasation
and accumulation in the extracellular space, explicitly yielding three separate peaks emerging from the original single
23
Na resonance. Each peak was associated with a compartment, with Na+
i being the unshifted peak (0 ppm) because
5−
TmDOTP could not enter the intracellular compartment,
and other peaks exhibiting [TmDOTP5− ]-dependent shifts.
In the tumor, the most-shifted peak was Na+
because the
b
5−
blood compartment had the largest [TmDOTP ], which was
corroborated by blood samples removed from the animal
and observing the same chemical shift in vitro (Figure 4.3d).
In the tumor, the intermediate peak in the middle corresponded to the extracellular Na+
e resonance. The splitting
was also evident outside of the tumor (i.e., in healthy tissue) where TmDOTP5− extravasated to a much lesser extent
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compared to tumor tissue (Figure 4.3b-c). The Na+
peak
b
+
+
was still most-shifted, whereas the Nai and Nae peaks were
less discernible. When there was significant overlap between
adjacent peaks, instead of peak integrals we used the peak
amplitudes to discriminate signals. The shifted bulk Na+
e
peak in healthy tissue confirmed that whatever degree of
TmDOTP5− extravasation occurred was sufficient to affect
the extracellular 23 Na signals, albeit less pronounced than
+
tumoral Na+
e . The unshifted Nai resonance was still at 0 ppm,
but partially eclipsed by the bulk Na+
e peak. These same patterns inside/outside the tumor were observed throughout
the brain (see Figure 4.4 for voxels in the same rat).
Figure 4.5 displays data from representative rats bearing (a)
RG2 and (b) U87 tumors, with the array of 23 Na-MRSI data
overlaid on top of the 1 H-MRI anatomy. The spectra from
individual voxels placed throughout the brain confirmed
only one 23 Na peak prior to infusion (Figure 4.5, black spectra), corresponding to Na+
T , but upon infusion the single
peak separated into two additional peaks (Figure 4.5, green
spectra).
Prior to TmDOTP5− infusion (Figure 4.5, black spectra) ventricular voxels [1 and 2 in Figure 4.5(a,b)] exhibited purely
Lorentzian lineshapes characterized by a single 𝑇2 , while
those in the normal brain [5 and 6 in Figure 4.5(a,b)] and
tumor [3 and 4 in Figure 4.5(a,b)] displayed super-Lorentzian
lineshapes indicative of multiple 𝑇2 values. This is because
the ventricles are comprised almost entirely of cerebrospinal
fluid (CSF), in which all Na+ is aqueous, whereas some
Na+ ions in tissue can be bound. These observations are in
agreement with prior 23 Na-MRI results[235, 334, 389–391].
Administration of TmDOTP5− resulted in the emergence of
multiple 23 Na peaks (Figure 4.5, green spectra), particularly
within the tumor. However, the positive downfield shifts
seen in healthy tissue suggest the paramagnetic effects of
TmDOTP5− reached the extracellular space even with limited
extravasation. We found the most shifted peak sufficiently
far from the other two peaks present and attributed it to

∫ +0.25 ppm

only Na+
, with an integral (
b

Na+
) reflecting the
b
−0.25 ppm
∫ +0.25 ppm
blood sodium concentration [Na+ ]b . Likewise −0.25 ppm Na+
e
∫ +0.25 ppm
+
+
+
and −0.25 ppm Nai measured [Na ]e and [Na ]i , respectively.
Tumor voxels [3 and 4 in Figure 4.5(a,b)] exhibited spectra
where the three peaks were most notably present. Thus,
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+
the chemical shifts of the Na+
, Na+
e , and Nai peaks can
b
be respectively placed at the same peak positions. Shifts of
this nature were evident throughout the entire depth of the
brain for both animals ( Figure 4.6). Ventricular voxels [1
and 2 in Figure 4.5(a,b)] displayed only one Lorentzian peak
shifted to the same extent as Na+
e in healthy tissue voxels
[5 and 6 in Figure 4.5(a,b)], albeit in the latter with superLorentzian lineshape. shifts coincide because CSF and the
extracellular space are physically in contact with unrestricted
exchange of aqueous Na+ . Given the shiftability 𝑠 [paraCA𝑛− ]
is 2.77 ppm/mM measured in vitro (Figure 4.1), the tumor
vasculature contained no more than 0.7 mM TmDOTP5−
based on the range of shifts observed. Since the blood 23 Na
signal experiences the greatest shift, the (extracellular) tissue
therefore encountered even less TmDOTP5− , in agreement
with prior observations[316].

In Vivo Depiction of Transmembrane and
Transendothelial Na+ Gradients
Integration of compartmentalized 23 Na spectra (Figure 4.3Figure 4.6) generated spatial maps which depicted relative [Na+ ] in each compartment
∫
∫ from which the transmem+
+
brane (ΔNa∫mem = ∫Nae − Na+
i ) and transendothelial
+
+
+
(ΔNaend = Nab − Nae ) gradient maps could also be
calculated, as shown in Figure 4.7 for multiple axial slices
bearing an RG2 tumor. This 3D high-resolution demonstration of the in vivo Na+ biodistribution divulges spatial
heterogeneity, where the relative [Na+ ] of each compartment
is a function of the compartment volume and the amount of
Na+ in that compartment. It should be noted that TmDOTP5−
extravasation under current conditions is sufficient to observe paramagnetic effects even in healthy brain tissue[321],
and as shown in the 𝑇2 maps and concomitant Δ𝑅 2 map
(given by inverse of difference between 𝑇2 maps obtained after and before TmDOTP5− infusion) for RG2 (Figure 4.7) and
U87 (Figure 4.8) tumor rats. While Δ𝑅 2 can generally depict
the difference between [TmDOTP5− ] in healthy and tumor
tissues[324], it cannot separate [TmDOTP5− ] in blood and
extracellular compartments within the tumor. Therefore Δ𝑅 2
map cannot fully quantify these separately, while 23 Na-MRSI
spectra can separate these two signals.
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∫

There was markedly increased Na+
in the tumor, which
b
was not observed elsewhere in normal brain. There was
∫ also
high degree of heterogeneity within the tumor. The Na+
e
map revealed the largest values in the ventricles (CSF) and
smaller values in the tumor with a slight extent of heterogeneity. Outside the tumor, the bulk∫ peak occurred in the
Na+
region of integration for Na+
e . The
i map unsurprisingly showed values that were about one order of ∫magnitude
lower
throughout the brain compared to the Na+
and
b
∫
+
+
Nae maps, since [Na ]i (10 mM) is an order of magnitude
smaller
than [Na+ ]b and [Na+ ]e (150 mM). Furthermore, the
∫
Na+
i values were not significantly different between the
tumor and healthy tissue.
The ΔNa+
mem values in the tumor were significantly lower
compared to the healthy tissue ( 𝑝 < 0.05) and the
∫ map displayed a similar level of heterogeneity as the Na+
e map,
+
suggesting that ΔNamem is driven primarily by the decrease in
+
Na+
e . Ventricular voxels still showed high values in ΔNamem ,
indicating the large magnitude of Na+
e in CSF. Likewise,
+
the significant elevation of ΔNaend in the tumor was driven
primarily by the Na+
increase, and ΔNa+
values were sigb
end
nificantly larger in the tumor compared to healthy tissue
( 𝑝 < 0.05). This feature was more pronounced in superficial
regions of the brain because draining veins run vertically
down from cortical surface to white matter and these blood
vessels are perpendicular to the main field, thereby enhancing bulk magnetic susceptibility effect on surrounding tissue,
which has been reported in vitro[346]. This phenomenon
is similar to blood oxygenation level-dependent functional
MRI contrast mechanisms[392–394]. For both ΔNa+
mem and
+
ΔNaend gradients, statistical significance was achieved even
after excluding ventricle values. These patterns could also
be visualized by looking at slice projections of the compartmental and gradient values for the same RG2-bearing animal
along a constant coronal position (Figure 4.7). For the RG2
tumor, the tumoral increases in Na+
and ΔNa+
were highest
b
end
superficially (slices 1-4). Conversely, peritumoral values of
+
Na+
e and ΔNamem increased with depth up to a point in the
middle of the brain (slices 3-4) before diminishing. Intratumoral Na+
e , however, did not vary significantly with depth.
+
Nai also decreased inside the tumor but not significantly.
+
The ΔNa+
mem and ΔNaend respectively behaved similarly to
Na+
and Na+
e since they were the primary drivers of those
b
gradients. Similar observations were made for U87 tumors
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(Figure 4.8) regarding Na+ in each compartment and the
corresponding gradients.
Throughout
the entire cohort of animals
(Figure 4.11a,b), the
∫
∫
+
mean Na+
values
were
larger
and
Na
e values were lower
b
in the tumor compared to normal tissue. These trends were
significant in RG2 ( 𝑝 < 0.005) and U87 (∫𝑝 < 0.05) tumors
while there was no significant difference in Na+
i for all three
tumors (Figure 4.11a). Identical trends were also observed
in ΔNa+
and ΔNa+
mem values, and significantly so in RG2
end
( 𝑝 < 0.005) and U87 ( 𝑝 < 0.05) tumors. Moreover, ΔNa+
end
was significantly stronger in RG2 and U87 tumors compared
to U251 ( 𝑝 < 0.05) (Figure 4.11b).
Since a strengthened ΔNa+
is indicative of impaired vasend
1
cular integrity, we employed H-DCE-MRI to reliably image
vascular dynamics and function[306]. Of the four parameters
which can be obtained by fitting 1 H-DCE-MRI data from
a two-compartment exchange model, the volume transfer
constant (𝐾 trans ) and plasma volume fraction (𝑣 𝑝 ), as shown
in Figure 4.11c, both followed the trends of ΔNa+
across
end
tumor types: in RG2 and U87 tumors compared to U251,
there was a significant difference (𝐾 trans : 𝑝 < 0.005 and 𝑣 𝑝 :
𝑝 < 0.05; for plasma flow rate (𝐹𝑝 ) and extracellular volume fraction (𝑣 𝑒 ) see Figure 4.12). Although significance was
marginal for 𝐹𝑝 , the mean values followed suit (Figure 4.12).
The 1 H-DCE-MRI data displayed regions of low 𝐹𝑝 and larger
𝑣 𝑒 within an exemplary slice of a U251 tumor, indicative of
a necrotic core, which RG2 and U87 animals lacked (Figure 4.13). Reduced ΔNa+
in U251 tumor could be a marker
end
of necrosis presence as evidenced by lower 𝐾 trans and 𝑣 𝑝 in
U251 tumors. These results suggest that U251 tumors would
have lower tissue and blood oxygenation. Additionally, 𝑣 𝑒
on average was smaller than 𝑣 𝑝 , indicating a high degree
of tumor
angiogenesis. These findings further substantiate
∫
+
the Nab and ΔNa+
results derived from the 23 Na-MRSI
end
studies. Given 𝑣 𝑒 and 𝑣 𝑝 heterogeneity, we attribute 23 Na
peaks downfield of 2 ppm to agent pooling from ineffective
agent clearance.

∫

∫

∫

+
+
+
Figure 4.14 shows Na+
, Na+
e , Nai , ΔNaend , and ΔNamem
b
maps across all tumor cell lines (RG2, U87, U251). The trends
seen previously pervaded all animals, but to varying degrees
based on the tumor type. The Na+
elevation, and concomitant
b
+
ΔNaend strengthening, were most pronounced for the RG2
tumor, followed by U87 and then U251. The heterogeneity of
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∫

+
Na+
and Δ
b
∫ Naend also followed the same order, as did the
+
decrease in Na+
e and weakening of ΔNamem . In all tumors,
Na+
and Na+
e patterns respectively drove the behaviors of
b
+
ΔNaend and ΔNa+mem .
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Figure 4.3: Demonstration of 23 Na peak separation in vivo following TmDOTP5− administration into a rat
brain bearing a U251 tumor. (a) 1 H-MRI of an axial slice displaying the anatomical tumor boundary (white
outline). The 23 Na-MRSI is overlaid on top of the 1 H-MRI. Candidate voxels (b) inside and (c) outside the
tumor are indicated (yellow boxes). Before TmDOTP5− delivery, a single 23 Na peak was observed at 0 ppm,
5−
corresponding to total sodium (Na+
T ), both inside and outside the tumor (black spectra). Following TmDOTP
delivery, compartmental peak separation was achieved to varying extents throughout the brain (blue spectra).
Within the tumor (top spectra), this separation was most pronounced due to a compromised blood-brain barrier
(BBB), which permits substantial accumulation of TmDOTP5− in the extracellular space. Outside of the tumor
(bottom spectra), such a high degree of extravasation would not be possible, but some shifting is still observed.
The TmDOTP5− distribution in the brain warrants labeling the most shifted peak as blood sodium (Na+
), which
b
occurred consistently around 2 ppm. The unshifted peak, which has no access to TmDOTP5− , is intracellular
+
sodium (Na+
i ). The intermediate peak, therefore, is extracellular sodium (Nae ), which is shifted more inside the
tumor than outside in healthy tissue. Similar spectroscopic patterns are observed throughout all voxels in vivo.
See Figure 4.4 for a slice below the present. (d) in vitro analysis of blood samples from the tumor-bearing rat show
that the 23 Na blood peak occurred around 2 ppm, which coincided with the most-shifted peak we observed in
tumor voxels. This confirmed that the most-shifted peak in the observed 23 Na spectra after TmDOTP5− infusion
comes from blood. All spectra were magnitude-corrected and line-broadened by 10 Hz.
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Figure 4.4: Multi-voxel demonstration of 23 Na peak separation in vivo following TmDOTP5− administration
into a rat brain bearing a U251 tumor. 1 H MRI of an axial slice displaying the anatomical tumor boundary
(white outline). The 23 Na-MRSI is overlaid on top of the MRI. Candidate voxels inside and outside the tumor are
indicated (yellow boxes with numbers). Before delivery of the agent, a single 23 Na peak was observed at 0 ppm in
5−
all voxels (black spectra), corresponding to total sodium (Na+
delivery, compartmental
T ). Following TmDOTP
peak separation was achieved to varying extents throughout the brain (green spectra). Tumor voxels (1-3)
exhibited a fair amount of peak separation due to the leaky blood-brain barrier (BBB), with blood sodium (Na+
)
b
consistently around 2 ppm, extracellular sodium (Na+
e ) in the range 0.5-1 ppm, and the unshifted intracellular
sodium (Na+
i ) at 0 ppm. Voxels outside the tumor (4-6) were slightly shifted in the positive direction, suggesting
the paramagnetic effects of TmDOTP5− reach the extracellular space even with limited extravasation. Similar
spectroscopic patterns are observed throughout all voxels in vivo. See Figure 4.3 for a slice above the present. All
spectra were magnitude-corrected and line-broadened by 10 Hz.
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Figure 4.5: Comparison of 23 Na peak separation in rats bearing RG2 and U87 tumors. For rats bearing an (a)
RG2 and (b) U87 tumor, the tumor boundary is outlined in white, with voxels of interest indicated in yellow
squares (with numbers), and spectra acquired before and after TmDOTP5− delivery shown in black and green,
respectively. Tumor voxels 3 and 4 in (a) RG2 and (b) U87 tumor rats exhibited a fair amount of peak separation
+
due to the leaky BBB. Na+
shift was consistently around 2 ppm, and Na+
i shift was at 0 ppm, whereas Nae
b
shift in the tumor was in the range 0.5-1 ppm. Healthy tissue voxels 5 and 6 in (a) RG2 and (b) U87 tumor rats
were slightly shifted in the positive direction, suggesting the paramagnetic effects of TmDOTP5− reach the
extracellular space even with limited extravasation. Ventricular voxels 1 and 2 in (a) RG2 and (b) U87 tumor rats
displayed a single unshifted Lorentzian peak before and a shifted Lorentzian peak after TmDOTP5− injection.
This is attributed to the dominant 23 Na signal contribution in the ventricles coming from cerebrospinal fluid
(CSF), which contains free (i.e., unbound) aqueous Na+ . The position of the shifted ventricle peak coincided
with the Na+
e peak position in other regions of the brain. This agrees with expectation because CSF is in physical
contact with the extracellular space with free exchange of aqueous Na+ between the two compartments. Similar
spectroscopic patterns are observed throughout all voxels in vivo. See Figure 4.6 for several slices for each rat
shown here. All spectra were magnitude-corrected and line-broadened by 10 Hz.
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Figure 4.6: Multi-slice comparison of RG2 and U87 tumors. Comparison of 23 Na peak separation in rats
bearing an (a) RG2 and (b) U87 tumor. The tumor boundary is outlined in white, spectra acquired before and
after TmDOTP5− delivery are shown in black and green, respectively, and the yellow dots represent the same
transverse coordinates across multiple slices. In both cases, “slice 1” is the most superficial axial slice with a
visible tumor and slice thickness is 1 mm with no gap. The Na+
peak was present at 2 ppm throughout the
b
entire depth of the brain in both tumors, and was more shifted than Na+
e , which was encountered around 0.5-1
ppm. The Na+
peak
was
observable
at
0
ppm.
Similar
spectroscopic
patterns
are observed throughout all voxels
i
in vivo. See Figure 4.5 for detailed comparison of voxels inside and outside these tumors. All spectra were
magnitude-corrected and line-broadened by 10 Hz.
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+
Figure 4.7: Spatial distributions of compartmentalized 23 Na signals (Na+
, Na+
e , Nai ) as well as transendotheb
+
+
lial (ΔNaend ) and transmembrane (ΔNamem ) gradients in an RG2 tumor. The high-resolution 1 H-MRI data
are shown in the left four columns, whereas the lower resolution 23 Na-MRSI data are shown in the next five
columns on the right. The left column shows the tumor location (white outline) on the anatomical 1 H-MRI
(left), whereas the next two columns show the 𝑇2 maps (range shown: 0-100 ms) before and after TmDOTP5−
injection, and the subsequent column depicts the Δ𝑅 2 map (i.e., difference between 1/𝑇2 maps before and
after, range shown: 0 – 30 s−1 ), which is proportional to [TmDOTP5− ] in healthy and tumor tissues. Since Δ𝑅 2
values are more heterogeneous within the tumor, the 23 Na-MRSI data are needed to separate the blood and
extracellular compartment signals for the tumor. Since the integral of each 23 Na peak represents ∫the [Na∫+ ], the
+
+
respective three columns show the integral maps of Na+
Na+
, Na+
e,
b ∫
∫
∫ b , Na∫e , and Nai from left to
∫ right (i.e.,
∫
+
+
+
+
+
+
Nai ). The last two columns on the right show 𝑑 = Nab − Nae and ΔNamem = Nae − Nai . The Na+
b
map reveals low values in healthy
tissue compared to tumor tissue, and within the tumor boundary a high
∫
degree of heterogeneity. The Na+
tumor
e map reveals low values in tumor and normal tissues, but within the ∫
boundary a small degree of heterogeneity is visible while ventricular voxels show very high values. The Na+
i
map reveals low values ubiquitously except some ventricular voxels. The ΔNa+
map reveals dramatically high
end ∫
values within the tumor only. The ΔNa+
was driven primarily by an increase of Na+
inside the tumor and
end
b
which was more pronounced in superficial regions of the brain compared to deeper slices. The ΔNa+
mem map
shows low values in tumor tissue compared to∫normal tissue, although ventricular voxels show very high values.
∫
The ΔNa+
Na+
Na+
mem is driven primarily by decreased
e and thus shows similar level of heterogeneity as the
e
map. All maps use the same color scale and are relative. See Figure 4.8 for an example for a U87 tumor.
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+
Figure 4.8: Spatial distributions of compartmentalized 23 Na signals (Na+
, Na+
e , Nai ) as well as transendothelial
b
+
+
(ΔNaend ) and transmembrane (ΔNamem ) gradients in a U87 tumor. The high-resolution 1 H-MRI data are shown
in the left four columns, whereas the lower resolution 23 Na-MRSI data are shown in the next five columns on
the right. The left column shows the tumor location (white outline) on the anatomical MRI (left), whereas the
next two columns show the 𝑇2 maps (range shown: 0-100 ms) before and after TmDOTP5− injection, and the
subsequent column depicts the Δ𝑅 2 map (i.e., difference between 1/𝑇2 maps before and after, range shown:
0-30 s−1 ), which is proportional to [TmDOTP5− ] in healthy and tumor tissues. Since Δ𝑅 2 values are more
heterogeneous within the tumor, the 23 Na-MRSI data are needed to separate the blood and extracellular
compartment signals for the tumor. Since integral of 23 Na peak in each compartment represents ∫the [Na∫+ ], the
+
+
respective three columns show the integral maps of Na+
, Na+
and Na+
e,∫
i ∫from left to right (i.e.,∫ Nab , ∫ Nae ,
b
∫
+
+
+
+
+
+
Nai ). The last two columns on the right show the ΔNaend = Nab - Nae and ΔNamem = Nae - Na+
i .
∫
+
The Nab map reveals low values in healthy tissue compared to tumor tissue, and within the tumor boundary
∫
high degree of heterogeneity is visible. The Na+
e map reveals low values in tumor and normal tissues, but
within the tumor
boundary
small
degree
of
heterogeneity
is visible while ventricular voxels show very high
∫
values. The Na+
map
reveals
low
values
ubiquitously
except
some ventricular voxels. The ΔNa+
map reveals
i
end
∫
+
dramatically high values within the tumor only. The ΔNaend was driven primarily by an increase of Na+
b
inside the tumor and which was more pronounced in superficial regions of the brain compared to deeper
slices. The ΔNa+
tissue, although ventricular
mem map shows low values in tumor tissue compared to normal
∫
+
voxels show very high values. The ΔNa+
is
driven
primarily
by
decreased
Na
mem
e and thus shows similar level
∫
+
of heterogeneity as the Nae map. All maps use the same color scale and are relative. See Figure 4.7 for an
example for a RG2 tumor.
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Figure 4.9: Coronal projections of compartmentalized 23 Na signals (Na+
, Na+
e , Nai ) as well as transendotheb
+
+
lial (ΔNaend ) and transmembrane (ΔNamem ) gradients in an RG2 tumor. (a) Axial 1 H-MRI indicating the
tumor (white outline) across slices (same as Figure 4.7), where the yellow line indicates the position for a coronal
+
projection. (b) Spatially varying 23 Na signals for Na+
, Na+
e , and Nai are shown with blue, orange, and yellow
b
lines, respectively, where the vertical black lines indicate the tumor boundary. The Na+
signal (blue) is clearly
b
elevated in the tumor, and most elevated in slices 1-4 (or superficially). Behavior of Na+
signal
(blue) is inversely
b
related to Na+
signal
(orange),
which
is
high
outside
the
tumor
and
weaker
inside
the
tumor.
While
intratumoral
e
+
Na+
signal
(blue)
is
high
in
slices
1-4,
the
peritumoral
Na
signal
(orange)
is
highest
in
slices
3-4.
Comparatively,
e
b
the Na+
i signal (yellow) does not vary significantly across slices, but slightly lower inside the tumor than outside
+
+
the tumor. (c) Behaviors of ΔNa+
mem (green) and ΔNaend (magenta) signals closely mimic patterns of Nae and
+
+
Nab signals, respectively, indicating that each of those Na compartments is the primary driver of the respective
Na+ gradient. See Figure 4.10 for a similar example for a U87 tumor.
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Figure 4.10: Coronal projections of compartmentalized 23 Na signals (Na+
, Na+
e , Nai ) as well as transendothelial
b
+
+
(ΔNaend ) and transmembrane (ΔNamem ) gradients in an U87 tumor. (a) Axial MRI indicating the tumor (white
outline) across slices (same as Figure 4.8), where the yellow line indicates the position for a coronal projection.
+
(b) Spatially varying 23 Na signals for Na+
, Na+
e , and Nai are shown with blue, orange, and yellow lines,
b
respectively, where the vertical black lines indicate the tumor boundary. The Na+
signal (blue) is clearly elevated
b
in the tumor, and most elevated in slice 3 (or medially). This pattern is similar for Na+
e signal (orange) but the
elevation is outside the tumor. Thus behavior of Na+
signal
(blue)
is
inversely
related
to Na+
e signal (orange).
b
+
+
Both intratumoral Nab signal (blue) and peritumoral Nae signal (orange) are highest in slices 3. The Na+
i
signal (yellow) varies slightly across slices. It is highest in slices 1-2, and negligible in slice 3-5. (c) Behaviors of
ΔNa+mem signal (green) and ΔNa+end signal (magenta) closely mimic patterns of Na+e and Na+b signals, respectively,
indicating that each of those Na+ compartments is the primary driver of the respective Na+ gradient. See
Figure 4.9 for a similar example for a RG2 tumor.
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Figure 4.11: Statistical comparisons between intracellular, extracellular, and vascular compartments
∫
∫ across
RG2, U87, and U251 tumors with 23 Na-MRSI and 1 H-DCE-MRI. (a) Relation between Na+
,
Na+
e and
b
∫
∫
+
+
Nai across tumor and healthy tissues. For the RG2 and U87 tumors, the Nab values were significantly
∫
higher than normal tissue ( 𝑝 < 0.005, #). Also for these tumors, the Na+
e values were significantly lower than
normal tissue ( 𝑝 < 0.05, *). The mean values for the U251 tumor roughly
∫ followed the same trend but were not
significant. Furthermore, there was no significant difference between Na+
i values in tumor and normal tissues
for any of the three tumor types. (b) Relations between tumor and normal tissues for ΔNa+
and ΔNa+
mem for
end
+
the three tumor types. Tumor ΔNaend values were significantly larger than normal values ( 𝑝 < 0.005, #), which
were non-positive (data not shown). Moreover, ΔNa+
in RG2 and U87 tumors was significantly greater than in
end
the U251 tumor ( 𝑝 < 0.05, *), indicative of vascular differences between the tumor types. ΔNa+
mem values were,
on average, weaker in tumor compared to normal tissue, but significant only in RG2 and U87 tumors ( 𝑝 < 0.05,
*). Based on Figure 4.9 and Figure 4.10, it is clear that the relation between ΔNa+
and ΔNa+
mem is negative. (c)
end
1
trans
H-DCE-MRI data for 𝐾
and 𝑣 𝑝 values, which
are
known
to
reveal
information
regarding
vascular structure
∫
+
+
trans
trans
and function. 𝐾
follows the same patterns as Nab and ΔNaend across tumor types. 𝐾
( 𝑝 < 0.005, #) and
𝑣 𝑝 ( 𝑝 < 0.05, *) were both significantly larger in RG2 and U87 tumors, compared to U251. See Figure 4.12 for the
𝐹𝑝 and 𝑣 𝑒 1 H-DCE-MRI parameters for each tumor type. See Figure 4.13 for exemplary maps of 1 H-DCE-MRI
parameters for individual animals from each tumor type.
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Figure 4.12: Comparisons of 𝐹𝑝 and 𝑣 𝑒 1 H-DCE-MRI parameters between RG2, U87 and U251 tumors. For
all tumor types, mean 𝐹𝑝 values (left) closely followed patterns for 𝐾 trans (see Figure 4.11c), but there was only
a marginally significant difference between tumor types. There was also no significant difference between 𝑣 𝑒
values (right) for the different tumor types. These values, however, are smaller than the observed 𝑣 𝑝 values (see
Figure 4.11c), which suggests that the vascular portion of all tumor types studied dominates over the interstitial
space. See Figure 4.13 for exemplary maps of 1 H-DCE-MRI parameters for animals from each tumor type.
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Figure 4.13: Exemplary maps of 1 H-DCE-MRI parameters from representative animals from each tumor
type. 1 H-DCE-MRI parameters were calculated only for the tumor, and overlaid on 𝑇1 -weighted anatomical
images. Values for 𝐾 trans and 𝐹𝑝 are reported in 10−3 min−1 . As measures of vascularity, these values reveal
heterogeneity throughout all three tumor types, but overall significantly larger values are present for RG2 and
U87 relative to U251 (see Figure 4.11c). Small regions with low 𝐾 trans and 𝐹𝑝 near the center of the U251 tumor
suggest areas of low perfusion and are indicative of a necrotic core, which U251 tumors have been shown to
have. Furthermore, 𝑣 𝑝 values tend to be larger throughout the tumor compared to 𝑣 𝑒 which suggests the large
presence of vasculature within tumor tissue. The necrotic core in U251, defined by the low-𝐹𝑝 region within
the tumor, shows a corresponding region of elevated 𝑣 𝑒 suggesting the lack of vasculature in areas with low
perfusion. These findings help to confirm the elevated Na+
signals observed in 23 Na-MRSI are consequences
b
of enhanced vascularity. See Figure 4.11c for the distribution of 𝐾 trans and 𝑣 𝑝 values, and Figure 4.12 for the
distribution of 𝐹𝑝 and 𝑣 𝑒 values.
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Figure 4.14: Representative maps of compartmentalized 23 Na signals (Na+
, Na+
e , Nai ) as well as transendotheb
+
+
lial (ΔNaend ) and transmembrane (ΔNamem ) gradients in U251, U87, and RG2 tumors. The left column shows
1
the tumor location (white outline) on the anatomical
∫
∫ H-MRI for∫ animals bearing (a) U251, (b) U87 and (c) RG2
+
+
tumors. The respective three columns show Nab , Na+
∫e , and Na∫i maps. The last two columns on the right
Na+
show the ΔNa+
and ΔNa+
and Na+
e are high and low, respectively, and
mem maps. In all tumors the
b
end
+
+
thus are the main drivers for a high ΔNaend and a low ΔNamem .
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4.5 Discussion
Implications of Current Findings
Our results enabled comparisons of Na+ physiology and
distributions among RG2, U87, and U251 gliomas. Both U87
and U251 are human-derived cell lines, whereas RG2 is derived from rat glioma[217, 395]. Experimentally the U251
tumor is most heterogeneous, since U251 cells grow erratically and anisotropically compared with RG2 and U87 cells.
Additionally the U251 tumor is more invasive and infiltrative than U87[221], and U251 cells display greater necrosis,
expression of hypoxia-inducible factor 1-alpha (HIF1 𝛼 ) and
of Ki67, indicating higher rates of proliferation[396]. Cells
also test positive for glial fibrillary acidic protein (GFAP)
and vimentin, and exhibit neovascularization and angiogenesis. U87 cells are also positive for vimentin and exhibit
significant angiogenesis but do not develop necrosis. Neither
U251 nor U87 exhibits endothelial proliferation, a common
hallmark of human-derived GBM lines[221]. The RG2 tumor
exhibits invasiveness and induces BBB disruption, producing
edema surrounding the tumor where pericytes help promote angiogenesis to increase permeability of the tumor
vasculature[397]. These data concur with our findings. We
observed that the negative correlation between the transmembrane and transendothelial gradients were strong in the
RG2 and U87 lines but weak for U251. The increase of the
transendothelial gradient nearly matched the decrease of the
transmembrane gradient in U87 tumors, and exceeded in
RG2, which matched behavior regarding BBB permeability.
Higher density of blood vessels or higher blood volume
would explain higher 23 Na signal but not necessarily higher
Na+ concentration in the blood. Although the blood vessels
are leaky to Gd3+ , the elevated transendothelial gradient
suggests that the BBB is impermeable to Na+ , which is well
known[365].
Alkylating chemotherapy agents attach an alkyl group to
DNA of cancer cells to keep them from replicating. For example, temozolomide (TMZ) achieves cytotoxicity by methylating the O6 position of guanine. O6 -methylguanine-DNAmethyltransferase (MGMT) is a DNA repair enzyme, which
ordinarily repairs the naturally occurring DNA lesion O6 methylguanine back to guanine and prevents mistakes during
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DNA replication and transcription. Unfortunately, MGMT
can also protect tumor cells by the same process and neutralize the cytotoxic effects of agents like TMZ. If the MGMT
gene is silenced by methylation in tumor cells (i.e. MGMTnegative or MGMT-methylated), its DNA repair activity is
diminished and the tumor’s sensitivity to chemotherapy is
amplified. This suggests that MGMT-positive tumor cells become resistant to chemotherapy, and therefore would possess
a depolarized 𝑉𝑚 due to its proliferative state.
A recent study demonstrated higher MGMT mRNA expression for RG2 compared to U87[398]. Another study showed
that the 50% inhibition concentration (IC50 ) of TMZ for U87
and U251 cells are comparable[399]. Together, these suggest
that RG2 is most resistant to chemotherapy presumably due
to its augmented proliferative/replicative state, and hence a
depolarized 𝑉𝑚 . These observations partially agree with our
results, where RG2 and U87 tumors maintain a depolarized
𝑉𝑚 for their proliferative/replicative state to persist.

Study Highlights
In vitro 23 Na shifts were most dependent on [TmDOTP5− ]
given its high shiftability ( 𝑠 [paraCA𝑛− ] = 2.77 ppm/mM),
whereas shiftability due to pH and temperature effects were
negligible within physiological ranges ( 𝑠 pH = 0.25 ppm/pH
unit; 𝑠𝑇 = 0.03 ppm/◦ C). The maximum pH difference between glioma and brain tissue is 0.4 pH units[319, 321, 322,
324] whereas temperature differences of 0.5 ◦ C are extremely
unusual in the brain[318, 320, 323]. Under these extreme
conditions, the respective 23 Na shift variations caused by pH
and temperature would be 0.1 ppm and 0.015 ppm. Meanwhile, TmDOTP5− can reach in vivo concentrations close to
1-2 mM in blood and interstitial spaces[315, 316, 400] which
would cause 23 Na shifts of 2.8-5.5 ppm. While we did not
attempt to calculate [TmDOTP5− ] in each voxel using the
sodium shiftability, this was specifically used to discern that
the most shifted peaks were from the blood and extracellular
(or CSF) compartments, respectively. Given observed 23 Na
line widths in vivo on the order of 0.4 ppm, TmDOTP5−
concentration effects dominate the shifting effect (96-98%).
Therefore, 23 Na shiftability can be considered a univariate
function of [TmDOTP5− ] in vivo.
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These observations enabled attributing individual 23 Na peaks
to specific in vivo pools for blood, extracellular and intracellular spaces arising from compartmental differences in
[TmDOTP5− ] upon intravenous administration (1 𝜇mol/g).
The shifts in tumor tissue (0.5-1 ppm) were more conspicuous
compared to peritumoral tissue, but lower than in blood (2
ppm), suggesting larger [TmDOTP5− ] in the blood compartment. Additionally, the blood and extracellular peaks were
separated by 1.5 ppm, much larger than their line widths
(0.4 ppm), indicating minimal cross-compartmental contributions.
Integrating the separated 23 Na peaks enabled spatial mapping of Na+ compartments and gradients in vivo. In the tumor,
compared to normal tissue, the transendothelial Na+ gradient was stronger and the transmembrane Na+ gradient was
weaker due to elevated blood and decreased extracellular
23
Na signals. Current agent concentration does not affect the
Na+ gradients, simply the chemical shift position of the 23 Na
peak for each compartment. However, an order of magnitude
higher agent concentration would affect the Na+ gradients
due to the amount of Na+ ions co-infused. The enhanced
23
Na blood signals in tumors complied with dynamic 1 HDCE-MRI scans based on gadolinium (Gd3+ ) uptake, which
revealed a higher degree of vascularity in RG2 and U87 tumors. Extracellular Na+ signal in the ventricles was also very
high due to the dominant presence of the agent in CSF[400].
However, ventricular 23 Na peaks were Lorentzian whereas
tissue 23 Na peaks appeared super-Lorentzian, since CSF contains primarily aqueous Na+ and thus a single 𝑇2 component,
whereas semi-solid Na+ binding in tissue resulted in multiple
𝑇2 components[401].

Comparison with Previous Work
The present in vitro data improve upon earlier attempts at
quantifying 23 Na shiftability using paraCA𝑛− versus many
parameters like pH, temperature and other cations[345].
However, the findings focused more on characterizing the
dependence on each parameter (linear, sigmoidal, etc.) rather
than considering relevant in vivo conditions. Additionally, the
model was not employed in the context of the brain/other
tissues. Our 23 Na shiftability model does not require assessing the effects of cationic competition for attraction to
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TmDOTP5− [344] because other cations are not present in
blood and/or extracellular spaces in concentrations comparable to Na+ [358].
Prior in vivo 23 Na spectroscopy studies utilizing TmDOTP5−
in the brain failed to elucidate spatial information by only
focusing on global data acquisition and/or localized voxels[330, 331]. The findings reported two broadened peaks, an
unshifted intracellular peak and a shifted extracellular peak.
Based on two peaks over limited spatial regions, these studies
could not comment specifically on the spatial distribution
of transmembrane gradient. Furthermore, the blood 23 Na
signal was not separated so the transendothelial gradient
could not be assessed. The shifting capability of TmDOTP5−
for separating 23 Na resonances in tumor tissue was demonstrated in situ, but still at a global level and without mention
of Na+
specifically[332, 333].
b
Recently, 23 Na-MRI methods have been preferred clinically
over spectroscopic methods[335]. Such relaxometric modalities exploit differences in diffusion and relaxation behavior
between Na+ ions inside/outside the cell, because intracellular ions are generally considered less mobile due to binding.
Due to the spin-3/2 of 23 Na, this binding amplifies the relative contribution of nuclear satellite transitions and permits
the use of MQF techniques to isolate signals from individual
in vivo compartments. However, these 23 Na-MRI methods
are currently limited for probing intracellular Na+ because
they fail to completely suppress 23 Na signals from the blood
and extracellular compartments[335]. While 23 Na-MRI results with MQF or ADC can be compared with 23 Na-MRSI
results, duration of all experimental measurements will require several hours and may put strain on animal’s physiology.
However future studies can compare MRSI data with ADC
and/or MQF data in different groups.
Our method avoids this practical 23 Na-MRI limitation to
provide physiological information about all relevant compartments, and thus enables estimation of transendothelial
and transmembrane gradients. Overall, the 23 Na-MRSI results agree with prior findings that a depolarized 𝑉𝑚 (i.e.,
weakened transmembrane gradient) is responsible for tumor proliferation[199]. Given that both the cell membrane
and BBB help to maintain the ionic level of the extracellular
fluid[364, 365], our results also show that the transendothelial gradient is significantly enhanced in the same tumors that
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show enhanced permeability (i.e., RG2 and U87). Together
these suggest that the current 23 Na-MRSI scheme can be used
to study the perturbed sodium homeostasis in vivo within
the neurovascular unit.

Technical Limitations
This technique, while a crucial first step towards mapping
the spatial distribution of Na+ in vivo, cannot absolutely
+
quantify [Na+ ], although the ratios of Na+
, Na+
e , and Nai
b
integrals measured reflect the physiological ratios mentioned
earlier outside of the tumor, and are altered inside the tumor.
Including a quantifiable standard can usually circumvent this
limitation because 23 Na-NMR has no endogenous species
that can be used as a standard. However, using the strong CSF
signal in vivo remains a possibility for future explorations.
Setups involving Na+ phantoms with relatively large [TmDOTP5− ]
within the field-of-view (FOV) alongside the body region
being imaged could be used, but these would hinder the shim
around the subject’s body part being imaged, a technical necessity for the 23 Na-MRSI method, and these components are
difficult to cover with surface coils. Additionally, broad pointspread functions make quantifications in external phantom
standards challenging, though they are perhaps the best
option presently[402]. Moreover, radio frequency (RF) inhomogeneity was not directly addressed in this study. To
partially circumvent this shortcoming we used axial slices
(parallel to the plane of the RF coil) to a depth of the brain
where sufficient sensitivity was achievable. However this
limitation could be overcome with use of adiabatic RF pulses
in the future.
Contrast agents with lanthanide(III) ions (Ln3+ ) are popular
in molecular imaging with 1 H-MRI[317, 403],but clinically
the preference is probes with Gd3+ conjugated to linear or
cyclical chelates[404, 405]. The most biocompatible Gd3+
chelates are based on 1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetate (DOTA4− ) because they are both kinetically and
thermodynamically stable[406]. A LnDOTA− carries a -1
charge. But if a phosphonate group is attached to each of
the pendant arms in DOTA4− , then DOTP8− is formed and
complexation with Ln3+ permits a -5 charge (e.g. TmDOTP5− ).
The majority of paraCA𝑛− that will work for the type of
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Na-MRSI experiments described here are based on Ln3+
complexes, because these give rise to large hyperfine shifts
with minimal 1 H relaxation enhancement[350]. But there is
growing attention to complexes with similar paramagnetic
properties from transition(II) metal ions (Tn2+ ), such as
Fe2+ , Ni2+ , or Co2+ [407]. The Tn2+ -based paraCA𝑛− has the
potential for clinical use because of superior biocompatibility.
Some Tn2+ complexes designed could carry a -5 charge,
but studies need to explore the safest and most effective
paraCA𝑛− for 23 Na-MRSI experiments.
23

Another limitation is the infusion of a small amount of Na+
with the paraCA𝑛− itself. TmDOTP5− exists commercially in
the form Na5 TmDOTP, so a small amount of Na+ is being
added. Since [TmDOTP5− ] does not exceed 2 mM in the brain
vasculature (as determined by the maximum Na+
shift), there
b
+
is at most 1.3% increase of the endogenous [Na ] in blood/extracellular spaces. In regions with high [TmDOTP5− ] and
low [Na+ ], like necrotic core of tumors, the infused Na+ may
represent a larger percentage. However, necrotic cores can be
identified with 𝑇2 -weighted 1 H-MRI scans. Since extracellular Na+ is shifted less than blood, it is doubtful that enough
Na5 TmDOTP extravasation occurs to significantly alter the
relative Na+ levels between compartments and impact the
conclusions drawn from this study. Future studies with selective BBB opening using focused ultrasound can resolve
the uncertainties if intracellular Na+ is lower or higher in
tumor compared to normal tissue. Furthermore, we are confident that this additionally infused Na+ does not enter the
intracellular compartment and confound the results. Studies
indicate that aggressive cancers express embryonic isoforms
of voltage-gated sodium channels[408–410]. Since 𝑉𝑚 during
the embryonic state is depolarized[199], this suggests there
is little Na+ influx from the extracellular compartment.
Another confounding factor is the use of isoflurane during
both the repeated 1 H-MRI tumor monitoring scans, and the
terminal 23 Na-MRSI imaging session. The use of anesthesia
may be necessary to reduce movement errors in awake animal MRI/MRSI experiments, but all precautions should be
taken to reduce the period of anesthesia exposure. However
accuracy of this 23 Na-MRSI method is ultimately dependent
on accurate estimation of [TmDOTP5− ] per voxel. While
𝑇2 maps before and after TmDOTP5− injection can partly
estimate [TmDOTP5− ] in healthy and tumor tissues, this
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approach cannot separate [TmDOTP5− ] in blood and extracellular compartments within the tumor. However, future
spatial resolution improvements of 23 Na-MRSI in relation
to 1 H-MRI could enable this approach to be implemented
better with improved estimates of [TmDOTP5− ] in blood and
extracellular spaces across all voxels.

4.6 Conclusion
This study is the first to image the transformed transmembrane and transendothelial gradients of gliomas using TmDOTP5−
for 3D 23 Na-MRSI at high spatial resolution (1 𝜇L/voxel). The
in vivo data consistently revealed ΔNa+
mem weakening and
+
ΔNaend strengthening within tumors compared to normal
tissue, which agree with prior findings[199] and suggest a
redistribution of tumoral Na+
e to the blood compartment.
There is good evidence to propose that these measurements
could potentially probe stages of the cell cycle, and perhaps,
angiogenic behavior. The described method could empower
testing of novel chemotherapy and anti-angiogenic drugs for
GBM models, and this even at a preclinical level would be
significant. This method could potentially be translated into
patients by synthesizing transition metal-based paraCA𝑛−
such that suitable therapies can be targeted based on MGMT
screening in GBM patients.
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The previous chapters have demonstrated the versatility of
sodium-23 (23 Na) nuclear magnetic resonance (NMR) and
magnetic resonance spectroscopic imaging (MRSI) in quantifying compartmental in vivo concentrations. The studies
have provided the first applications of 23 Na-MRSI in vivo
and particularly in the context of cancer, as well as divulging
more of the 23 Na chemical shifting and line broadening mechanisms in magnetic resonance spectroscopy (MRS) during
interactions of sodium ions (Na+ ) with paramagnetic contrast
agents. X-nuclei NMR has not found as many clinical applications as it has preclinical applications, presumably due to
low sensitivity and receptivity which would require unrealistic patient scan times to obtain decent signal-to-noise ratio
(SNR). However, phosphorus-31 (31 P) NMR has been used
clinically to probe energy metabolism in different patient
tissues[411].
X-nuclei imaging, however, can fill gaps in understanding
which traditional proton (1 H) imaging and spectroscopy
cannot adequately fill. For example, as was mentioned extensively in earlier chapters, 1 H magnetic resonance imaging
(MRI) has played an invaluable role in cancer diagnostics and
theragnostics. Identification of the tumor is usually defined
by regions of contrast enhancement via contrast agent uptake
on a 𝑇1 - or 𝑇2 -weighted image, because of the leaky bloodbrain barrier (BBB) which allows for greater accumulation of
the agent in tumor tissue compared to normal tissue, a phenomenon described earlier as the enhanced permeation and
retention (EPR) effect. However, other studies have demonstrated that this is not always the best indicator for presence
of a tumor, as low-grade gliomas have shown massive MRI
contrast enhancement[412, 413], while conversely certain tumors have appeared identical to normal tissue in terms of
MRI contrast and detected 𝑇2 values[414, 415]. Due to these
shortcomings, traditional agent-free 23 Na-MRI was shown
to impart physiologically relevant information such as total
Na+ levels through standard pulse-acquire sequences[338,
416–418] as well as putatively bound Na+ levels through mul-
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tiple quantum filtering (MQF) techniques which exploit the
altered transverse relaxation dynamics of bound Na+ [419].
Interestingly, the filtered 23 Na signal from bound Na+ was
shown to correlate in tumors with the expression of the proliferation marker Ki-67[418]. In a more complete clinical study,
Biller and colleagues demonstrated that the proportion of
the total 23 Na signal that comes from bound Na+ exhibits
predictive power for the mutation status of isocitrate dehydrogenase (IDH), a clinically relevant biomarker discussed
earlier in this text that is suggestive of patient prognosis[420].
Therefore, these recent 23 Na MRI advancements have started
to demonstrate clinical applicability despite the physical
limitations of X-nuclei compared to 1 H NMR.

5.1

23

Na Linewidth Studies

The development of an accurate 23 Na-MRSI method using
paramagnetic lanthanide-based agents to ascertain compartmentalized Na+ distributions enables subsequent experiments which previously would have been difficult to perform.
For example, it was demonstrated in Chapter 3 that Tm3+ containing agents induced both 23 Na chemical shifts and
line broadening. Due to the large concentration shiftability
of TmDOTP5− , Na+ compartmentalization in vivo was analyzed through the lens of chemical shift (Chapter 4) due to
distinct 23 Na NMR peak separability. However, the changes
in line width induced by TmDOTP5− can also be visualized,
as is shown for an exemplary slice of a rat bearing a U87
tumor in Figure 5.1a,b. TmDOTP5− induced visible 23 Na
line broadening throughout the brain (Figure 5.1c-e), with
the most substantial changes occurring within the tumor,
which follows from previous discussions about superior
TmDOTP5− accumulation within the tumor due to a compromised blood-brain barrier (BBB). It should be noted that the
line widths reported after TmDOTP5− administration (ΓTm )
(Figure 5.1d) are exaggerated due to the fact that chemical
shift effects will cause 23 Na peak separation that enhance the
overall full width at half maximum (FWHM) for the particular voxel, especially for the tumor where large [TmDOTP5− ]
values result in well-separated peaks. However, examining
a tumoral voxel (Figure 5.1b) reveals that despite this, the
resolved peaks for blood, extracellular, and intracellular
Na+ exhibit different line widths, where the most-shifted
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peak (i.e., blood Na+ ) also is the broadest. Regardless, the
change in the linewidth caused by TmDOTP5− (ΔΓTm ) can
be easily obtained (Figure 5.1e), and comparing this to maps
of transendothelial (ΔNa+
) and transmembrane (ΔNa+
mem )
end
gradients (Figure 5.1f,g) reflects similar patterns, specifically
the 1/ΔNa+
mem map (Figure 5.1h).These results corroborate
the concentration-dependence of chemical shift and line
width as outlined in the model presented in Chapter 3, and
suggest that the ΓTm map could be used as a close surrogate
of the ΔNa+
mem map.

Figure 5.1: Demonstration of 23 Na line broadening with TmDOTP5− . (a) 1 H MRI of an exemplary brain
slice from a U87-bearing rat overlaid with 23 Na-MRSI (red), with (b) spectra before (black) and after (green)
TmDOTP5− infusion from a tumor voxel (brown square in (a)). The black and green spectra are before (Γ0 ) and
after (ΓTm ) TmDOTP5− infusion. Γ0 and ΓTm maps for the slice are displayed in (c) and (d) where the colors
represent different extent of line broadening in ppm units, while the difference of these (ΔΓTm ) are shown in (e).
+
The transendothelial (ΔNa+
) and transmembrane (ΔNa+
mem ) Na gradients are displayed in (f) and (g). Finally
end
+
+
the inverse transmembrane Na gradient map (1/ΔNamem ) is shown in (h). In all images, the tumor boundary
is outlined in white and the brown square indicates the voxel shown in (b). Broadening was observed more
strongly in the tumor than outside, although broadening was observed peritumorally as well. TmDOTP5− -based
broadening was confounded by the fact that separation into three peaks resulted in abnormally large linewidths,
in part due to significant shifting as well. All data are from the same rat.

Chapter 3 also demonstrated that the broadening capabilities
(𝛽 𝑐 ) of Tm3+ - and Gd3+ -agents are comparable. Motivated
by the prior analysis of TmDOTP5− -induced 23 Na line width
in vivo (Figure 5.1), we also infused GdDOTP5− into a rat
bearing a U87 glioma and saw line broadening throughout
the brain (Figure 5.2). The experiment followed the protocol
identical to the one described in Chapter 4, except with
GdDOTP5− which was synthesized according to the reaction
procedure outlined in Chapter ??. Since the shiftability of
GdDOTP5− is smaller than that of TmDOTP5− (Figure 5.2a-c),
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the erroneous chemical shift contribution to the voxel-wise
FWHM is negligible so the changes in broadening observed
(Figure 5.2d) can be reliably attributed to interactions between
Na+ and GdDOTP5− .

Figure 5.2: Demonstration of
23
Na line broadening with
GdDOTP5− . (a) 1 H MRI of brain
slices from a U87-bearing rat overlaid with 23 Na-MRSI (red), with
linewidth maps (b) before (Γ0 )
and (c) after (ΓGd ) GdDOTP5− infusion. The change in linewidth
(ΔΓ = ΓGd −Γ0 ) is shown in (d). In
all columns, the tumor boundary
is outlined in white. Slice 1 is the
most superficial slice, while slice
3 is the deepest slice. Broadening was observed throughout the
brain, and strongest in the tumor.

In Figure 5.2, slice 1 is the most superficial slice and slice 3
is the deepest slice. The broadening observed is strongest
in the tumor, which follows from enhanced Gd3+ retention
due to the leaky BBB. There is also observable broadening
in the ventricles, though these values are smaller than the
surrounding tissue. This is because linewidth is proportional
to 𝑅 2 , which is smaller for fluids in the ventricles where
spin-spin dephasing is reduced because Na+ interacts less
with GdDOTP5− . Similar to the previous analysis of line
broadening Tm3+ (Figure 5.1), this tumoral line broadening from Gd3+ is suggestive of altered 23 Na transmembrane
gradients. This was confirmed by seeing correlations between elevated transendothelial Na+ gradients (ΔNa+
) from
end
5−
TmDOTP —based chemical shift analysis, and enhanced
tumoral line broadening from GdDOTP5− —based linewidth
analysis performed in the same U87-bearing rat (Figure 5.3).
GdDOTP5− was infused before TmDOTP5− was into the rat,
with sufficient time allowed to clear the GdDOTP5− from the
system.
This preliminary study employing 23 Na-MRSI with GdDOTP5−
demonstrates the feasibility of our method using agents other
than TmDOTP5− and looking at linewidth instead of only
the chemical shift in order to identify the transmembrane
gradient of brain tumors. Because Gd3+ -based agents are
approved for clinical use by the FDA for MRI contrast, our
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Figure 5.3: A comparison of 23 Na-MRSI results from TmDOTP5− -based chemical shift analysis and
GdDOTP5− -based linewidth analysis. Superficial (top) and deeper (bottom) (a) 1 H MRI axial slices are
from the same U87-bearing rat. GdDOTP5− was infused before TmDOTP5− was infused into the rat, with
sufficient time allowed to clear the GdDOTP5− from the system. (b) Transmembrane (ΔNa+
mem ), (c) inverse
+
+
transmembrane (1/ΔNa+
mem ), and (d) transendothelial (ΔNaend ) Na gradients were calculated from infusion
of TmDOTP5− , while (e) line broadening was calculated from infusion of GdDOTP5− . There is an observable
+
23
correlation between the ΔNa+
mem weakening, the ΔNaend strengthening, and the Na line broadening.

Na-MRSI method with a Gd3+ -agent can be safely used
on human subjects to provide clinically relevant information on the Na+ biodistribution with minimal invasiveness
(see Section 5.4).
23

5.2 Sorafenib Treatment
Another direction in which our method can be applied concerns the ability to monitor the effects of cancer chemotherapies. Given the intimate involvement between Na+ concentrations and tumorigenesis[199], changes in the compartmentalized 23 Na signals should reflect changes in the respective
Na+ concentrations throughout the course of the therapy.
Sorafenib (Figure 5.4) is an FDA-approved chemotherapy
which has primarily been used as a frontline for cancers
like hepatocellular carcinoma[421], although lenvatinib has
started to demonstrate stronger efficacy[422, 423]. However,
sorafenib has been garnering recent attention for its effects
on GBM[424]. It is a kinase inhibitor which targets vascular
endothelial growth factor receptor (VEGFR) and plateletderived growth factor receptor (PDGFR). Sorafenib is also
an agonist of adenosine monophosphate (AMP)-activated
protein kinase (AMPK), which has been shown to suppress
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tumors[425]. In the context of GBM, sorafenib has produced
favorable patient prognoses in combination with other therapies like bevacizumab and everolimus[426].

Figure 5.4: Chemical structure of
sorafenib.

We conducted preliminary 23 Na-MRSI studies (Figure 5.5)
of sorafenib treatment on U87-bearing rats in a procedure
identical to the in vivo studies outlined in Chapter ??. For
these treated rats, sorafenib (at a dose of 0.1 g/kg BW) was
administered via oral gavage daily starting on the ninth
day after tumor inoculation. Sorafenib was dissolved in
dimethylsulfoxide (DMSO) before oral administration. The
23
Na-MRSI studies were conducted on a pair of rats, in
which one was given the standard sorafenib treatment while
the other was given only DMSO as a control. Each rat was
imaged 15 days after intracranial injection of U87 tumor
cells. The treated animal at day 15 is burdened by a much
smaller tumor compared to the untreated, which suggests
sorafenib has therapeutic potential for gliomas. Moreover, the
sodium distributions in both rats generally follow the trends
described in Chapter 4, namely elevated 23 Na signal from
the blood and decreased signal from the extracellular tissue
from the tumor compared to the surrounding unburdened
parenchyma. However, for the untreated rat, this region
of altered sodium levels is much larger since the tumor
is much larger, and the 23 Na integrals are larger in the
untreated animal than in the treated animal. Because these
integral values are dependent on chemical shift induced by
TmDOTP5− , this suggests that sorafenib is impairing the Na+
gradient across compartments. This has implications for both
Na+ distributions and access to the brain by contrast agents
for 23 Na-MRSI. This follows from the fact that sorafenib is a
VEGFR inhibitor, such that angiogenesis is downregulated,
where both the transendothelial and transmembrane Na+
gradients are reduced in the sorafenib-treated rat.
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+
Figure 5.5: Demonstration of altered transendothelial (ΔNa+
) and transmembrane (ΔNa+
mem ) Na gradients
end
with sorafenib treatment. 23 Na-MRSI results with TmDOTP5− for rats bearing U87 gliomas treated administered
pure dimethylsulfoxide (DMSO, top) and sorafenib at a dose of 0.1 g/kg BW dissolved in DMSO (bottom). Both
∫the untreated and treated
∫ rats exhibit sodium biodistributions similar to what was seen in Chapter 4 (elevated
Na+
and
decreased
Na+
e in the tumor), but they differ in tumor size and integral magnitude, leading to
b
+
reduced Na gradients.

5.3 Electrophysiological Recordings
The electrophysiological alterations examined in tumors so
far by 23 Na-MRSI, namely weakened ΔNa+
mem , ultimately
have consequences for the membrane potential (𝑉𝑚 ), which
is related to the proliferation potential of cells has been described in the literature[199]. However, the studies have not
provided a complete validation of this perturbed electrophysiology.
For rats bearing a U87 glioma, electrical activity was recorded
both within the tumor and in the cortex on the contralateral
hemisphere (Figure 5.6). These U87 rats were placed in a
stereotactic holder on a vibration-free table in a Faraday
cage. The scalp was removed, exposing the skull, and the
periosteum was cleared out. AgNO3 sticks were applied
to stop the subsequent bleeding. The bone wax from the
initial tumor injection site was removed, and a second hole
was drilled on the contralateral hemisphere to expose the
cortex. High-impedance mircoelectrodes were inserted in
each hole to measure electrical activity[427], which was
recorded using Spike2 software (CED, Cambridge, UK).
The extracellular signal was used to measure the multiunit activity (MUA; filtered within 0.5− 5 kHz) and neuronal
firing rate (determined from spike sorting). Both MUA and
firing rate were found to be drastically decreased in tumor
compared to normal tissue (see top and bottom panels of
Figure 5.6). In normal tissue cells within the vicinity of
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the microelectrode fired at a rate of 10-15 Hz, whereas in
tumor tissue the cells only fired at a rate of 0.1-0.3 Hz. These
comply with theoretical expectations regarding sustained
depolarization of tumoral 𝑉𝑚 . These electrical recordings
provide a pseudovalidation of the weakened ΔNa+
mem we
23
observed using in vivo Na-MRSI.

Figure 5.6: Electrical recordings inside and outside the tumor from a rat bearing a U87 glioma. 1 H MRI
(middle) of a U87-bearing rat. The tumor is outlined in red. Electrical recordings from high-impedance electrodes
placed in the tumor (top) and a contralateral cortical region (bottom) are displayed, with arrows pointing to
the exact locations of electrode placement. The extracellular signal, multi-unit activity (MUA), and firing rate
were all decreased within the tumor compared to the normal region of the brain. This demonstrates a sustained
depolarization of the membrane potential (𝑉𝑚 ) in the tumor, which complies with the weakened transmembrane
Na+ gradient (ΔNa+
mem ) found in tumors as well.

5.4 Human Translation
The majority of the work presented in this thesis revolves
around preclinical studies, mainly due to the fact that TmDOTP5− ,
the most promising spectroscopic contrast agent, is not clinically approved. All approved contrast agents are compounds
containing Gd3+ (e.g., Dotarem, Gadovist, etc). For this reason, at present, chemical shift-based 23 Na-MRSI is difficult to
translate into the clinic. While it is reasonable that the success
of the in vivo studies may stimulate efforts towards getting
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approval for Tm3+ -containing compounds, especially by the
Food and Drug Administration (FDA) in the United States,
the current regulatory landscape motivates the 23 Na-MRSI
studies discussed earlier which involve Gd3+ -containing
agents (Section 5.1). Although GdDOTP5− has not yet been
approved, the chemical similarity to Dotarem and Gadovist
can expedite the process. Moreover, the prior experiments can
be conducted using Dotarem and Gadovist while reasonably
expecting similar results.
Moreover, issues of practicality impact the potential for human translation, mainly regarding imaging time. Clinical
MRIs (based on the 1 H signal) typically are purely anatomical and therefore last only a few minutes. This expected
timeframe is convenient for both the patients, who do not
have to spend a long time remaining still in the bore, and the
caregivers, who can image more patients per day and also
spend less time analyzing anatomical images (as opposed
to richer data). For these reasons, the in vivo 23 Na-MRSI
scans currently would not be ideal for a clinical setting. One
iteration of the scan lasts 20 minutes, and the entire session
is prolonged by slow infusion of TmDOTP5− (15 𝜇L/min).
While this rate can most likely be increased for human subjects, who are less sensitive than rats, the scan time remains
a clinically undesirable issue.

5.5 The Utility of Bulk Magnetic
Susceptibility
The phenomenon of bulk magnetic susceptibility (BMS)induced chemical shift was introduced as a confounding
factor which had to be addressed in Chapter 3. The shift
arises from the presence of any paramagnetic contrast agent,
excluding the interaction with Na+ , and has been shown in
our data and the literature[329, 346] to be orientation- and
geometry-dependent.
While it has normally been treated as a nuisance, there is
potential to exploit the BMS shift as an imaging marker. In
vivo, the BMS shift is introduced mainly due to the orien®0 field. Based on what was
tation of blood vessels to the 𝐵
found in Chapter 3, the relative contribution of BMS to the
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total chemical shift is very large for Gd3+ -containing compounds (unlike Tm3+ -containing compounds). Therefore,
measurement of chemical shift after in vivo administration of
a compound like GdDOTP5− allows for imaging of the BMS
phenomenon despite limited hyperfine shift. This further
provides an imaging marker that can make translation to the
clinic (Section 5.4) more feasible.

5.6 Final Thoughts
This project has demonstrated the utility of in vivo 23 NaMRSI methods in conjunction with lanthanide-based contrast
agents to reveal relevant physiological information about Na+
ions which otherwise cannot be measured by standard 1 HNMR-based methods. While many prior invasive Na+ studies
have arrived at a multitude of conclusions for Na+ activity in
tumors, the results here have produced strong evidence for
transmembrane gradient weakening and transendothelial
gradient strengthening manifested by a redistribution of
tumoral Na+ to the blood vessels. The majority of recent in
vivo applications of 23 Na NMR has focused on 23 Na MRI, and
the studies presented in this thesis are some of the first to
reintroduce spectroscopy-based 23 Na methods in vivo, which
were seen as less useful and more cumbersome. Due to this
gravitation away from 23 Na-MRS and MRSI, spectroscopic
models were underdeveloped. However, in this work, the theory of Na+ interactions with these lanthanide-based contrast
agents was examined rigorously. Both the 23 Na chemical shift
and line broadening phenomena were discussed not only
in terms of concentration, but through a more fundamental
lens by looking at charges on different species, as well as
variations in electron distributions which ultimately affect
Na+ exchange. It is the hope of this work in its entirety to
inspire future studies, even beyond those mentioned previously, which further inform our studies of cancer and other
diseases, and pave the way for more novel designs of contrast
agents as well as 23 Na-MRSI applications. While this method
was developed in the context of glioblastoma, the use of
paramagnetic agents in 23 Na-MRSI can be readily applied to
any pathology underscored by aberrant Na+ levels. X-nuclei
imaging has elucidated a plethora of information otherwise
inaccessible by 1 H MRI, and has potential to supplement
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clinical imaging to improve patient prognosis and directing
treatments.
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